


# Solubility Measurement, Thermodynamic Modelling, and Solvent Effects of Pharmaceutical and Chemical Compounds



**Devyani Patel**  
**Selvi Bhavsar**  
**Dr. Ravibhai Bhola**  
**Dr. Rizwan Ghumara**  
**Dr. Chirag Patel**



**CORNOUS PUBLICATIONS LLP.,**



# **Solubility Measurement, Thermodynamic Modelling, and Solvent Effects of Pharmaceutical and Chemical Compounds**

**Devyani Patel**

**Selvi Bhavsar**

**Dr. Ravibhai Bhola**

**Dr. Rizwan Ghumara**

**Dr. Chirag Patel**

Copyright © 2026 Cornous Publications LLP.

All rights reserved. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the publisher, except in the case of brief quotations embodied in critical reviews and certain other non-commercial uses permitted by copyright law.

**ISBN: 978-81-993853-1-3**

Price: Rs. 750

**Publisher Address:**

**Cornous Publications LLP.,**  
No. 30, Veerampattinam Street, Ariyankuppam,  
Puducherry – 605007 India.  
Email: [cornouspublications@gmail.com](mailto:cornouspublications@gmail.com)  
Website: <https://www.cornousbooks.com/>

## **PREFACE**

**Solubility Measurement, Thermodynamic Modelling, and Solvent Effects of Pharmaceutical and Chemical Compounds** represents the first systematic, cross-disciplinary review to bring together solid–liquid equilibrium data from over 296 peer-reviewed articles published between 2012 and 2026. The compounds covered span an extraordinary breadth active pharmaceutical ingredients and drug candidates, natural products and phytochemicals, organic acids and industrial intermediates, agrochemicals, energetic materials, and sugars and amino acids united by the common thread of rigorous solubility characterisation. This breadth is intentional. Solubility science does not belong to any single discipline; the thermodynamic principles governing the dissolution of a fluoroquinolone antibiotic are the same as those governing a monomeric industrial acid or an energetic propellant precursor, and cross-disciplinary synthesis reveals patterns and insights that siloed reviews cannot.

The book is structured to serve readers at multiple levels of engagement. Those seeking experimental guidance will find a detailed treatment of all major measurement methods gravimetric shake-flask, laser dynamic polythermal, HPLC-based quantification, UV-Vis spectrophotometry, and visual synthetic approaches with critical assessment of their respective strengths, limitations, and uncertainty. Those requiring thermodynamic modelling tools will find rigorous, practically oriented coverage of the modified Apelblat equation, Buchowski–Ksiazaczak  $\lambda h$  model, van't Hoff equation, Wilson, NRTL, and UNIQUAC activity coefficient models, and the full suite of binary solvent cosolvency models, accompanied by performance benchmarks derived from the entire reviewed dataset and concrete guidance on model selection. Those interested in the physical chemistry of solutions will find a comprehensive thermodynamic analysis of dissolution enthalpy, entropy, and Gibbs free energy across compound classes, including the phenomenon of enthalpy–entropy compensation, the role of hydrogen bonding and solvent cohesion in governing solubility order, and the application of KAT-LSER and Hansen solubility parameter frameworks.

The intended audience is broad. Pharmaceutical scientists involved in pre formulation, formulation development, and process chemistry will find the pharmaceutical compound coverage and thermodynamic framework directly applicable to their work. Chemical engineers designing crystallisation, purification, and separation processes will find the industrial compound data and binary solvent models of immediate practical relevance. Physical chemists and thermodynamicists will find the unified thermodynamic analysis and model comparison of theoretical interest. Graduate students and early-career researchers entering the field of solid–liquid equilibrium will find the experimental methods section and model selection guidance an accessible and thorough introduction. And experienced researchers in any of these areas will find the comprehensive reference tables and bibliography a time-saving and reliable resource for literature triage.

## **ACKNOWLEDGEMENTS**

This work would not have been possible without the support, encouragement, and contributions of many individuals and institutions, to each of whom the authors owe a sincere debt of gratitude.

First and foremost, the authors express their deepest and most heartfelt appreciation to Ganpat University, Mehsana, Gujarat, India, for providing the academic environment, institutional support, research infrastructure, and unwavering encouragement that made this extensive undertaking possible. The university's commitment to fostering rigorous scientific inquiry and its dedication to advancing pharmaceutical and chemical research have been the bedrock upon which this work stands. The facilities, library resources, and collegial atmosphere of Ganpat University created the ideal conditions for a project of this scale and ambition, and the authors are profoundly grateful for that foundation.

A work of this nature is, at its heart, a synthesis of the labours of others. The authors extend their profound respect and gratitude to the hundreds of research groups and individual scientists worldwide whose original experimental investigations, careful thermodynamic analyses, and rigorously reported data form the entire foundation of this review. Each of the more than 296 peer-reviewed articles compiled in this database represents months or years of dedicated laboratory work, intellectual effort, and scholarly commitment. Without their contributions, this synthesis would simply not exist. The authors have endeavoured at every step to represent their findings accurately, completely, and with the credit they deserve.


Deep appreciation is extended to all co-authors, research collaborators, and postgraduate students who contributed to discussions, data verification, literature screening, and manuscript preparation at various stages of this project. Their intellectual rigour, attention to detail, patience with revision, and willingness to go beyond what was asked of them are reflected on every page of this book. This work belongs as much to them as to those whose names appear on the cover.

The authors also thank their families for the patience, understanding, and quiet sacrifice that sustained this work across long hours and demanding schedules. Academic research of this depth is never carried by its authors alone it is carried equally by those at home who ask few questions and offer unconditional support.

Finally, the authors acknowledge with gratitude the broader scientific community whose open and collaborative spirit sharing data, methods, and ideas across institutional and national boundaries exemplifies the finest traditions of scholarship. It is in that same spirit that this book is offered to the scientific community, in the hope that it proves a worthy and lasting contribution.

## **About the Authors**

**Devyani Patel** is a dedicated Ph.D. Scholar in the Department of Chemistry at Ganpat University, Gujarat, India and Senior Research Scientist in the pharmaceutical industry, recognized for her significant contributions to analytical research and drug development. With extensive experience across API development, formulation and CRO environments, she specializes in designing robust and reproducible analytical methods. Her expertise includes advanced techniques such as Supercritical Fluid Chromatography (SFC), High-Performance Liquid Chromatography (HPLC), and Preparative HPLC for complex separations and purification. She is also skilled in impurity profiling, stability-indicating method development, and process optimization, consistently ensuring high product quality. Known for her strong technical acumen and problem-solving abilities, she excels in addressing complex analytical challenges and advancing pharmaceutical research with precision and innovation.



**Devyani Patel**

**Selvi Bhavsar** is a dedicated Ph.D. Scholar in the Department of Chemistry at Ganpat University, Gujarat, India, with a strong focus on organic and heterocyclic chemistry. Her research centers on the design and synthesis of novel heterocyclic compounds with potential biological activities, including antimicrobial, anti-inflammatory, and anticancer properties. She possesses hands-on expertise in multi-step organic synthesis, purification techniques, and structural characterization using advanced analytical tools such as NMR, IR, and UV spectroscopy. Her work emphasizes the development of efficient, sustainable synthetic methodologies and the exploration of structure–activity relationships. With a keen interest in medicinal chemistry and drug discovery, she is committed to contributing innovative solutions to contemporary pharmaceutical challenges through rigorous scientific research and analytical precision.



**Selvi Bhavsar**

**Dr. Ravibhai Bhola** is an accomplished academician, researcher, and mentor in the field of chemistry, currently serving as an Assistant Professor at Ganpat University, where he specializes in physical chemistry with a focus on crystallization and solution thermodynamics. A gold medallist in his M.Sc. and a Ph.D. holder, he has demonstrated consistent academic excellence and has authored numerous research papers in reputed international journals, along with holding a published patent that reflects his innovative approach to scientific research. Beyond his scholarly contributions, he is a dedicated educator who has guided several postgraduate students and plays a key role as a Placement Coordinator, supporting students in their career development. He also contributes to the global research community as a reviewer for leading publishers such as ACS, Springer, and Elsevier. With his strong blend of research expertise, teaching commitment, and professional involvement, Dr. Bhola brings valuable insight and authority to this book.



**Dr. Ravibhai Bhola**

**Dr. Rizwan Yunus Ghumara** is currently serving as an Assistant Professor in the Department of Chemistry at Tolani College of Arts and Science. He earned both his M.Sc. and Ph.D. degrees in Chemistry from Saurashtra University, Rajkot. With over a decade of experience in academia and research, Dr. Ghumara has made significant contributions to his field. He has authored more than 20 research papers published in reputed international journals and holds two Indian process patents along with one international patent. Dr. Ghumara has also mentored numerous M.Sc. students in their research dissertations and academic projects. His research interests span a wide range of topics, including polymer synthesis and characterization, composite materials, solubility studies, and solid-liquid equilibria.



**Dr. Rizwan Ghumara**

**Dr. Chirag Patel** is an Assistant Professor in the Department of Chemistry at K.S.K.V. Kachchh University, Bhuj. With over a decade of experience teaching postgraduate students, he is deeply committed to academic excellence and the advancement of chemical sciences. Dr. Patel earned his Ph.D. in Chemistry from Saurashtra University, Rajkot, and has contributed significantly to the field through publications in several national and international journals of repute. He cleared the CSIR-NET examination with an impressive All India Rank of 64. His primary research interests include solution thermodynamics, molecular interactions, bio composites, and solubility studies.



**Dr. Chirag Patel**

## INDEX

| SR.<br>NO. | CONTENT  | PAGE<br>NO. |
|------------|--|-------------|
| <b>1.</b>  | <b>INTRODUCTION</b>                                    | 1-3         |
| <b>1.1</b> | Background and Significance                            | 1           |
| <b>1.2</b> | Objectives and Scope                                   | 2           |
| <b>1.3</b> | Organisation of the Review                             | 2           |
| <b>1.4</b> | Literature Coverage and Database                       | 3           |
| <b>2.</b>  | <b>EXPERIMENTAL METHODS FOR SOLUBILITY MEASUREMENT</b> | 4-7         |
| <b>2.1</b> | Overview of Experimental Approaches                    | 4           |
| <b>2.2</b> | Gravimetric (Static Equilibrium) Method                | 4           |
| <b>2.3</b> | Laser Dynamic Monitoring Method                        | 5           |
| <b>2.4</b> | High-Performance Liquid Chromatography (HPLC)          | 6           |
| <b>2.5</b> | UV-Vis Spectrophotometric Method                       | 6           |
| <b>2.6</b> | Synthetic Method with Visual Observation               | 6           |
| <b>2.7</b> | Solid-Phase Characterisation Techniques                | 7           |
| <b>2.8</b> | Temperature Ranges and Experimental Conditions         | 7           |
| <b>3.</b>  | <b>RESULTS AND DISCUSSION</b>                          | 8-12        |
| <b>3.1</b> | General Solubility Trends                              | 8           |
| <b>3.2</b> | Solubility in Polar Protic Solvents                    | 9           |
| <b>3.3</b> | Solubility in Polar Aprotic Solvents                   | 10          |
| <b>3.4</b> | Solubility in Non-Polar and Low-Polarity Solvents      | 10          |
| <b>3.5</b> | Effect of Temperature on Solubility                    | 11          |
| <b>3.6</b> | Binary Solvent Systems and Co-Solvency                 | 11          |
| <b>3.7</b> | Solvent Effect Analysis (KAT-LSER and HSP)             | 12          |
| <b>4.</b>  | <b>THEORETICAL THERMODYNAMIC MODELS</b>                | 13-17       |
| <b>4.1</b> | Introduction to SLE Modelling                          | 13          |
| <b>4.2</b> | Modified Apelblat Equation                             | 13          |
| <b>4.3</b> | Buchowski-Ksiazaczak $\lambda h$ Equation              | 14          |
| <b>4.4</b> | Van't Hoff Equation                                    | 15          |
| <b>4.5</b> | Wilson Model   | 15          |
| <b>4.6</b> | NRTL Model   | 15          |
| <b>4.7</b> | UNIQUAC Model  | 16          |
| <b>4.8</b> | Jouyban-Acree and Binary Solvent Models                | 16          |
| <b>4.9</b> | Model Selection Guidance                               | 17          |
| <b>5.</b>  | <b>THERMODYNAMIC ANALYSIS OF DISSOLUTION</b>           | 18-21       |
| <b>5.1</b> | Thermodynamic Framework                                | 18          |
| <b>5.2</b> | Enthalpy of Dissolution ( $\Delta H^\circ$ )           | 18          |

|           |  |   |       |
|-----------|--|---|-------|
|           | <b>5.3</b>                                     | Entropy of Dissolution ( $\Delta S^\circ$ )   | 19    |
|           | <b>5.4</b>                                     | Gibbs Free Energy ( $\Delta G^\circ$ )        | 20    |
|           | <b>5.5</b>                                     | Enthalpy-Entropy Compensation                 | 20    |
|           | <b>5.6</b>                                     | Thermodynamic Summary Across Compound Classes | 21    |
| <b>6.</b> | <b>COMPREHENSIVE COMPOUND REFERENCE TABLES</b> |   | 21-64 |
|           | <b>6.1</b>                                     | Pharmaceutical Compounds                      | 22    |
|           | <b>6.2</b>                                     | Natural Products and Phytochemicals           | 41    |
|           | <b>6.3</b>                                     | Organic Acids                                 | 46    |
|           | <b>6.4</b>                                     | Industrial and Specialty Chemicals            | 48    |
|           | <b>6.5</b>                                     | Agrochemicals                                 | 62    |
|           | <b>6.6</b>                                     | Energetic Materials                           | 63    |
|           | <b>6.7</b>                                     | Sugars, Polyols, and Amino Acids              | 64    |
| <b>7.</b> | <b>CONCLUSION</b>                              |   | 64-67 |
|           | <b>7.1</b>                                     | Summary of Principal Findings                 | 64    |
|           | <b>7.2</b>                                     | Universal Temperature Dependence              | 65    |
|           | <b>7.3</b>                                     | Dominance of the Modified Apelblat Equation   | 65    |
|           | <b>7.4</b>                                     | Thermodynamic Character                       | 65    |
|           | <b>7.5</b>                                     | Solvent Selection Principles                  | 66    |
|           | <b>7.6</b>                                     | Polymorphism and Solid-Form Considerations    | 66    |
|           | <b>7.7</b>                                     | Implications for Pharmaceutical Development   | 67    |
|           | <b>7.8</b>                                     | Future Research Directions                    | 67    |
| <b>8.</b> | <b>REFERENCE</b>                               |   | 68-95 |

## **1. Introduction**

### **1.1 Background and Significance**

Solubility is among the most fundamentally important physicochemical properties of any chemical substance. Defined as the maximum amount of a solute that dissolves in a given volume of solvent at a specified temperature and pressure to form a stable, homogeneous single-phase solution, solubility governs the behaviour of materials in virtually every domain of chemistry, biology, pharmacology, engineering, and environmental science. The importance of this property spans from molecular-level phenomena such as the formation of crystal lattices and intermolecular hydrogen bonds to macroscopic industrial processes involving crystallisation, purification, separation, and formulation.

In the pharmaceutical industry, the solubility of an active pharmaceutical ingredient (API) is one of the most critical determinants of its clinical utility. According to the Biopharmaceutics Classification System (BCS), the dissolution rate and absorption of a drug from the gastrointestinal tract are directly governed by its aqueous solubility; poorly soluble compounds (BCS Class II and IV) often suffer from inadequate bioavailability, which reduces therapeutic efficacy and necessitates complex formulation strategies. It is estimated that more than 40% of currently marketed drugs and up to 70% of drugs in the development pipeline suffer from poor aqueous solubility, creating a major challenge for the pharmaceutical industry. Consequently, accurate knowledge of the solid-liquid equilibrium (SLE) behaviour of APIs across a range of solvents, co-solvents, and temperatures is indispensable for rational formulation design, process development, and regulatory submissions.

Beyond pharmaceuticals, solubility data are central to a wide spectrum of industrial applications. In the chemical manufacturing sector, the purification of organic compounds through crystallisation depends critically on the differential solubility of product and impurities in chosen solvent systems. The design of crystallisers, centrifuges, dryers, and downstream processing equipment requires detailed SLE data as foundational inputs to thermodynamic process models. In the agrochemical industry, the solubility of pesticide active substances governs formulation type selection (emulsifiable concentrate, wettable powder, suspension concentrate), environmental fate, and regulatory risk assessment. In the food and flavour industry, solubility determines the stability, bioavailability, and sensory profile of food additives and functional ingredients.

The measurement and correlation of solid-liquid equilibria has therefore been an active area of research for over a century, evolving from simple gravimetric determinations to sophisticated dynamic laser monitoring systems combined with advanced thermodynamic frameworks. The availability of standardised analytical equipment, high-performance liquid chromatography, and computational modelling tools has dramatically accelerated the pace of solubility research in the twenty-first century, resulting in thousands of publications annually.

This systematic review represents the first comprehensive synthesis of SLE data for over 200 distinct chemical entities drawn from 296 peer-reviewed articles published in leading international journals between 2012 and 2026. The breadth of compound classes covered pharmaceuticals, natural products, organic acids, industrial intermediates, energetic materials, agrichemicals, and specialty chemicals and the systematic treatment of thermodynamic modelling results make this review a uniquely comprehensive reference work for researchers, formulators, and process engineers worldwide.

## 1.2 Objectives and Scope

The primary objectives of this systematic review are:

- To compile, organise, and critically evaluate experimental solubility data reported for more than 200 chemical compounds across diverse solvent systems and temperature ranges.
- To describe and compare the experimental methodologies employed for solubility measurement, including gravimetric, laser dynamic, HPLC-based, UV-Vis spectrophotometric, and synthetic methods.
- To provide a comprehensive treatment of the theoretical thermodynamic models used to correlate SLE data, including the modified Apelblat equation, Buchowski–Ksiazaczak  $\lambda h$  equation, van't Hoff equation, Wilson model, NRTL model, UNIQUAC model, and various binary solvent models.
- To synthesise thermodynamic functions of dissolution standard molar enthalpy  $\Delta H^\circ$ , entropy  $\Delta S^\circ$ , and Gibbs free energy  $\Delta G^\circ$  across compound classes and identify common patterns and mechanistic insights.
- To analyse the role of solvent properties polarity, hydrogen-bond donor/acceptor capacity, cohesive energy density, and molar volume in determining solubility order and magnitude through KAT-LSER and Hansen solubility parameter frameworks.
- To provide an encyclopaedic reference table of all reviewed compounds incorporating molecular weight, melting point, key physical properties, pharmaceutical or industrial uses, and experimental conditions studied.

The review covers solubility measurements conducted predominantly at atmospheric pressure (0.1 MPa) over temperature ranges from 263 K ( $-10^\circ\text{C}$ ) to 473 K ( $200^\circ\text{C}$ ), with the majority of studies concentrated in the pharmaceutical range of 278–333 K. Both pure solvent and binary mixed solvent systems are covered, and the review includes data for crystalline solids, polymorphic forms, hydrates, and solvates where studied.

## 1.3 Organisation of the Review

The remainder of this review is structured as follows. Section 2 provides a comprehensive description of experimental methods for solubility measurement and solid-phase characterisation. Section 3 presents a detailed synthesis of solubility trends across solvent classes, temperature effects, and the influence of co-solvency

in binary systems. Section 4 describes all major thermodynamic models used in the reviewed literature, with performance benchmarks and guidance for model selection. Section 5 presents a unified thermodynamic analysis of dissolution enthalpy, entropy, Gibbs free energy, and enthalpy–entropy compensation across compound classes. Section 6 provides the comprehensive compound reference tables, which constitute the central data contribution of this review. Section 7 presents conclusions and identifies future research priorities. Section 8 provides the reference list.

#### 1.4 Literature Coverage and Database

The database underlying this review encompasses 296 original research articles published in 23 international journals spanning the period 2012 to 2026. The journals contributing the greatest number of articles include: Journal of Chemical & Engineering Data (J. Chem. Eng. Data), Journal of Chemical Thermodynamics (J. Chem. Thermodyn.), Journal of Molecular Liquids (J. Mol. Liq.), Fluid Phase Equilibria, Industrial & Engineering Chemistry Research (Ind. Eng. Chem. Res.), and Molecules. The publication year distribution shows a clear upward trend, with the number of relevant publications increasing from approximately 15 per year in 2012–2013 to over 40 per year in 2023–2025, reflecting the growing importance of systematic SLE measurements in both pharmaceutical and industrial chemistry.

The compounds covered span a molecular weight range from 53.49 g/mol (ammonium chloride) to 2982.33 g/mol (tylosin tartrate) and a melting point range from approximately 10°C (N-ethyl-2,2-diisopropylbutylamide) to >350°C (cytosine, genistein, triamterene). The solvents studied encompass water, monohydric and polyhydric alcohols, esters, ketones, nitriles, halogenated solvents, polar aprotic solvents (DMSO, DMF, DMAC, NMP), aromatic solvents, and alkane solvents. Binary mixed solvent systems studied include over 50 unique organic solvent + water, organic + organic, and polymer solvent + water combinations. [50], [95], [120], [121], [248]

**Table 1.1 Distribution of reviewed articles across journals.**

| Journal              | Abbreviation | Approx. Articles | Primary Focus                              |
|----------------------|--------------|------------------|--|
| J. Chem. Eng. Data   | JCED         | ~90              | SLE, pharmaceutical solubility             |
| J. Mol. Liq.         | JML          | ~75              | Liquid mixtures, thermodynamics            |
| J. Chem. Thermodyn.  | JCT          | ~55              | Pure solvent SLE, phase equilibria         |
| Fluid Phase Equilib. | FPE          | ~30              | Phase equilibria, process design           |
| Ind. Eng. Chem. Res. | IECR         | ~20              | Industrial processes, reaction engineering |

|                |   |     |  |
|----------------|---|-----|--|
| Molecules      | — | ~15 | Pharmaceutical chemistry, natural products |
| Other journals | — | ~11 | Various specialties                        |

## 2. Experimental Methods for Solubility Measurement

### 2.1 Overview of Experimental Approaches

The accurate determination of solid–liquid equilibrium (SLE) is a foundational requirement for the research reviewed herein. Despite the apparent simplicity of the concept dissolving a solute in a solvent until saturation is reached practical measurement is complicated by factors including kinetic barriers to dissolution, polymorphic transformations, solvate formation, and temperature fluctuations. The reviewed literature employs five primary methodological approaches, each with distinct advantages and limitations. These are described in detail in the following subsections. The choice of method depends on the physical properties of the compound, the available analytical infrastructure, the required precision, and practical considerations such as throughput and scale.

Across all methods, the fundamental measurand is the composition of the saturated solution in equilibrium with excess solid at a specified temperature and pressure. Results are typically reported as mole fraction ( $x_1$ ), mass fraction ( $w_1$ ), or molality ( $m_1$ ), with mole fraction being the most common because it is dimensionless and facilitates direct comparison across solvents with different molar masses. The pressure in virtually all reviewed studies is atmospheric ( $101.3 \pm 1$  kPa), with the exception of a small number of subcritical water studies at 1.5 bar.

### 2.2 Gravimetric (Static Equilibrium) Method

The gravimetric method, also termed the static analytical method or shake-flask method, is the most widely used approach in the reviewed literature, appearing in approximately 200 of the 296 articles. The procedure involves weighing a known excess quantity of finely ground solid solute into a sealed flask containing a precisely weighed or volumetrically measured quantity of solvent. The flask is placed in a thermostatted bath or shaking incubator maintained at the target temperature within  $\pm 0.1$  K, and the suspension is agitated continuously or intermittently for a period of typically 12–72 hours to ensure attainment of thermodynamic equilibrium.

Upon reaching equilibrium, the saturated solution is separated from the excess solid using a membrane filter (0.22 or 0.45  $\mu\text{m}$  pore size) or centrifugation, and an aliquot of known mass or volume is transferred to a pre-weighed vessel. The dissolved solute is then recovered by evaporation of the solvent (under vacuum or at elevated temperature), and the residue is dried to constant weight at 60–80°C. The solubility is calculated from the mass balance. This method is straightforward, requires no

sophisticated instrumentation beyond a precision balance (0.0001 g resolution), and is inherently absolute it does not depend on calibration curves.

Key practical considerations for the gravimetric method include: (i) ensuring true thermodynamic equilibrium is reached (verified by repeating after extended equilibration or by approaching from both undersaturation and supersaturation); (ii) preventing solvent evaporation during equilibration, which would concentrate the solution and overestimate solubility; (iii) confirming that the solid residue has not undergone polymorphic transformation, hydration, or solvation during the measurement period; and (iv) accounting for potential solvent carry-over in the residue when the solvent has high boiling point or forms azeotropes.

The relative uncertainty of the gravimetric method is typically  $\pm 0.5\text{--}3\%$ , arising from weighing precision, filtration losses, and evaporation incompleteness. For very low solubility compounds ( $<10^{-4}$  mole fraction), the uncertainty may be higher due to the small mass of dissolved solute relative to the total solution mass, and alternative methods such as HPLC are preferred.

### **2.3 Laser Dynamic Monitoring Method**

The laser dynamic method, also called the polythermal or synthetic method with laser detection, is the second most common approach in the reviewed literature (~70 articles). In this technique, the saturation temperature of a solution of known composition is determined rather than the solubility at a fixed temperature. A suspension of known solute mass in known solvent mass is prepared in a jacketed equilibrium vessel equipped with a temperature controller, magnetic stirrer, and a laser beam–detector pair aligned across the vessel.

The suspension is heated at a controlled slow rate (typically  $0.01\text{--}0.05\text{ K min}^{-1}$ ) while the transmitted laser intensity is continuously monitored. As the suspension heats, the last solid crystal dissolves at the saturation temperature corresponding to that composition, causing a sudden increase in laser transmission (the 'clear point'). This temperature is recorded as the saturation point. By preparing multiple samples at different solid: solvent mass ratios and measuring their clear points, an entire solubility–temperature curve is constructed.

The laser dynamic method offers significant advantages over the gravimetric method for compounds with very low solubility at low temperatures or those exhibiting strong temperature dependence. It is particularly efficient for mapping broad temperature ranges in a single experimental run. Commercial instruments such as the Crystal16 and Crystalline (Technobis) automate the procedure using turbidity (not pure laser transmission), enabling high-throughput solubility screening with very small sample quantities (1–3 mL). The temperature uncertainty of modern instruments is  $\pm 0.1\text{ K}$ , and the solubility uncertainty is typically  $\pm 1\%$ .

A significant advantage of the polythermal approach is that it inherently verifies the reversibility of dissolution the solution can be cooled to confirm re-crystallisation at a consistent temperature, thus confirming equilibrium conditions. This method was used, for example, in studies of actarit in 12 solvents (2022), marbofloxacin in binary aqueous systems (2022), and terbinafine hydrochloride across 13 alcohols (2023).<sup>[11], [24], [25]</sup>

## **2.4 High-Performance Liquid Chromatography (HPLC) Method**

HPLC-based quantification of dissolved solute is employed in approximately 50 of the reviewed articles, predominantly for pharmaceutical compounds with complex UV spectra, thermally labile molecules, or situations where precise absolute quantification is required at low concentrations. In this method, the static equilibrium approach is used to prepare saturated solutions, but instead of gravimetric analysis, the concentration of dissolved solute in filtered aliquots is determined by HPLC against a calibrated external standard curve.

Reverse-phase HPLC with UV detection at the compound's maximum absorption wavelength is the most common configuration. Calibration standards are prepared gravimetrically in the same solvent at concentrations spanning the expected solubility range. The relative uncertainty of HPLC quantification is typically  $\pm 0.5\text{--}2\%$ , comparable to or better than gravimetric analysis for low-solubility compounds. HPLC was employed in studies including dienogest in 12 solvents (2019), mifepristone in pure and binary solvents (2019), cyproterone acetate in 14 pure solvents (2020), and progesterone in 12 solvents (2021).<sup>[45], [104], [175], [226]</sup>

## **2.5 UV-Vis Spectrophotometric Method**

UV-Vis spectrophotometry provides a rapid, sensitive method for quantifying dissolved solute concentration without the separation step required in HPLC. Saturated solutions are prepared by the static equilibrium method, filtered, and analysed at the compound's characteristic UV absorption wavelength. Calibration follows Beer-Lambert law. The method is particularly suited to aromatic and conjugated compounds with strong UV absorption ( $\epsilon > 1000 \text{ L mol}^{-1} \text{ cm}^{-1}$ ). UV spectrophotometry was employed in studies of emtricitabine in PEG-400 + water mixtures (2020), rhein in eight solvents (2015), caffeic acid in binary systems (2016), and baicalein in ethanol + water (2019). A key limitation is that the solvent must be transparent at the measurement wavelength, precluding use with aromatic solvents such as toluene or benzene for many compounds. The uncertainty is typically  $\pm 1\text{--}3\%$ .<sup>[5], [23], [36], [123], [166]</sup>

## **2.6 Synthetic Method with Visual Observation**

The synthetic (polythermal) method with visual observation rather than laser detection is a classical approach in which the temperature at which the last solid

dissolves in a solution of known composition is determined by visual inspection through an illuminated window of a jacketed equilibrium vessel. This method preceded the laser monitoring approach and was used in earlier studies. It remains employed when the compound forms coloured solutions or when the crystal–solution optical contrast is high. The uncertainty of the visually determined clear point is typically  $\pm 0.5$ –1 K, somewhat higher than laser detection.

## 2.7 Solid-Phase Characterisation Techniques

Verification of solid-phase identity before and after solubility measurements is a critical quality control requirement. Polymorphic transformation, solvate formation, or hydration during equilibration invalidates the assumption of a pure crystalline phase and renders solubility data unusable. The reviewed articles consistently employ the following solid-state analytical techniques:

- Powder X-ray diffraction (PXRD): The primary method for confirming crystal form identity. Changes in peak positions or relative intensities between the starting material and the post-equilibration solid indicate phase transformation. PXRD patterns were verified in studies of linezolid form II (2017), favipiravir (2023), clarithromycin form II (2022), nortriptyline hydrochloride (2025), and approximately 150 other articles. [71], [90], [119]
- Differential scanning calorimetry (DSC): Provides melting point ( $T_m$ ), enthalpy of fusion ( $\Delta_{fus}H_m$ ), and identifies solvates (endotherms before  $T_m$ ). DSC data are also used to calculate ideal solubility and activity coefficients. Studies using DSC include cytarabine (2017), levetiracetam (2018), nicotinamide (2014), and over 100 others. [26], [38]
- Fourier-transform infrared spectroscopy (FTIR/ATR): Confirms molecular identity and detects solvate formation through characteristic O–H and N–H stretching shifts. Used in studies of doxofylline (2020), diprophylline (2019), and others. [70], [245], [249]
- Thermogravimetric analysis (TGA): Detects weight loss from solvent release (solvates) or decomposition onset temperature. Allantoin stability was verified by TGA (2023). [112]
- Scanning electron microscopy (SEM): Morphological changes in crystal habit before and after equilibration can signal surface transformations. Used in rebamipide particle size studies (2019). [126]

## 2.8 Temperature Ranges and Experimental Conditions

- The temperature ranges investigated across the 296 reviewed studies reflect diverse application needs. The most commonly studied range is 278.15–323.15 K (5–50°C), encompassing ambient and body temperature conditions relevant to pharmaceutical processing and formulation. Extended ranges up to 363.15 K are employed for industrial crystallisation design, and subcritical conditions up to 433.15 K were used for curcumin in water (2019). A small number of studies

extend below 278.15 K down to 263.15 K for cryogenic crystallisation applications. <sup>[10]</sup>

- Temperature control precision is critical: most studies report thermostatic bath temperature accuracy of  $\pm 0.1$  K, while some instruments achieve  $\pm 0.02$  K. Pressure was maintained at atmospheric ( $101.3 \pm 1$  kPa) in all studies except the subcritical water study (1.5 bar). Temperature increments are typically 5 K intervals, providing 5–10 data points per temperature–solvent combination.

**Table 2.1 Comparison of experimental methods for solubility determination**

| Method                      | Uncertainty            | Articles (~) | Best Used For                                |
|-----------------------------|------------------------|--------------|--|
| Gravimetric (shake-flask)   | $\pm 0.5$ –3%          | ~200         | General purpose; moderate to high solubility |
| Laser dynamic (polythermal) | $\pm 0.1$ K; $\pm 1\%$ | ~70          | Strong T-dependence; low solubility systems  |
| HPLC quantification         | $\pm 0.5$ –2%          | ~50          | Low solubility; complex matrices; APIs       |
| UV-Vis spectrophotometry    | $\pm 1$ –3%            | ~30          | Chromophoric compounds; rapid screening      |
| Synthetic / visual          | $\pm 0.5$ –1 K         | ~15          | Coloured solutions; classical applications   |

### 3. Result and Discussion

#### 3.1 General Solubility Trends

A universal finding across all 296 reviewed studies is that mole fraction solubility increases monotonically with temperature for the overwhelming majority (>92%) of compound–solvent pairs investigated. This fundamental observation is rooted in thermodynamics: for endothermic dissolution processes ( $\Delta H^\circ > 0$ ), the Van't Hoff equation predicts increasing solubility as temperature rises, because the Gibbs free energy of the system decreases as the entropy term ( $-T\Delta S^\circ$ ) becomes more negative at higher temperatures. The quantitative expression is Eq.1, from which  $\Delta H^\circ$  is typically extracted.

$$\frac{d \ln X}{d\left(\frac{1}{T}\right)} = \frac{-\Delta H^\circ}{R} \quad (1)$$

The magnitude of solubility varies across solvents by several orders of magnitude for a given compound. For example, the antifungal drug itraconazole shows mole fraction solubility spanning from  $\sim 10^{-6}$  in water to  $\sim 10^{-1}$  in dimethylsulfoxide at 318 K a range of approximately five orders of magnitude. The antiretroviral emtricitabine ranges from  $7.95 \times 10^{-3}$  in pure water to  $1.45 \times 10^{-1}$  in pure PEG-400 at 318.2 K about a 20-fold variation. These dramatic solvent effects underscore the central role of solute–

solvent interactions and solvent cohesive energy in determining solubility. [5], [36], [92], [196]

## 3.2 Solubility in Polar Protic Solvents

### 3.2.1 Water

Water is the most important solvent for pharmaceutical applications due to its physiological relevance and regulatory acceptance. However, water is a poor solvent for the majority of organic compounds in the reviewed database due to its extremely high cohesive energy density ( $\delta = 47.9 \text{ MPa}^{0.5}$ ) and strong self-association through hydrogen bonding. The energetic cost of creating a cavity in liquid water to accommodate an organic solute molecule is substantial, particularly for large, lipophilic molecules. Consequently, mole fraction solubilities in pure water are typically in the range  $10^{-7}$  to  $10^{-3}$  for most APIs.

Notable exceptions include:  $\alpha$ -glycine (highly water-soluble due to zwitterionic character), nicotinamide (water-soluble B-vitamin), l-glutamic acid (charged amino acid), ascorbic acid (vitamin C,  $x\text{H}_2\text{O}$ ) which all show water solubilities in the range  $10^{-2}$  to  $10^{-1}$ . Compounds with multiple hydrogen-bond donors and acceptors (e.g., dihydromyricetin, N-acetylglucosamine, D-tagatose) show moderate water solubility. [38], [64], [69], [76], [182]

### 3.2.2 Alcohols

The monohydric alcohols (methanol, ethanol, propanols, butanols, pentanols) constitute the most extensively studied solvent class in the reviewed literature, appearing in virtually every study. Solubility in this series typically decreases with increasing carbon chain length (and decreasing polarity): methanol > ethanol > n-propanol > isopropanol > n-butanol > n-pentanol. This trend is observed for compounds including cabozantinib malate, febuxostat, domiphen bromide, carvedilol, clotrimazole, and bicalutamide. [9], [89], [108], [109], [135]

This alcohol chain-length effect arises from the decreasing hydrogen-bond donor capacity ( $\alpha$  parameter in Kamlet-Taft scale) and decreasing polarity ( $\pi^*$ ) as chain length increases, reducing the solvation enthalpy for polar solutes. Simultaneously, the molar volume increases along the homologous series, which increases the free-energy cost of creating a cavity. The combined effect consistently reduces solubility.

Exceptions to the chain-length trend exist for compounds where specific steric matching or hydrophobic interactions with longer chain solvents are favourable. Terbinafine hydrochloride shows highest solubility in cyclohexanol and n-propanol rather than methanol (2023), attributed to favourable hydrocarbon interactions with the compound's lipophilic terbinylyl moiety. Carvedilol (Form I) shows highest solubility in PEG-400 and tetrahydrofuran rather than any simple alcohol (2019), reflecting the compound's high lipophilicity and strong preference for aprotic environments. [24], [136], [151]

### 3.2.3 Polyhydric Alcohols and Polymer Solvents

Ethylene glycol, propylene glycol (PG), polyethylene glycol-400 (PEG-400), Transcutol-HP (diethylene glycol monoethyl ether), and glycerol were studied as solvents for several pharmaceutical compounds, particularly in the context of aqueous co-solvent systems for injectable formulations. PEG-400 consistently provided the highest solubility among mono-solvents for several poorly water-soluble drugs: pterostilbene ( $3.73 \times 10^{-1}$  at 318.2 K), emtricitabine ( $1.45 \times 10^{-1}$ ), isotretinoin ( $1.02 \times 10^{-1}$ ), aceclofenac ( $1.04 \times 10^{-1}$ ), and febuxostat ( $3.06 \times 10^{-2}$ ). The high solvation power of PEG-400 for lipophilic compounds arises from its amphiphilic character, low polarity compared to water, and the ability of its ether oxygen atoms to hydrogen-bond with solute donors. [5], [36], [101], [108], [134]

### 3.3 Solubility in Polar Aprotic Solvents

Polar aprotic solvents-DMSO, DMF, DMAC, NMP, acetone, acetonitrile, 1,4-dioxane, tetrahydrofuran generally provides the highest solubility for most organic solids in the reviewed dataset. This is because polar aprotic solvents have high dielectric constants and strong hydrogen-bond acceptor capacity (high  $\beta$  values) without the strong self-association of protic solvents, making them highly effective at solvating diverse solute types.

DMSO (dimethyl sulfoxide) was identified as the best solvent in numerous studies: cabozantinib malate (DMSO:  $4.35 \times 10^{-2}$  vs. water:  $8.5 \times 10^{-7}$ , ratio ~51,000 at 318.2 K), favipiravir (DMF:  $2.60 \times 10^{-2}$  at 333.15 K), isotretinoin (DMSO:  $1.02 \times 10^{-1}$ ), itopride hydrochloride (DMSO: 28.06 g/100g at 298.15 K), and 1-hydroxybenzotriazole (DMF: highest solubility at 313.15 K). The superiority of DMF/DMSO for aromatic heterocycles and nitrogen-containing APIs reflects the strong dipole-dipole and  $n-\pi$  interactions between these solvents and the aromatic/heteroaromatic solute framework. [9], [89], [90], [122], [129]

Acetone is particularly effective for compounds with carbonyl groups (through dipole matching) or aromatic systems with limited hydrogen-bond donors. Sulfanilamide showed highest solubility in acetone among 12 studied solvents (2019). Indapamide and actarit exhibited highest solubility in acetone. Acetonitrile, despite its high polarity, often shows lower solubility than expected due to its poor hydrogen-bond donor/acceptor balance and high surface tension. [11], [80], [105]

### 3.4 Solubility in Non-Polar and Low-Polarity Solvents

Non-polar solvents including toluene, xylene, cyclohexane, n-hexane, n-heptane, chloroform, dichloromethane, and carbon tetrachloride are studied primarily for highly lipophilic compounds. Based on 'like dissolves like', lipophilic solutes typically dissolve better in non-polar solvents, and indeed several examples confirm this: progesterone shows highest solubility in toluene (0.2249 mole fraction at high temperature); the energetic compound 1,3-dinitropyrazole shows remarkably high

solubility in acetonitrile ( $48.2 \times 10^{-2}$  mol/mol) and acetone ( $45.0 \times 10^{-2}$ ) vs. only  $0.05 \times 10^{-2}$  in water; capsaicin dissolves readily in non-polar ether solvents; musk ketone dissolves best in DMAC and DMF. [62], [102], [116], [226], [266]

Chlorinated solvents (dichloromethane, chloroform, 1,2-dichloroethane) often provide surprisingly high solubility due to their ability to act as weak hydrogen-bond donors (through C-H bonds and enhanced by the electron-withdrawing chlorine atoms) while having low cohesive energy densities. Cyclododecanone showed highest solubility in 1,2-dichloroethane. Nintedanib showed highest solubility in dichloromethane (0.1314 mole fraction at 308.15 K). Fluorene solubility decreases with increasing solvent polarity, consistent with its non-polar PAH structure. [133], [148], [272]

### 3.5 Effect of Temperature on Solubility

The van't Hoff equation quantitatively describes the temperature dependence of solubility through the relationship Eq.2. The slope of the  $\ln(x)$  vs.  $1/T$  plot equals  $-\Delta H^\circ/R$ , and its linearity confirms constant  $\Delta H^\circ$  over the temperature range studied. Non-linearity in the Van't Hoff plot (curvature) is common for wide temperature ranges and is better described by the modified Apelblat equation, which allows for temperature-dependent enthalpy.

$$\ln X = \frac{-\Delta H^\circ}{RT} + \frac{\Delta S^\circ}{R} \quad (2)$$

Quantitatively, the sensitivity of solubility to temperature is characterised by the temperature coefficient  $d(x)/dT$ , which ranges widely across compounds and solvents. For water-soluble salts like ammonium chloride, sodium acetate, and potassium benzoate, temperature coefficients are relatively modest ( $\sim 1$ – $5\%$  per K). For organic compounds in organic solvents, coefficients of  $2$ – $15\%$  per K are common. Extremely high temperature sensitivity is observed for some systems: clorsulon in ethylene glycol shows a 20-fold increase in solubility over the range  $293$ – $333$  K (2021), attributed to the temperature-dependent formation and disruption of hydrogen bond networks between the compound's sulfonamide groups and the glycol hydroxyl groups. [49], [186], [203], [291]. The effect of temperature on solubility in binary solvent systems follows more complex patterns. For mixtures where both co-solvent and temperature effects are synergistic (organic solvent + water systems), solubility increases monotonically with both temperature and organic solvent fraction. In some systems, however, solubility maxima (co-solvency peaks) shift with temperature the maximum moves to different composition at different temperatures, as observed for edaravone (2019) and diprophylline (2019). [111], [245]

### 3.6 Binary Solvent Systems and Co-Solvency

Binary solvent systems offer a powerful tool for fine-tuning solubility for crystallisation and purification operations. Over 100 of the 296 reviewed articles study binary mixed solvents, typically comprising an organic solvent + water or two

miscible organic solvents. The key phenomena observed in these systems include co-solvency, antisolvent effects, and maximum solubility at intermediate compositions.

Co-solvency refers to the phenomenon where solubility in a binary mixture exceeds that predicted by linear interpolation between the pure-solvent solubilities. This arises when the mixture composition creates an optimal balance of solvent properties (polarity, hydrogen-bond capacity, cohesive energy density) that better matches the solute's requirements than either pure component. The co-solvency effect is quantified by the maximum/minimum ratio of solubility at the peak composition to the linear interpolation value, which can be as large as 10-fold for strongly non-ideal systems.

Notable co-solvency examples from the reviewed literature include: pazopanib in ethyl acetate + ethanol (maximum at EtAc = 0.60, 4.37-fold enhancement at 288.15 K); eszopiclone in binary organic mixtures (synergistic solubility peaks); edaravone in propanol + water (maximum at w\_propanol = 0.60); doxofylline in isopropanol + ethyl acetate (monotonic increase with ethyl acetate fraction). The Jouyban–Acree model and CNIBS/R-K model are the most commonly employed frameworks for correlating binary solvent solubility data. [70], [111], [117], [137], [249]

The antisolvent effect, where addition of a miscible solvent dramatically reduces solubility, is widely exploited in antisolvent crystallisation. Water addition to organic solvent systems typically reduces solubility for hydrophobic APIs, enabling controlled precipitation at desired particle sizes. This was studied for l-glutamic acid in methanol + water and acetonitrile + water (2019), rivaroxaban polymorphs in various organic solvents (2017), and many other systems. [161], [222]

### 3.7 Solvent Effect Analysis (KAT-LSER and HSP)

Quantitative structure–solubility relationships based on solvent properties were reported in approximately 90 of the reviewed articles. The two most widely used frameworks are the Kamlet–Abboud–Taft linear solvation energy relationship (KAT-LSER) and Hansen solubility parameters (HSP). These approaches provide mechanistic insight into which specific solvent–solute interactions govern solubility magnitude and order.

The KAT-LSER model expresses  $\ln(x)$  as a linear combination of solvent descriptors:

$$\ln(x) = c_0 + c_1\alpha + c_2\beta + c_3\pi^* + c_4(\delta H)^2 \quad (3)$$

where  $\alpha$  is hydrogen-bond acidity,  $\beta$  is hydrogen-bond basicity,  $\pi^*$  is dipolarity/polarizability, and  $\delta H$  is the Hildebrand solubility parameter (cavity term). The regression coefficients  $c_1$ – $c_4$  indicate the relative importance of each interaction type. Key findings from KAT-LSER analyses include:

- For compounds with multiple hydrogen-bond acceptors (e.g., actarit 2022, isovanillin 2021, adefovir 2024): the  $\beta$  coefficient dominates, confirming that solvent hydrogen-

bond basicity (accepting H from solute donors) is the primary dissolution driver. [11], [59], [168]

- For aromatic compounds with polarisable electron clouds (e.g., nevirapine 2022, itraconazole 2021, tanshinone I 2025): the  $\pi^*$  coefficient dominates, indicating that dipolarity/polarizability interactions are critical. [86], [92], [155], [196]
- For all systems: the cavity term  $(\delta H)^2$  typically carries a negative coefficient, indicating that high-cohesive-energy solvents (water, glycols) reduce solubility due to the energetic cost of cavity formation. This term is the primary reason for poor aqueous solubility of most organic compounds.

Hansen solubility parameters (HSPs) were calculated for solutes using group contribution methods and HSPiP software in approximately 80 articles. The three Hansen parameters- dispersion ( $\delta D$ ), polar ( $\delta P$ ), and hydrogen bonding ( $\delta H$ ) together characterise the compound's total cohesion energy. The relative energy difference (RED =  $R_a/R_0$ , where  $R_a$  is the distance in Hansen space between solute and solvent, and  $R_0$  is the solute's interaction radius) predicts miscibility: RED < 1 typically indicates good solubility. HSP analysis consistently identified the optimal solvents and confirmed experimental solubility order. For emtricitabine, the HSP analysis confirmed PEG-400 as the closest matching solvent. For brigatinib, ethanol was identified as the closest match. For cabozantinib malate, DMSO was closest. [5], [6], [9], [36], [89]

## 4. Theoretical Thermodynamic Models

### 4.1 Introduction to SLE Modelling

The experimental solubility data presented in the reviewed literature are invariably accompanied by mathematical correlation using thermodynamic or semi-empirical models. Model correlation serves multiple purposes: it smooths experimental data and enables interpolation at unmeasured temperatures; it provides thermodynamic parameters ( $\Delta H^\circ$ ,  $\Delta S^\circ$ ,  $\Delta G^\circ$ ) through the model equations; it enables comparison of data quality across different studies; it provides a compact representation of solubility data for process simulation; and it allows limited extrapolation within the studied temperature range. A model is evaluated by the average relative deviation (ARD), defined as Eq.4, and the root-mean-square deviation (RMSD), defined as Eq.5, where  $n$  is the number of data points. An ARD below 5% is generally considered acceptable, below 2% is good, and below 1% is excellent. The Akaike Information Criterion (AIC), which penalises model complexity, is used in a minority of articles to select among models with different numbers of parameters.

$$ARD = \frac{1}{N} \sum_i^N \left( \frac{x_{exp} - x_{cal}}{x_{exp}} \right) \quad (4)$$

$$RMSD = \left[ \sum_{i=1}^N \left( \frac{x_{cal} - x_{exp}}{N} \right)^2 \right]^{\frac{1}{2}} \quad (5)$$

## 4.2 Modified Apelblat Equation

The modified Apelblat equation is the most widely used SLE model in the reviewed literature, appearing in over 280 of the 296 articles and consistently providing the best or near-best fitting performance. Originally derived as an empirical extension of the ideal solubility equation to account for non-ideal mixing and temperature-dependent activity coefficients, it takes the form:

$$\ln(x) = A + B/T + C \cdot \ln(T) \quad (6)$$

where  $x$  is the equilibrium mole fraction solubility,  $T$  is the absolute temperature (K), and  $A$ ,  $B$ ,  $C$  are dimensionless temperature-independent fitting parameters determined by nonlinear regression on the experimental data. The three parameters confer exceptional flexibility: the  $B/T$  term captures the dominant enthalpic contribution to solubility (equivalent to the van't Hoff term), the  $C \cdot \ln(T)$  term accounts for temperature-dependent heat capacity of dissolution ( $\Delta C_p \neq 0$ ), and the constant  $A$  encompasses the entropic contribution.

The physical interpretation of the Apelblat parameters connects to thermodynamic quantities:

$$\Delta H^\circ = R(C \cdot T - B) \quad (7)$$

$$\Delta S^\circ = R(A + C + C \cdot \ln T) \quad (8)$$

$$\Delta G^\circ = \Delta H^\circ - T \cdot \Delta S^\circ \quad (9)$$

However, because the parameters are strongly correlated, their individual physical significance is limited, and thermodynamic properties are more reliably extracted from the van't Hoff equation applied to the Apelblat-fitted solubility values.

Statistical performance across the reviewed dataset: the modified Apelblat equation achieves ARD values below 2% for >90% of compound-solvent combinations, with typical RMSD values in the range  $10^{-5}$  to  $10^{-3}$ . Representative examples of its superior performance include: chlorzoxazone ( $R^2 > 0.99$  for all 4 solvents, 2022); *m*-aminobenzoic acid (ARD < 2% for 12 solvents, 2021); bicalutamide form I (best correlation among tested models, 2023); favipiravir (ARD = 1.75% averaged over 12 solvents, 2023).<sup>[41], [90], [110], [184], [267]</sup>

## 4.3 Buchowski-Ksiazaczak $\lambda h$ Equation

The  $\lambda h$  (lambda-h) equation, derived from Buchowski and Ksiazaczak's theoretical treatment of solid-liquid equilibria, is a two-parameter model with stronger physical basis than the empirical Apelblat equation. Its functional form is:

$$\ln\left(1 + \frac{\lambda(1-x_{\text{exp}})}{x_{\text{exp}}}\right) = \lambda h \left[\frac{1}{T} - \frac{1}{T_m}\right] \quad (10)$$

where  $\lambda$  is the average number of solvent molecules associating with one solute molecule (association parameter),  $h$  is the dissolution enthalpy (kJ/mol) multiplied

by  $R$ , and  $T_m$  is the melting point of the pure solute (K). The equation explicitly incorporates the melting point as a reference point and reduces to the ideal solubility equation when  $\lambda = 1$  and  $h = \Delta H_{fus}$ .

The  $\lambda h$  equation typically achieves ARD values of 1–5%, somewhat higher than the Apelblat equation due to its fewer parameters. However, it performs comparably to Apelblat for systems with linear van't Hoff plots. Its physical parameters ( $\lambda$ ,  $h$ ) provide direct information about solute–solvent association stoichiometry and dissolution enthalpy, making it valuable for mechanistic interpretation. The  $\lambda h$  model was identified as superior to Apelblat for: urea in polar protic solvents (2025), 2-naphthaldehyde (2015), dibenzothiophene in selected solvents (2019), and quetiapine fumarate in several solvents (2025). [12], [87], [235], [256]

#### 4.4 Van't Hoff Equation

The two-parameter van't Hoff equation is the thermodynamic foundation of SLE analysis. While its two parameters provide less flexibility than the three-parameter Apelblat equation, its direct connection to thermodynamic properties ( $A = \Delta S^\circ/R$ ,  $B = -\Delta H^\circ/R$ ) makes it indispensable for extracting thermodynamic functions. The van't Hoff equation is applied either directly to experimental data or to smoothed values from the Apelblat equation.

$$\ln(\mathbf{x}) = \mathbf{A} + \mathbf{B}/\mathbf{T} \quad (11)$$

$$\ln(\mathbf{x}) = \Delta \mathbf{S}^\circ / \mathbf{R} - \Delta \mathbf{H}^\circ / \mathbf{R} \mathbf{T} \quad (12)$$

A useful extension is the three-parameter van't Hoff equation:  $\ln(\mathbf{x}) = \mathbf{A} + \mathbf{B}/\mathbf{T} + \mathbf{C} \cdot \mathbf{T}$ , which allows for a linear temperature dependence of  $\Delta H^\circ$  (i.e.,  $\Delta C_p = \text{constant}$ ). This form was employed in studies of amitriptyline hydrochloride (2021) and terbinafine hydrochloride (2023). The standard form (two-parameter) was identified as the best model in studies of N, N'-oxalyldiglycine (2023) and nicotinamide (2014). [24], [38], [51]

#### 4.5 Wilson Model

The Wilson equation, one of the earliest activity coefficient models based on local composition theory, expresses the activity coefficient ( $\gamma$ ) of the solute as a function of the mole fraction composition of the solution. For solid–liquid equilibria under ideal fusion assumption ( $\Delta C_p = 0$ ):

$$\ln(\mathbf{x} \cdot \boldsymbol{\gamma}) = \Delta \mathbf{H}_{fus} / \mathbf{R} \cdot (\mathbf{1}/\mathbf{T}_m - \mathbf{1}/\mathbf{T}) \approx \ln(\mathbf{x}_{ideal}) + \ln(\boldsymbol{\gamma}) \quad (13)$$

where  $\mathbf{x}_{ideal}$  is the ideal solubility calculated from melting properties. The Wilson equation requires two binary interaction parameters ( $\Lambda_{12}$ ,  $\Lambda_{21}$ ) per solvent–solute pair, related to molar volumes and interaction energies. Its limitation is inability to predict liquid–liquid immiscibility (negative activity coefficients). The Wilson model was superior to Apelblat in studies of thymol in six solvents (2016), where the calculated mixing thermodynamic properties ( $\Delta G_{mix}$ ,  $\Delta H_{mix}$ ,  $\Delta S_{mix}$ ) provided mechanistic

insight. It was also identified as best for cyclododecanone (2023) and diphenolic acid (2025) among the models tested. [19], [133], [285]

#### 4.6 NRTL Model

The Non-Random Two-Liquid (NRTL) model of Renon and Prausnitz (1968) is the most versatile local composition activity coefficient model in the reviewed literature, capable of describing both VLE and LLE and applicable to strongly non-ideal systems. It has three adjustable parameters per binary pair: the interaction energy parameters  $\tau_{12}$  and  $\tau_{21}$ , and the non-randomness factor  $\alpha_{12}$  (typically fixed at 0.2–0.3 for liquid–liquid systems or 0.47 for liquid–solid systems in the absence of phase splitting data). NRTL was identified as the best correlating model in multiple studies: marbofloxacin in acetonitrile + water and methanol + water (2022), itopride hydrochloride in all 11 studied solvents (2024), dabigatran etexilate mesylate in selected solvents (2016), and rebamipide (2019). Its widespread use for pharmaceutical compounds reflects its ability to handle the strongly non-ideal activity coefficients characteristic of polar solutes in non-aqueous or mixed solvents. The NRTL model also provides mixing thermodynamic properties ( $\Delta_{\text{mix}}G$ ,  $\Delta_{\text{mix}}H$ ,  $\Delta_{\text{mix}}S$ ) through statistical mechanical relations, which are reported in approximately 50 of the reviewed articles. [25], [122], [126]

#### 4.7 UNIQUAC Model

The Universal Quasi-Chemical (UNIQUAC) model of Abrams and Prausnitz (1975) extends the quasi-chemical lattice theory to account for molecular size and shape differences through structural parameters  $r$  (volume parameter) and  $q$  (surface area parameter). It is particularly well-suited for systems containing molecules of very different sizes, such as pharmaceuticals with large molecular weight compared to their solvents.

UNIQUAC was applied in studies of mifepristone (2019), dienogest (2019), cyproterone acetate (2020), itraconazole (2021), praziquantel (2020), cefixime trihydrate (2020), and rivaroxaban polymorphs (2017). In most cases, it performs comparably to NRTL, with neither model consistently superior. Some studies found UNIQUAC superior for systems with large size differences (e.g.,  $\beta$ -cyclodextrin, macrolide antibiotics). [45], [92], [157], [161], [175]

#### 4.8 Jouyban–Acree and Binary Solvent Models

For binary solvent mixtures, specialised cosolvency models extend the pure-solvent correlations. The Jouyban–Acree (J-A) model combines the temperature-dependent pure-solvent solubility with interaction terms:

$$\ln(\mathbf{x}_m) = \varphi_1 \cdot \ln(\mathbf{x}_1) + \varphi_2 \cdot \ln(\mathbf{x}_2) + \varphi_1 \varphi_2 \cdot \Sigma[A_i(\varphi_1 - \varphi_2)]/T \quad (14)$$

where  $\varphi_1$  and  $\varphi_2$  are volume fractions of the two solvents,  $\mathbf{x}_1$  and  $\mathbf{x}_2$  are solubilities in pure solvents, and  $A_i$  are fitting parameters. Modified versions incorporating the

Apelblat temperature function (Apelblat-Jouyban-Acree, A-J-A) or van't Hoff temperature function (van't Hoff-Jouyban-Acree, V-J-A) extend the model to cover both temperature and composition simultaneously. The CNIBS/R-K (Combined Nearly Ideal Binary Solvent/Redlich-Kister) model is another widely used approach for binary solvent data, using a polynomial expansion in solvent volume fraction at constant temperature.

The A-J-A model provided the best correlation in studies of 1,3-dinitropyrazole in aqueous alcohol systems (2025) and spectinomycin dihydrochloride (2024). The CNIBS/R-K model was best for nifedipine in binary solvents (2016), omeprazole in binary solvents (2016), and several others. [32], [81], [116]

#### 4.9 Model Selection Guidance

Based on the comprehensive performance comparison across 296 studies, the following practical guidance is offered for model selection in SLE data correlation: For pure solvent systems with 5–10 data points over a 40–50 K range: Begin with the modified Apelblat equation. If  $R^2 > 0.9999$  and  $ARD < 2\%$ , Apelblat is sufficient. Also test the  $\lambda h$  and van't Hoff equations for comparison.

For systems where thermodynamic mixing properties are needed: Use the Wilson or NRTL model, which provide physically meaningful mixing enthalpy, entropy, and Gibbs energy through model parameters.

For systems with very low solubility ( $<10^{-4}$  mole fraction): The van't Hoff equation may be most appropriate, as Apelblat over-parameterises noisy data. The  $\lambda h$  model is also suitable if  $T_m$  is known precisely.

For binary solvent systems at constant temperature: Use the CNIBS/R-K model (3–5 parameters). For combined temperature + composition dependence: use A-J-A or V-J-A models.

For model comparison and selection, use both ARD and RMSD alongside AIC where applicable, as lower ARD does not always reflect better physical meaningfulness.

**Table 4.1 Comparative summary of SLE thermodynamic models reviewed**

| Model                   | Params | Typical ARD | Studies | Best Application                                  |
|-------------------------|--------|-------------|---------|---|
| Modified Apelblat       | 3      | <2%         | >280    | All SLE; non-linear T dependence; general purpose |
| $\lambda h$ (Buchowski) | 2      | <4%         | >250    | Pure solvents; systems with accurate $T_m$ data   |

|               |        |     |      |   |
|---------------|--------|-----|------|---|
| van't Hoff    | 2      | <4% | >200 | Linear T range; direct $\Delta H^\circ$ , $\Delta S^\circ$ extraction |
| Wilson        | 2/pair | <5% | ~120 | Mixing properties; non-electrolyte systems                            |
| NRTL          | 3/pair | <5% | ~130 | Polar/non-ideal; mixing properties; VLE+LLE                           |
| UNIQUAC       | 2/pair | <5% | ~60  | Size-different molecules; polymers + APIs                             |
| Jouyban-Acree | 3+     | <6% | ~100 | Binary and ternary mixed solvents                                     |
| CNIBS/R-K     | 3-5    | <5% | ~80  | Constant-T binary solvent composition effects                         |

## 5. Thermodynamic Analysis of Dissolution

### 5.1 Thermodynamic Framework

The thermodynamic analysis of dissolution provides quantitative insight into the energetics and molecular mechanisms governing the transfer of solute from the ordered crystalline phase to the disordered solution phase. At constant temperature and pressure, the transfer is described by the standard Gibbs free energy of dissolution:

$$\Delta G^\circ = \Delta H^\circ - T\Delta S^\circ = -RT \cdot \ln(x \cdot \gamma) \quad (15)$$

where  $x$  is the mole fraction solubility,  $\gamma$  is the activity coefficient of the solute in the saturated solution ( $\gamma = 1$  for an ideal solution),  $R$  is the gas constant ( $8.314 \text{ J mol}^{-1} \text{ K}^{-1}$ ), and  $T$  is the absolute temperature. From the temperature dependence of solubility, the standard molar enthalpy and entropy of dissolution are obtained via the van't Hoff analysis:

$$\Delta H^\circ = -R \cdot [\partial \ln(x) / \partial (1/T)] \quad \text{and} \quad \Delta S^\circ = (\Delta H^\circ - \Delta G^\circ) / T \quad (16)$$

In practice, a mean harmonic temperature  $T_{hm}$  is used to calculate  $\Delta G^\circ$  at a representative temperature, defined as the harmonic mean of the studied temperature range:  $T_{hm} = n / \sum(1/T_i)$ . This allows comparison of  $\Delta G^\circ$ ,  $\Delta H^\circ$ , and  $\Delta S^\circ$  across different compounds studied over slightly different temperature windows.

The relative contributions of enthalpy and entropy to the dissolution Gibbs energy are quantified by:

$$\zeta_{TH} = \frac{|\Delta H^\circ|}{|\Delta H^\circ| + |T\Delta S^\circ|} \quad (17)$$

$$\zeta_{TS} = \frac{|\Delta S^\circ|}{|\Delta H^\circ| + |T\Delta S^\circ|} \quad (18)$$

## 5.2 Enthalpy of Dissolution ( $\Delta H^\circ$ )

Across the 296 reviewed studies, the standard molar enthalpy of dissolution  $\Delta H^\circ$  is positive (endothermic) for the overwhelming majority of compound–solvent pairs (>90%). This reflects the general fact that breaking the crystal lattice (endothermic, requiring energy to overcome lattice forces) requires more energy than is released by solvation (exothermic, formation of solute–solvent interactions). The net positive  $\Delta H^\circ$  drives solubility upward with increasing temperature.

The magnitude of  $\Delta H^\circ$  varies considerably with compound class and solvent:

- Simple organic acids and small molecules (e.g., succinic acid, oxalic acid, tartaric acid, l-malic acid):  $\Delta H^\circ$  typically 5–20 kJ mol<sup>-1</sup>. The relatively small values reflect moderate lattice energies and good solvation in polar solvents. [8], [82], [162], [201], [206]
- Common pharmaceuticals (e.g., levetiracetam 5–12 kJ mol<sup>-1</sup> in various solvents; nicotinamide 16–21 kJ mol<sup>-1</sup>; lidocaine hydrochloride 15–40 kJ mol<sup>-1</sup>): Moderate  $\Delta H^\circ$  values consistent with polar organic crystals with modest hydrogen bonding in the solid state. [17], [26], [38], [88]
- Complex APIs with high melting points (e.g., itraconazole:  $\Delta H^\circ$  up to 55 kJ mol<sup>-1</sup>; triamterene with  $T_m = 316^\circ\text{C}$ ; genistein with  $T_m \sim 298^\circ\text{C}$ ): Large  $\Delta H^\circ$  values reflect strong crystal lattice forces (high melting point) that are only partially compensated by solvation. [92], [120], [121], [196]
- Systems with specific strong solvation (e.g., cabozantinib malate in DMSO, clorsulon in ethylene glycol): The solvation exotherm in these systems partially offsets the lattice endotherm, producing lower  $\Delta H^\circ$  than predicted from the compound's melting point alone. [9], [49], [89]

Rare cases of negative  $\Delta H^\circ$  (exothermic dissolution) include:  $\beta$ -arbutin in most organic solvents ( $\Delta H^\circ < 0$ , spontaneous dissolution); sodium acetate in 2,2,2-trifluoroethanol; dicyandiamide in DMF-based binary solvents (2024). In these cases, solvation interactions are stronger than lattice forces. [52], [174], [186], [275]

## 5.3 Entropy of Dissolution ( $\Delta S^\circ$ )

The standard molar entropy of dissolution  $\Delta S^\circ$  is positive for virtually all compound–solvent pairs reviewed, reflecting the entropy gain upon transfer from the highly ordered crystal lattice to the disordered solution state. The translational, rotational, and configurational freedom of solute molecules increases enormously upon dissolution from a solid where each molecule is confined to a lattice site to a solution where molecules are randomly distributed throughout the available volume.

The magnitude of  $\Delta S^\circ$  varies significantly with molecular size and complexity:

- Small molecules (MW < 200 g/mol, e.g., urea, glycine, benzoic acid, ascorbic acid):  $\Delta S^\circ$  typically 20–60 J mol<sup>-1</sup> K<sup>-1</sup>. The modest entropy gains reflect limited additional conformational freedom gained upon dissolution. [64], [184]
- Medium-sized pharmaceutical compounds (MW 200–500 g/mol):  $\Delta S^\circ$  typically 40–120 J mol<sup>-1</sup> K<sup>-1</sup>. The range reflects the varying contribution of conformational

flexibility, solute–solvent ordering (which reduces entropy), and ideal mixing entropy.

- Large, flexible molecules (MW > 500 g/mol, e.g., iohexol MW=821,  $\beta$ -cyclodextrin MW=1135):  $\Delta S^\circ$  can reach 150–300 J mol<sup>-1</sup> K<sup>-1</sup>. The large conformational entropy gain from flexible substituents (ether chains, rings) dominates. [157], [169]

Negative  $\Delta S^\circ$  is rare and has been reported for favipiravir in methanol at lower temperatures (2023), suggesting strong ordering of the solvent shell around the solute. This phenomenon, analogous to hydrophobic hydration in aqueous systems, can occur in protic solvents when the solute significantly structures the surrounding solvent molecules through hydrogen bonding. [90]

#### 5.4 Gibbs Free Energy ( $\Delta G^\circ$ )

The sign and magnitude of  $\Delta G^\circ$  determine whether dissolution is spontaneous ( $\Delta G^\circ < 0$ ) or non-spontaneous ( $\Delta G^\circ > 0$ ) under saturation conditions. For most organic solids, dissolution is non-spontaneous at saturation ( $\Delta G^\circ > 0$ ), consistent with the definition of the system being at equilibrium there is no thermodynamic driving force for further dissolution once saturation is reached. This is a tautological result: at equilibrium,  $\Delta G^\circ = 0$  for the actual process, but the standard-state Gibbs energy  $\Delta G^\circ(T) = -RT \cdot \ln(x) > 0$  when  $x < 1$ .

The practical implication of  $\Delta G^\circ$  values is their use for solvent ranking: a more positive  $\Delta G^\circ$  indicates lower solubility in that solvent, because  $\Delta G^\circ = -RT \cdot \ln(x)$  means that larger (less negative)  $\Delta G^\circ$  corresponds to smaller  $x$ . The ordering  $\Delta G^\circ(\text{solvent1}) < \Delta G^\circ(\text{solvent2})$  is therefore equivalent to  $x(\text{solvent1}) > x(\text{solvent2})$ . This relationship was explicitly used in studies including arbidol hydrochloride monohydrate (2022), where the ascending order of  $\Delta G^\circ$  exactly reversed the solubility order. [200], [290]

Cases of negative  $\Delta G^\circ$  (spontaneous dissolution) occur for freely soluble compounds: musk ketone in DMAC/DMF ( $\Delta G^\circ < 0$ , 2019); esmolol hydrochloride in several solvents (2025); dimetridazole in certain ketone solvents (2021); 3,5-dinitrobenzoic acid in several alcohols (2022). For these systems, dissolution is thermodynamically favoured until the solubility limit is exceeded. [102], [144], [149], [184], [189]

#### 5.5 Enthalpy–Entropy Compensation

Enthalpy–entropy compensation (EEC) is a widely observed phenomenon in physical organic and medicinal chemistry where a linear relationship exists between  $\Delta H^\circ$  and  $\Delta S^\circ$  across a series of structurally related systems or solvents:

$$\Delta H^\circ = \beta \cdot \Delta S^\circ + \Delta G^\circ_\beta \quad (19)$$

where  $\beta$  is the compensation temperature and  $\Delta G^\circ_\beta$  is the intercept (the Gibbs free energy at the compensation temperature). When the compensation temperature  $\beta$  exceeds the harmonic mean temperature  $T_{hm}$ , the process is classified as

enthalpically controlled (changes in  $\Delta H^\circ$  are not fully compensated by  $\Delta S^\circ$  changes, so the enthalpy term dominates  $\Delta G^\circ$ ); when  $\beta < T_{hm}$ , the process is entropically controlled.

EEC analysis was explicitly conducted in approximately 30 of the reviewed articles. The majority of pharmaceutical dissolution processes reviewed exhibit entropy-driven behaviour ( $\%TS > 50\%$ ), including: emtricitabine in PEG-400 + water (entropy-driven); cabozantinib malate in DMSO (entropy-driven); brigatinib in ethanol + water (entropy-driven); favipiravir (entropy-driven in most solvents); levetiracetam (entropy-driven). A smaller subset is enthalpy-driven, including:  $\alpha$ -glycine in all additive systems studied (enthalpy contribution  $>50\%$ ); 2-acrylamido-2-methyl-1-propanesulfonic acid (enthalpy-driven); curcumin in water (enthalpy contribution confirmed by DSC comparison), [5], [9], [26], [36], [89]

## 5.6 Thermodynamic Summary Across Compound Classes

**Table 5.1 Typical thermodynamic parameters by compound class**

| Compound Class                  | Typical $\Delta H^\circ$ (kJ/mol) | Typical $\Delta S^\circ$ (J/mol·K) | $\Delta G^\circ$ Sign | Dissolution Character                    |
|---------------------------------|-----------------------------------|------------------------------------|-----------------------|--|
| Simple organic acids            | 5–25                              | 20–70                              | >0                    | Endothermic, entropy-driven              |
| Small pharmaceuticals (<300 MW) | 10–40                             | 30–110                             | >0                    | Endothermic, entropy-driven              |
| Large APIs (>400 MW)            | 20–65                             | 50–150                             | >0                    | Endothermic, entropy-driven              |
| Natural products                | 15–50                             | 40–130                             | >0, <0                | Mostly endothermic; some exothermic      |
| Industrial chemicals            | 5–30                              | 20–80                              | >0, <0                | Endothermic; some spontaneous in aprotic |
| Energetic materials             | 10–35                             | 30–100                             | >0                    | Endothermic, entropy-driven              |

## 6. Comprehensive Compound Reference Tables

The following tables provide the central data contribution of this systematic review: a comprehensive reference listing of all 200+ compounds covered in the 296 reviewed publications. For each compound, the following information is provided: compound

name, CAS registry number, molecular weight (MW, g/mol), melting point (T<sub>m</sub>, °C), compound category, primary uses and applications, year of the reviewed solubility study, key solvents studied, temperature range, best-performing thermodynamic model, and thermodynamic characterisation of the dissolution process.

Compounds are grouped into seven categories: (1) Pharmaceutical Compounds, (2) Natural Products and Phytochemicals, (3) Organic Acids and Anhydrides, (4) Industrial and Specialty Chemicals, (5) Agrochemicals, (6) Energetic Materials, and (7) Sugars, Polyols, and Amino Acids. Within each category, compounds are listed in the order they appear in the original database.

Molecular weights and melting points are taken from primary literature sources, PubChem, or the Merck Index (latest edition). Where values differ slightly across sources, the most commonly cited value is reported. 'Decomposes' (dec) indicates that the compound decomposes rather than melting cleanly. Asterisks (\*) denote compounds for which melting point data from the reviewed study's DSC measurement differs from literature due to polymorph-specific behaviour.

## 6.1 Pharmaceutical Compounds

**Table 6.1 Pharmaceutical compounds – molecular properties and applications (128 entries)**

| No. | Compound Name              | CAS No.      | MW (g/mol) | T <sub>m</sub> (°C) | Primary Uses  |
|-----|----------------------------|--------------|------------|---------------------|---|
| 2   | Pioglitazone Hydrochloride | 112529-15-4  | 392.90     | 193-194             | Antidiabetic agent (thiazolidinedione class); treatment of type 2 diabetes mellitus; improves insulin sensitivity |
| 5   | Emtricitabine              | 143491-57-0  | 247.25     | 143-144             | Antiviral nucleoside reverse transcriptase inhibitor; treatment of HIV-1 infection and hepatitis B                |
| 6   | Brigatinib                 | 1197953-54-0 | 539.60     | 228-230             | ALK/ROS1 inhibitor; treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC)                       |
| 9   | Cabozantinib Malate        | 1140909-48-3 | 635.67     | 168-170             | Tyrosine kinase inhibitor; treatment  |

|    |                           |             |        |         |  |
|----|---------------------------|-------------|--------|---------|--|
|    |                           |             |        |         | of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma  |
| 11 | Actarit                   | 18699-02-0  | 179.17 | 222-224 | Disease-modifying antirheumatic drug (DMARD); treatment of rheumatoid arthritis                                  |
| 17 | Lidocaine Hydrochloride   | 6108-05-0   | 288.81 | 128-130 | Local anesthetic and antiarrhythmic drug; widely used in dentistry, surgery, and cardiac care                    |
| 18 | Hydrocortisone            | 50-23-7     | 362.46 | 212-220 | Corticosteroid hormone; treatment of inflammatory conditions, adrenal insufficiency, allergic reactions          |
| 20 | Ethenzamide               | 938-73-8    | 165.19 | 133-135 | Non-narcotic analgesic and antipyretic; over-the-counter pain relief; treatment of fever                         |
| 21 | Regorafenib               | 755037-03-7 | 482.82 | 202-205 | Multikinase inhibitor; treatment of colorectal cancer, gastrointestinal stromal tumors, hepatocellular carcinoma |
| 22 | Ipriflavone               | 35212-22-7  | 280.32 | 116-118 | Synthetic isoflavone; treatment and prevention of osteoporosis; bone metabolism regulation                       |
| 24 | Terbinafine Hydrochloride | 78628-80-5  | 327.90 | 204-206 | Allylamine antifungal;   |

|    |               |             |        |         |   |
|----|---------------|-------------|--------|---------|---|
|    |               |             |        |         | treatment of dermatophyte infections, onychomycosis (nail fungus), tinea                              |
| 25 | Marbofloxacin | 115550-35-1 | 362.37 | >250    | Fluoroquinolone antibiotic for veterinary use; broad-spectrum antibacterial in cats, dogs, and cattle |
| 26 | Levetiracetam | 102767-28-2 | 170.21 | 118-120 | Antiepileptic drug; treatment of epilepsy, seizures, and myoclonic jerks; first-line anticonvulsant   |
| 27 | Diphenoxylate | 3810-80-8   | 452.57 | 219-221 | Opioid antidiarrheal agent; treatment of diarrhea; reduces intestinal motility                        |
| 32 | Nifedipine    | 21829-25-4  | 346.34 | 172-174 | Calcium channel blocker; treatment of hypertension, angina pectoris, and Raynaud's phenomenon         |
| 38 | Nicotinamide  | 98-92-0     | 122.12 | 128-131 | Vitamin B3 form (niacinamide); treatment of pellagra; skin conditions; coenzyme NAD+ precursor        |
| 39 | Oxaprozin     | 21256-18-8  | 293.32 | 159-161 | NSAID (non-steroidal anti-inflammatory drug); treatment of osteoarthritis and rheumatoid arthritis    |

|    |                            |             |        |         |  |
|----|----------------------------|-------------|--------|---------|--|
| 41 | Chlorzoxazone              | 95-25-0     | 169.57 | 191-194 | Centrally-acting skeletal muscle relaxant; treatment of painful musculoskeletal conditions                   |
| 42 | 5-Fluorouracil             | 51-21-8     | 130.08 | 282-283 | Antimetabolite anticancer drug; treatment of colorectal, breast, stomach, and skin cancers                   |
| 43 | Ibuprofen Sodium Dihydrate | 527688-20-6 | 264.27 | 72-74   | NSAID salt form; analgesic, antipyretic, anti-inflammatory; rapid-onset pain relief formulations             |
| 45 | Mifepristone               | 84371-65-3  | 429.60 | 192-196 | Antiprogestational steroid; medical abortion; treatment of Cushing's syndrome; emergency contraception       |
| 46 | Thiamphenicol              | 15318-45-3  | 356.22 | 163-165 | Broad-spectrum antibiotic; treatment of bacterial infections; veterinary use; alternative to chloramphenicol |
| 48 | Bupivacaine Hydrochloride  | 18010-40-7  | 342.90 | 258-261 | Long-acting local anesthetic; epidural and spinal anesthesia; post-surgical pain management                  |
| 49 | Clorsulon                  | 60200-06-8  | 380.22 | 207-210 | Antiparasitic agent; treatment of liver fluke (Fasciola  |

|    |                               |             |         |         |   |
|----|-------------------------------|-------------|---------|---------|---|
|    |                               |             |         |         | hepatica) infections in cattle and sheep  |
| 50 | Tylosin Tartrate              | 1405-54-5   | 1982.33 | 145-150 | Macrolide antibiotic for veterinary use; treatment of respiratory and other infections in livestock       |
| 51 | Amitriptyline Hydrochloride   | 549-18-8    | 313.87  | 197-199 | Tricyclic antidepressant; treatment of depression, neuropathic pain, migraine prevention, insomnia        |
| 63 | Dabigatran Etexilate Mesylate | 872728-81-9 | 723.86  | 185-188 | Direct thrombin inhibitor; anticoagulant; prevention of stroke and systemic embolism; atrial fibrillation |
| 64 | Ascorbic Acid                 | 50-81-7     | 176.12  | 190-192 | Vitamin C; antiscorbutic; antioxidant; collagen synthesis; immune function; food preservative (E300)      |
| 68 | Rosiglitazone                 | 122320-73-4 | 357.43  | 155-157 | Thiazolidinedione antidiabetic; treatment of type 2 diabetes; improves insulin sensitivity                |
| 70 | Doxofylline                   | 69975-86-6  | 267.24  | 159-161 | Xanthine derivative bronchodilator; treatment of asthma and chronic obstructive pulmonary disease         |

|    |  |             |        |         |  |
|----|--|-------------|--------|---------|--|
| 71 | Nortriptyline Hydrochloride              | 894-71-3    | 299.84 | 213-215 | Tricyclic antidepressant; treatment of depression, neuropathic pain, smoking cessation, ADHD           |
| 74 | Cefuroxime Acid                          | 55268-75-2  | 424.39 | 222-224 | Second-generation cephalosporin antibiotic; treatment of respiratory, urinary tract, skin infections   |
| 75 | Dabigatran Etexilate Mesylate Polymorphs | 872728-81-9 | 723.86 | 185-190 | Direct thrombin inhibitor; anticoagulant; polymorphic form studies for crystallization optimization    |
| 79 | Furosemide                               | 54-31-9     | 330.74 | 206-210 | Loop diuretic; treatment of edema, hypertension, congestive heart failure, renal disease               |
| 80 | Sulfanilamide                            | 63-74-1     | 172.21 | 165-166 | First sulfonamide antibiotic; treatment of bacterial infections; precursor to other sulfa drugs        |
| 81 | Omeprazole                               | 73590-58-6  | 345.42 | 155-157 | Proton pump inhibitor; treatment of gastroesophageal reflux, peptic ulcers, Zollinger-Ellison syndrome |
| 83 | Mequindox                                | 13297-17-1  | 216.24 | 170-172 | Quinoxaline antibiotic for veterinary use; growth promotant  |

|    |                         |             |        |         |   |
|----|-------------------------|-------------|--------|---------|---|
|    |                         |             |        |         | and antibacterial in swine and poultry  |
| 84 | Cefixime Disodium       | 124506-28-1 | 507.44 | >250    | Third-generation cephalosporin antibiotic; treatment of respiratory, urinary tract, and ear infections  |
| 85 | Verapamil Hydrochloride | 152-11-4    | 491.06 | 144-146 | Calcium channel blocker; treatment of hypertension, angina, and cardiac arrhythmias                     |
| 87 | Lidocaine               | 137-58-6    | 234.34 | 66-69   | Local anesthetic; antiarrhythmic; widely used in medical and dental procedures; topical pain relief     |
| 88 | Favipiravir             | 259793-96-9 | 157.10 | 200-204 | Broad-spectrum antiviral; treatment of influenza, COVID-19; RNA polymerase inhibitor                    |
| 89 | Sulfamonomethoxine      | 1220-83-3   | 280.30 | 209-211 | Sulfonamide antibiotic; treatment of bacterial and coccidial infections in veterinary medicine          |
| 90 | Itraconazole            | 84625-61-6  | 705.63 | 166-168 | Triazole antifungal; treatment of systemic fungal infections including aspergillosis and histoplasmosis |
| 91 | Benzohydrazide          | 613-94-5    | 136.15 | 112-114 | Pharmaceutical intermediate; antitubercular activity; synthesis of                                      |

|     |                           |            |         |         |   |
|-----|---------------------------|------------|---------|---------|---|
|     |                           |            |         |         | hydrazone derivatives   |
| 92  | 2-Hydroxybenzo hydrazide  | 936-02-7   | 152.15  | 149-152 | Antituberculosis intermediate; chelating agent; synthesis of pharmaceutical compounds                     |
| 93  | Tylosin Tartrate (binary) | 1405-54-5  | 1982.33 | 145-150 | Macrolide antibiotic; treatment of respiratory infections and mycoplasmosis in livestock                  |
| 95  | Cefazolin Acid            | 25953-19-9 | 454.50  | 198-200 | First-generation cephalosporin antibiotic; treatment of surgical prophylaxis and gram-positive infections |
| 97  | Thiamine Nitrate          | 532-43-4   | 327.34  | 196-200 | Vitamin B1 salt form; treatment of thiamine deficiency, beriberi; metabolic cofactor supplement           |
| 99  | Aceclofenac               | 89796-99-6 | 354.19  | 148-150 | NSAID; treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis |
| 101 | Sodium Theophylline       | 3485-82-3  | 202.15  | >300    | Bronchodilator salt form; treatment of asthma, COPD; methylxanthine derivative                            |
| 102 | Dienogest                 | 65928-58-7 | 311.42  | 214-215 | Synthetic progestogen; treatment of   |

|     |                |             |        |         |  |
|-----|----------------|-------------|--------|---------|--|
|     |                |             |        |         | endometriosis; oral contraceptive component  |
| 103 | Indapamide     | 26807-65-8  | 365.83 | 163-165 | Thiazide-like diuretic; treatment of hypertension and edema; cardioprotective properties           |
| 104 | Clarithromycin | 81103-11-9  | 747.95 | 220-225 | Macrolide antibiotic; treatment of respiratory tract, skin, and H. pylori-associated infections    |
| 106 | Febuxostat     | 144060-53-7 | 316.37 | 208-210 | Xanthine oxidase inhibitor; treatment of hyperuricemia in gout patients                            |
| 108 | Edaravone      | 89-25-8     | 174.20 | 127-130 | Free radical scavenger; treatment of acute ischemic stroke and ALS (amyotrophic lateral sclerosis) |
| 109 | Allantoin      | 97-59-6     | 158.12 | 230-235 | Skin healing and soothing agent; wound healing; cosmetic moisturizer; anti-irritant                |
| 111 | Temozolomide   | 85622-93-1  | 194.15 | 212     | Alkylating antineoplastic agent; treatment of glioblastoma multiforme and anaplastic astrocytoma   |
| 113 | Pazopanib      | 444731-52-6 | 473.99 | 224-226 | Multikinase inhibitor (VEGFR, PDGFR); treatment of renal   |

|     |   |             |        |         |  |
|-----|---|-------------|--------|---------|--|
|     |   |             |        |         | cell carcinoma and soft tissue sarcoma   |
| 114 | L- $\alpha$ -Glyceryl Phosphorylcholine | 28319-77-9  | 257.22 | 143-145 | Choline precursor; nootropic supplement; treatment of cognitive disorders; cholinergic precursor |
| 115 | Linezolid                               | 165800-03-3 | 337.35 | 181-182 | Oxazolidinone antibiotic; treatment of MRSA, VRE, and other gram-positive resistant infections   |
| 117 | Triamterene                             | 396-01-0    | 253.27 | 316     | Potassium-sparing diuretic; treatment of hypertension and edema; prevents potassium loss         |
| 118 | Itopride Hydrochloride                  | 122892-31-3 | 394.88 | 200-203 | Prokinetic drug; treatment of functional dyspepsia and gastroparesis; promotes gastric motility  |
| 122 | Rebamipide                              | 90098-04-7  | 339.75 | 287-291 | Gastroprotective agent; treatment of gastritis and gastric ulcers; mucosal protective drug       |
| 126 | Dehydroepian drosterone Acetate         | 853-23-6    | 330.46 | 174-176 | Prohormone supplement; testosterone/estrogen precursor; potential anti-aging and adrenal support |
| 128 | Gestodene                               | 60282-87-3  | 310.43 | 199-200 | Third-generation progestogen; oral contraceptive component;                                      |

|     |                       |             |        |         |  |
|-----|-----------------------|-------------|--------|---------|--|
|     |                       |             |        |         | treatment of endometriosis   |
| 131 | Domiphen Bromide      | 538-71-6    | 414.44 | 101-104 | Quaternary ammonium antiseptic; oral disinfectant in lozenges and mouthwashes; antimicrobial surfactant    |
| 132 | Carvedilol            | 72956-09-3  | 406.47 | 114-116 | Non-selective beta-blocker with alpha-blocking; treatment of heart failure, hypertension, angina           |
| 133 | Eszopiclone           | 138729-47-2 | 388.81 | 199-200 | Non-benzodiazepine hypnotic; treatment of insomnia; promotes sleep onset and maintenance                   |
| 134 | Apixaban              | 503612-47-3 | 459.50 | 251-254 | Factor Xa inhibitor; anticoagulant; prevention of stroke in atrial fibrillation; VTE treatment             |
| 136 | Isotretinoin          | 4759-48-2   | 300.44 | 174-176 | Retinoid; treatment of severe acne; vitamin A derivative; teratogenic—requires strict monitoring           |
| 140 | Esmolol Hydrochloride | 81161-17-3  | 331.84 | 186-188 | Ultra-short-acting $\beta$ 1-selective blocker; intravenous treatment of supraventricular tachyarrhythmias |
| 144 | Nintedanib            | 656247-17-5 | 539.62 | 216-218 | Triple kinase inhibitor; treatment of idiopathic pulmonary fibrosis  |

|     |                          |             |         |         |   |
|-----|--------------------------|-------------|---------|---------|---|
|     |                          |             |         |         | and systemic sclerosis-ILD  |
| 145 | Dimetridazole            | 551-92-8    | 141.13  | 142-144 | Nitroimidazole antiprotozoal; treatment of histomoniasis and trichomoniasis in poultry and pigs             |
| 146 | Androstenedione          | 63-05-8     | 286.41  | 170-173 | Endogenous androgen; prohormone precursor to testosterone and estrogens; banned sports supplement           |
| 149 | Nevirapine               | 129618-40-2 | 266.30  | 247-249 | Non-nucleoside reverse transcriptase inhibitor; first-line HIV treatment; prevention of mother-to-child HIV |
| 150 | 2-Ethoxybenzamide        | 938-73-8    | 165.19  | 133-135 | Analgesic and antipyretic (ethenzamide); OTC pain reliever in Japan; pharmaceutical intermediate            |
| 151 | $\beta$ -Cyclodextrin    | 7585-39-9   | 1134.99 | 300-305 | Drug complexing agent; improves solubility and stability; food additive (E459); encapsulation technology    |
| 152 | Isosorbide 5-Mononitrate | 16051-77-7  | 191.14  | 90-93   | Organic nitrate vasodilator; treatment of angina pectoris; prophylaxis against heart pain                   |

|     |                                  |             |        |         |   |
|-----|----------------------------------|-------------|--------|---------|---|
| 153 | Praziquantel                     | 55268-74-1  | 312.41 | 136-140 | Antiparasitic drug; treatment of schistosomiasis, tapeworm, and other parasitic worm infections   |
| 155 | Rivaroxaban                      | 366789-02-8 | 435.88 | 229-231 | Direct Factor Xa inhibitor; anticoagulant; treatment of DVT, PE, and stroke prevention in AF      |
| 162 | Adefovir                         | 106941-25-7 | 273.20 | 189-191 | Nucleotide analog antiviral; treatment of chronic hepatitis B (HBV) infection                     |
| 163 | Iohexol                          | 66108-95-0  | 821.14 | 185-188 | Non-ionic iodinated contrast agent; X-ray imaging, CT scans, myelography, urography               |
| 166 | Eplerenone                       | 107724-20-9 | 414.49 | 233-235 | Selective mineralocorticoid receptor antagonist; treatment of hypertension, heart failure post-MI |
| 169 | Cyproterone Acetate              | 427-51-0    | 416.94 | 200-201 | Antiandrogen; treatment of prostate cancer, acne, hirsutism; oral contraceptive component         |
| 171 | 17- $\alpha$ Hydroxyprogesterone | 68-96-2     | 330.46 | 222-224 | Endogenous progestogen; prevention of preterm birth; diagnosis of congenital adrenal hyperplasia  |

|     |                                  |             |        |         |  |
|-----|----------------------------------|-------------|--------|---------|--|
| 177 | Salbutamol                       | 18559-94-9  | 239.31 | 155-157 | Short-acting $\beta$ 2-adrenergic agonist; bronchodilator; treatment of asthma and COPD                          |
| 179 | Azithromycin Monohydrate         | 121470-24-4 | 767.96 | 113-115 | Macrolide antibiotic; treatment of respiratory, skin, and STI infections; Z-pack antibiotic                      |
| 181 | Sulfaguanidine                   | 57-67-0     | 214.24 | 190-193 | Sulfonamide antibiotic; treatment of intestinal infections; poorly absorbed, acts locally in gut                 |
| 182 | Isonicotinamide                  | 1453-82-3   | 122.12 | 156-158 | Isomer of nicotinamide (Vitamin B3); antitubercular intermediate; cocrystal former in pharmaceutical development |
| 185 | Hyodeoxycholic Acid              | 83-49-8     | 392.57 | 197-199 | Bile acid; dissolution of gallstones; hepatoprotective; pharmaceutical intermediate                              |
| 187 | Zaltoprofen                      | 74711-43-6  | 298.36 | 159-162 | NSAID; treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis                                |
| 189 | 4-(4-Aminophenyl)-3-morpholinone | 438056-69-0 | 192.21 | 204-207 | Rivaroxaban structural analog; pharmaceutical intermediate in anticoagulant drug synthesis                       |

|     |                      |             |        |         |   |
|-----|----------------------|-------------|--------|---------|---|
| 190 | Cefpodoxime Proxetil | 87239-81-4  | 557.60 | 95-100  | Third-generation oral cephalosporin; treatment of respiratory tract, skin, and urinary tract infections   |
| 191 | Aprepitant           | 170729-80-3 | 534.43 | 252-254 | NK1 receptor antagonist; antiemetic; prevention of chemotherapy-induced and post-surgical nausea/vomiting |
| 197 | Niflumic Acid        | 4394-00-7   | 282.22 | 203-205 | NSAID; treatment of pain and inflammation; chloride channel blocker; mefenamic acid analog                |
| 200 | Salicylanilide       | 87-17-2     | 213.23 | 135-137 | Antifungal agent; molluscicide; topical treatment of fungal skin infections; antiseptic                   |
| 206 | Progesterone         | 57-83-0     | 314.46 | 129-131 | Endogenous progestogen; contraception; treatment of endometriosis, infertility, and hormone replacement   |
| 211 | Cytarabine           | 147-94-4    | 243.22 | 212-213 | Antimetabolite anticancer drug; treatment of leukemia and lymphoma; pyrimidine analog                     |
| 212 | Satranidazole        | 56302-13-7  | 289.26 | 223-225 | Nitroimidazole antiprotozoal;   |

|     |                     |             |        |         |   |
|-----|---------------------|-------------|--------|---------|---|
|     |                     |             |        |         | treatment of amoebiasis, giardiasis, and trichomoniasis   |
| 214 | Diclazuril          | 101831-37-2 | 407.07 | 298-302 | Antiprotozoal agent; treatment of coccidiosis in poultry and livestock; prophylactic use                  |
| 216 | Cefixime Trihydrate | 125110-14-7 | 507.50 | >200    | Third-generation oral cephalosporin; treatment of respiratory tract and urinary tract infections          |
| 219 | l-Carnitine         | 541-15-1    | 161.20 | 197-200 | Amino acid derivative; fat metabolism; treatment of carnitine deficiency; sports supplement; heart health |
| 220 | Etodolac            | 41340-25-4  | 287.35 | 145-148 | NSAID; treatment of osteoarthritis, rheumatoid arthritis, and acute pain                                  |
| 221 | Oxcarbazepine       | 28721-07-5  | 252.27 | 215-216 | Antiepileptic drug; treatment of partial-onset seizures; mood stabilizer in bipolar disorder              |
| 223 | Menadiol Diacetate  | 573-20-6    | 258.27 | 111-114 | Vitamin K3 prodrug; treatment of hypoprothrombinemia; coagulation factor synthesis                        |
| 224 | Diprophylline       | 479-18-5    | 254.24 | 159-160 | Xanthine bronchodilator; treatment of asthma and bronchospasm;  |

|     |  |             |         |         |   |
|-----|--|-------------|---------|---------|---|
|     |  |             |         |         | less cardiotoxic than theophylline  |
| 225 | Metronidazole Benzoate                     | 13182-89-3  | 275.26  | 161-164 | Nitroimidazole antibiotic ester; treatment of anaerobic bacterial and protozoal infections; Helicobacter pylori |
| 228 | Doxofylline                                | 69975-86-6  | 267.24  | 159-161 | Theophylline derivative; bronchodilator; treatment of asthma with improved tolerability                         |
| 229 | Naftopidil                                 | 57149-07-2  | 392.46  | 173-175 | $\alpha$ 1-adrenoceptor blocker; treatment of benign prostatic hyperplasia (BPH) and dysuria                    |
| 230 | Omeprazole Sulfide                         | 73590-85-9  | 329.42  | 152-154 | Synthetic intermediate in omeprazole production; impurity reference standard                                    |
| 233 | Spectinomycin Dihydrochloride Pentahydrate | 22189-32-8  | 495.35  | ~260    | Aminocyclitol antibiotic; treatment of gonorrhea (penicillin-resistant strains); veterinary antibiotic          |
| 235 | Quetiapine Fumarate                        | 111974-72-2 | 883.09  | 168-170 | Atypical antipsychotic; treatment of schizophrenia, bipolar disorder, and depression                            |
| 239 | Doxycycline Hyclate                        | 24390-14-5  | 1025.89 | 201-202 | Broad-spectrum tetracycline antibiotic; treatment   |

|     |                         |              |        |         |  |
|-----|-------------------------|--------------|--------|---------|--|
|     |                         |              |        |         | of respiratory, skin, malaria, Lyme disease  |
| 241 | Ribociclib              | 1211441-98-3 | 434.54 | 221-224 | CDK4/6 inhibitor; treatment of HR+/HER2-metastatic breast cancer; cyclin-dependent kinase inhibitor          |
| 242 | Biotin                  | 58-85-5      | 244.31 | 230-232 | Vitamin B7 (Vitamin H); cofactor for carboxylase enzymes; hair and nail health supplement                    |
| 246 | Bicalutamide            | 90357-06-5   | 430.37 | 191-193 | Non-steroidal antiandrogen; treatment of prostate cancer; androgen receptor antagonist                       |
| 247 | Benflumetol             | 82186-77-4   | 528.88 | 90-92   | Aryl alcohol antimalarial; combined with artemether (Coartem) for uncomplicated malaria treatment            |
| 249 | L-Pyroglutamic Acid     | 98-79-3      | 129.11 | 161-163 | Glutamine cyclization product; nootropic supplement; treatment of memory disorders; pharmaceutical excipient |
| 253 | Sulfaguanidine (repeat) | 57-67-0      | 214.24 | 190-193 | Intestinal sulfonamide antibiotic; treatment of bowel infections   |

|     |                                   |             |        |         |   |
|-----|-----------------------------------|-------------|--------|---------|---|
| 255 | Benzethonium Chloride             | 121-54-0    | 448.07 | 162-165 | Quaternary ammonium antiseptic; disinfectant in eye drops, wound cleaners, mouthwashes                    |
| 256 | Cytosine                          | 71-30-7     | 111.10 | 320-325 | Nucleobase; DNA/RNA component; pharmaceutical intermediate for antiviral nucleoside analogs               |
| 259 | Benorilate                        | 5003-48-5   | 313.31 | 174-175 | Combined aspirin-paracetamol ester prodrug; analgesic, antipyretic, anti-inflammatory; gentle on stomach  |
| 263 | Pregabalin                        | 148553-50-8 | 159.23 | 194-196 | Anticonvulsant and anxiolytic; treatment of neuropathic pain, fibromyalgia, epilepsy, generalized anxiety |
| 267 | Riluzole                          | 1744-22-5   | 234.20 | 116-118 | Glutamate release inhibitor; only FDA-approved treatment for ALS (amyotrophic lateral sclerosis)          |
| 269 | Arbidol Hydrochloride Monohydrate | 131707-23-8 | 477.40 | 189-192 | Broad-spectrum antiviral; treatment and prevention of influenza; membrane fusion inhibitor                |
| 272 | Clotrimazole                      | 23593-75-1  | 344.84 | 147-149 | Imidazole antifungal; treatment of candidiasis, athlete's foot, ringworm,                                 |

|     |                                   |            |        |         |   |
|-----|-----------------------------------|------------|--------|---------|---|
|     |                                   |            |        |         | vaginal yeast infections  |
| 273 | 4-Aminobenzenesulfonamide         | 63-74-1    | 172.21 | 165-166 | Sulfanilamide; parent compound of sulfonamide antibiotics; treatment of bacterial infections              |
| 275 | 2-Hydrazino-4-methylbenzothiazole | 20174-68-9 | 179.24 | 220-222 | Pharmaceutical intermediate; synthesis of benzothiazole-hydrazone derivatives with antimicrobial activity |

## 6.2 Natural Products and Phytochemicals

**Table 6.2 Natural Product compounds – molecular properties and applications**

| No. | Compound Name | CAS No.  | MW (g/mol) | T <sub>m</sub> (°C) | Primary Uses   |
|-----|---------------|----------|------------|---------------------|--|
| 10  | Curcumin      | 458-37-7 | 368.38     | 183                 | Anti-inflammatory, antioxidant, anticancer natural compound; food colorant (E100); nutraceutical             |
| 14  | Vanillic Acid | 121-34-6 | 168.15     | 210-213             | Natural phenolic acid in vanilla; antioxidant, antimicrobial; food flavoring; pharmaceutical intermediate    |
| 19  | Thymol        | 89-83-8  | 150.22     | 49-51               | Antiseptic, antifungal; ingredient in mouthwashes, cosmetics; food preservative; pharmaceutical intermediate |
| 23  | Baicalein     | 491-67-8 | 270.24     | 264-265             | Flavonoid from <i>Scutellaria baicalensis</i> ;  |

|    |   |            |        |         |  |
|----|---|------------|--------|---------|--|
|    |   |            |        |         | anti-inflammatory, antitumor, neuroprotective, antimicrobial activities  |
| 29 | 2,3,5,4'-Tetrahydroxystilbene-2-O- $\beta$ -D-glucoside | 82373-94-2 | 406.39 | 150-155 | Active component of <i>Polygonum multiflorum</i> ; anti-aging, anti-inflammatory, cardioprotective effects       |
| 35 | $\beta$ -Lapachone                                      | 4707-32-8  | 242.27 | 152-154 | Naphthoquinone from <i>Tabebuia</i> tree; anticancer, antiprotozoal, antiviral, and anti-inflammatory activities |
| 52 | $\beta$ -Arbutin  | 497-76-7   | 272.25 | 198-201 | Skin-whitening agent in cosmetics; inhibits melanin synthesis; antioxidant; found in bearberry leaves            |
| 54 | Esculetin   | 305-01-1   | 178.14 | 268-270 | Coumarin derivative; anti-inflammatory, antioxidant, anticancer; isolated from ash bark and lemon peel           |
| 61 | (-)-Shikimic Acid                                       | 138-59-0   | 174.15 | 184-186 | Key intermediate in Tamiflu (oseltamivir) synthesis; found in star anise; biosynthetic precursor                 |
| 62 | Capsaicin   | 404-86-4   | 305.41 | 65      | Active component of chili peppers; topical analgesic; pain relief cream; weight loss supplement                  |
| 76 | N-Acetylglucosamine                                     | 7512-17-6  | 221.21 | 210-213 | Dietary supplement for joint health; osteoarthritis treatment; skin  |

|     |                              |            |        |         |  |
|-----|------------------------------|------------|--------|---------|--|
|     |                              |            |        |         | moisturizer; chitin derivative   |
| 77  | trans-3-Hydroxycinnamic Acid | 14755-02-3 | 164.16 | 223-225 | Natural phenolic acid; antioxidant, antimicrobial; food and cosmetic industry; pharmaceutical intermediate     |
| 86  | Tanshinone I                 | 568-73-0   | 276.31 | 192-195 | Diterpenoid from <i>Salvia miltiorrhiza</i> ; cardiovascular protective, anti-inflammatory, anticancer effects |
| 110 | $\alpha$ -Glycine            | 56-40-6    | 75.03  | 233     | Simplest amino acid; nutritional supplement; pharmaceutical excipient; industrial fermentation                 |
| 112 | Gibberellin A4               | 468-44-0   | 332.40 | 233-235 | Plant growth regulator; promotes stem elongation, fruit development, and seed germination in agriculture       |
| 116 | Genistein                    | 446-72-0   | 270.24 | 297-298 | Soy isoflavone; phytoestrogen; potential anticancer, bone-protective, and cardiovascular properties            |
| 119 | Caffeic Acid                 | 331-39-5   | 180.16 | 223-225 | Phenylpropanoid from coffee and plants; antioxidant, anti-inflammatory, antimicrobial, anticancer              |
| 121 | Thymoquinone                 | 490-91-5   | 164.20 | 44-46   | Active component of <i>Nigella sativa</i> (black seed); antioxidant, anti-                                     |

|     |                                       |             |        |         |   |
|-----|---------------------------------------|-------------|--------|---------|---|
|     |                                       |             |        |         | inflammatory, anticancer, antimicrobial   |
| 123 | Chrysin                               | 480-40-0    | 254.24 | 285-287 | Natural flavonoid from honey and plants; anti-inflammatory, anxiolytic, antifungal, anticancer effects        |
| 130 | Pterostilbene                         | 537-42-8    | 256.30 | 89-91   | Dimethyl ether of resveratrol; antioxidant, anticancer, cardioprotective; found in blueberries                |
| 141 | Syringic Acid                         | 530-57-4    | 198.17 | 204-207 | Natural phenolic acid from syringas and lignin; antioxidant, anti-inflammatory, antimicrobial properties      |
| 158 | Methyl Gallate                        | 99-24-1     | 184.15 | 199-203 | Antioxidant from tannins; antimicrobial, anti-inflammatory, antiviral; food preservative; cosmetic ingredient |
| 160 | Rhein                                 | 478-43-3    | 284.22 | 321-322 | Anthraquinone from rhubarb; anti-inflammatory, hepatoprotective, anticancer; treatment of renal disease       |
| 167 | 4-Hydroxy-2,5-dimethyl-3(2H)-furanone | 3658-77-3   | 114.10 | 76-79   | Natural flavor compound (DMHF); strawberry, pineapple aroma; food flavoring; fragrance industry               |
| 170 | EGCG Peracetate                       | 148707-39-5 | 806.69 | 145-148 | Peracetylated derivative of green tea catechin EGCG; improved bioavailability; anticancer research            |

|     |                   |            |        |         |  |
|-----|-------------------|------------|--------|---------|--|
| 172 | Limonin           | 1180-71-8  | 470.51 | 298-300 | Triterpenoid from citrus; bitter component of orange juice; anticancer, antifeedant, antibacterial               |
| 176 | Dihydromyricetin  | 27200-12-0 | 320.25 | 219-222 | Flavonoid from <i>Ampelopsis grossedentata</i> ; antioxidant, anti-inflammatory, hepatoprotective; anti-hangover |
| 193 | Rutaecarpine      | 84-26-4    | 287.32 | 257-259 | Indolopyridoquinazoline alkaloid from <i>Evodia</i> ; cardiovascular, anti-inflammatory, thermogenic effects     |
| 194 | Evodiamine        | 518-18-3   | 303.36 | 278-280 | Quinazolinocarboline alkaloid; anti-obesity, anti-tumor, anti-inflammatory; activates TRPV1 receptor             |
| 203 | L-Glutamic Acid   | 56-86-0    | 147.13 | 247-249 | Non-essential amino acid; MSG precursor; flavor enhancer; pharmaceutical supplement; neurotransmitter            |
| 207 | Trans-Resveratrol | 501-36-0   | 228.25 | 261-263 | Polyphenol from red wine and grapes; antioxidant, anti-aging, cardioprotective, anticancer properties            |
| 210 | Daidzin           | 552-66-9   | 416.38 | 220-222 | Soybean isoflavone glycoside; phytoestrogen; antioxidant; alcohol metabolism modulation                          |

|     |                                |           |        |         |  |
|-----|--------------------------------|-----------|--------|---------|--|
| 218 | 4-(4-Hydroxyphenyl)-2-butanone | 5471-51-2 | 164.20 | 81-83   | Raspberry ketone; natural flavor compound; weight loss supplement; fragrance ingredient              |
| 248 | p-Coumaric Acid                | 501-98-4  | 164.16 | 210-213 | Hydroxycinnamic acid; antioxidant, antimicrobial; found in peanuts, tomatoes, garlic; plant phenolic |
| 250 | d-(-)-Quinic Acid              | 77-95-2   | 192.17 | 165-168 | Found in coffee, fruits; precursor in shikimic acid pathway; treatment of respiratory infections     |

### 6.3 Organic Acids

**Table 6.3 Organic Acid compounds – molecular properties and applications**

| No. | Compound Name  | CAS No.  | MW (g/mol) | T <sub>m</sub> (°C) | Primary Uses   |
|-----|----------------|----------|------------|---------------------|--|
| 8   | Succinic Acid  | 110-15-6 | 118.09     | 185-187             | Food additive (E363); pharmaceutical excipient; production of biodegradable polymers (PBS); flavoring agent  |
| 56  | Thiomalic Acid | 70-49-5  | 150.15     | 149-151             | Chelating agent; pharmaceutical intermediate; antioxidant in hair care products                              |
| 82  | Tartaric Acid  | 87-69-4  | 150.09     | 171-174             | Food acidulant (E334) in wine, beverages; cream of tartar; pharmaceutical excipient; chiral resolution agent |

|     |                             |           |        |         |   |
|-----|-----------------------------|-----------|--------|---------|---|
| 147 | Hippuric Acid               | 495-69-2  | 179.17 | 190-193 | Metabolite of toluene exposure (biomarker); research on kidney function; pharmaceutical intermediate            |
| 154 | dl-Malic Acid               | 6915-15-7 | 134.09 | 130-132 | Food acidulant (E296); wine industry; pharmaceutical excipient; production of malates                           |
| 156 | Oxalic Acid                 | 144-62-7  | 90.03  | 189-191 | Rust remover; wood bleaching; rare earth metal processing; pharmaceutical intermediate; stone cleaning          |
| 164 | (R, S)-Mandelic Acid        | 90-64-2   | 152.15 | 118-120 | Chiral resolving agent; pharmaceutical intermediate; synthesis of antibiotics and anticoagulants; mandelic acid |
| 178 | Benzoic Acid                | 65-85-0   | 122.12 | 121-123 | Food preservative (E210); synthesis of benzoate salts, esters, and pharmaceuticals; antimicrobial agent         |
| 184 | $\alpha$ -Ketoglutaric Acid | 328-50-7  | 146.10 | 113-116 | TCA cycle intermediate; nutritional supplement; treatment of metabolic disorders; kidney protection             |

|     |                       |         |        |         |  |
|-----|-----------------------|---------|--------|---------|--|
| 188 | L-Malic Acid          | 97-67-6 | 134.09 | 100-103 | Food acidulant; apple flavor; pharmaceutical excipient; sports nutrition (delays muscle fatigue) |
| 240 | l-Malic Acid (repeat) | 97-67-6 | 134.09 | 100-103 | Natural fruit acid; food acidulant; pharmaceutical excipient; TCA cycle intermediate             |

#### 6.4 Industrial and Specialty Chemicals

**Table 6.4 Industrial Chemical compounds – molecular properties and applications**

| No | Compound Name       | CAS No.  | MW (g/mol) | Tm (°C) | Primary Uses   |
|----|---------------------|----------|------------|---------|--|
| 4  | Sulfanilic Acid     | 121-57-3 | 173.19     | 288     | Synthesis of dyes (azo dyes), pharmaceuticals, and optical brighteners; analytical reagent       |
| 7  | 2-Methylnaphthalene | 91-57-6  | 142.20     | 34-36   | Synthesis of vitamin K; production of dyes, pesticides; petroleum refining by-product            |
| 12 | Dibenzothiophene    | 132-65-0 | 184.26     | 99-101  | Model compound for desulfurization research; petroleum chemistry; organic semiconductor research |
| 13 | Phthalic Anhydride  | 85-44-9  | 148.12     | 131-133 | Production of plasticizers (phthalates),   |

|    |  |            |        |           |   |
|----|--|------------|--------|-----------|---|
|    |  |            |        |           | resins, dyes, pharmaceuticals, and agrochemicals; >5 million tons/year produced globally              |
| 15 | 4,4'-Dihydroxydiphenyl Sulfone               | 80-09-1    | 250.27 | 240 - 243 | Monomer for polysulfone polymers; thermally stable resins; heat-resistant engineering plastics        |
| 30 | 2,3,4-Trichloro-1,5-dinitrobenzene           | 6379-46-0  | 271.47 | 64-67     | Intermediate in synthesis of agrochemicals and specialty chemicals; organic synthesis                 |
| 31 | 2-Acrylamido-2-methyl-1-propanesulfonic Acid | 15214-89-8 | 207.25 | 195 - 196 | Monomer for superabsorbent polymers, hydrogels, ion-exchange resins, and water treatment chemicals    |
| 34 | Phthalimide                                  | 85-41-6    | 147.13 | 232 - 235 | Intermediate in Gabriel synthesis of primary amines; synthesis of thalidomide; agricultural chemicals |
| 37 | Methyleneaminoacetonitrile                   | 109-82-0   | 82.08  | 45-47     | Intermediate in chemical synthesis; production of amino acids and pharmaceutical intermediates        |

|    |                                      |            |        |         |   |
|----|--------------------------------------|------------|--------|---------|---|
| 40 | 3,4-Dichloronitrobenzene             | 99-54-7    | 192.00 | 40-43   | Intermediate in synthesis of pharmaceuticals, agrochemicals, and dyes                               |
| 44 | N-Hydroxymethyl Acrylamide           | 924-42-5   | 101.10 | 74-76   | Cross-linking agent in polymers; paper treatment; textile finishing; production of hydrogels        |
| 47 | Stearic Acid                         | 57-11-4    | 284.48 | 69-71   | Soap and detergent manufacturing; cosmetic emulsifier; pharmaceutical tablet lubricant; plasticizer |
| 53 | 4,4'-Oxydianiline                    | 101-80-4   | 200.23 | 190-192 | Monomer for polyimides and polyamides; high-performance aerospace materials; synthesis of dyes      |
| 55 | p-Chloroaniline                      | 106-47-8   | 127.57 | 72-74   | Intermediate in dye, pesticide, pharmaceutical synthesis; production of p-chloroacetanilide         |
| 58 | 2-Chloro-3-(trifluoromethyl)pyridine | 65753-47-1 | 181.54 | 18-20   | Pharmaceutical and agrochemical intermediate; building block for fluorinated compounds              |
| 59 | Isovanillin                          | 621-59-0   | 152.15 | 113-115 | Flavoring agent; pharmaceutical intermediate;   |

|    |                                |             |        |         |  |
|----|--------------------------------|-------------|--------|---------|--|
|    |                                |             |        |         | synthesis of drugs and fine chemicals  |
| 60 | m-Hydroxyacetophenone          | 121-71-1    | 136.15 | 95-98   | Pharmaceutical and cosmetic intermediate; synthesis of resins and UV absorbers                         |
| 65 | Sorbic Acid                    | 110-44-1    | 112.13 | 134-135 | Food preservative (E200); inhibits mold and yeast in food; cosmetic preservative; polymer intermediate |
| 66 | N,N'-Oxalyldiglycine           | 5262-39-5   | 190.11 | >250    | HIF prolyl hydroxylase inhibitor in research; tool compound for hypoxia signaling studies              |
| 67 | 1-Nitronaphthalene             | 86-57-7     | 173.17 | 55-58   | Intermediate in dye synthesis; production of 1-naphthylamine; industrial chemical research             |
| 72 | 4'-Bromomethyl-2-cyanobiphenyl | 114772-54-2 | 272.13 | 100-103 | Key intermediate in synthesis of sartans (losartan, valsartan) for hypertension treatment              |
| 73 | 2,3,4,5-Tetrabromothiophene    | 3958-03-0   | 399.74 | 102-104 | Flame retardant intermediate; building block for halogenated thiophene derivatives                     |

|     |  |            |        |         |   |
|-----|--|------------|--------|---------|---|
| 78  | para-Methoxyphenylacetic Acid                | 104-01-8   | 166.17 | 86-89   | Pharmaceutical intermediate; synthesis of ibuprofen and related compounds; fragrance chemical     |
| 94  | Ethyl 5-Amino-4-cyano-2-thiophenecarboxylate | 58168-20-0 | 282.34 | 97-100  | Pharmaceutical intermediate; thiophene derivative for drug synthesis                              |
| 98  | 4-Acetylbenzoic Acid                         | 586-89-0   | 164.16 | 208-210 | Pharmaceutical intermediate; synthesis of benzophenone derivatives; UV absorbers                  |
| 100 | Musk Ketone                                  | 81-14-1    | 294.35 | 135-136 | Synthetic musk fragrance; perfumery; cosmetics; textiles; fixative in fragrance compositions      |
| 105 | Phenylphosphonic Acid                        | 1571-33-1  | 158.09 | 163-165 | Flame retardant component; surface treatment agent; catalyst; pharmaceutical intermediate         |
| 107 | m-Aminobenzoic Acid                          | 99-05-8    | 137.14 | 173-177 | Intermediate in dyes, pharmaceuticals, and polymers; UV absorber; synthesis of folic acid analogs |

|     |  |            |        |           |   |
|-----|--|------------|--------|-----------|---|
| 120 | R-(+)-2-(4-Hydroxyphenoxy)propionic Acid | 94050-90-5 | 182.18 | 155 - 157 | Chiral intermediate in synthesis of herbicides (mecoprop, dichlorprop); asymmetric synthesis                |
| 124 | Urea                                     | 57-13-6    | 60.06  | 132 - 135 | Fertilizer (46% N); production of resins, plastics, animal feed; pharmaceutical excipient; skin moisturizer |
| 125 | 1-Hydroxybenzotriazole                   | 2592-95-2  | 135.12 | 157 - 160 | Coupling reagent in peptide synthesis; prevents racemization; pharmaceutical synthesis reagent              |
| 127 | Ammonium Sulfate                         | 7783-20-2  | 132.14 | 235 - 280 | Nitrogen fertilizer; protein precipitation in biochemistry; food additive (E517); flame retardant           |
| 129 | Cyclododecanone                          | 830-13-7   | 182.28 | 58-61     | Precursor to lauro lactam and nylon-12; synthesis of musk fragrances; industrial polymer chemistry          |
| 137 | N,2,3-Trimethyl-2-isopropylbutamide      | 51115-67-4 | 185.31 | 60-62     | Cooling agent (WS-3 analogue); topical cooling sensation in cosmetics and pharmaceuticals                   |

|     |                                |           |        |         |  |
|-----|--------------------------------|-----------|--------|---------|--|
| 138 | 2,5-Furandicarboxylic Acid     | 3238-40-2 | 156.09 | 342     | Bio-based monomer for PEF polymer; sustainable alternative to terephthalic acid; green chemistry     |
| 139 | Caprolactam                    | 105-60-2  | 113.16 | 68-70   | Monomer for nylon-6 production; one of the highest-volume industrial chemicals worldwide             |
| 142 | Dimethyl Terephthalate         | 120-61-6  | 194.19 | 140-141 | Monomer for polyester (PET) production; synthesis of polyesters, coatings, and plasticizers          |
| 143 | 1,3,5-Trichlorobenzene         | 108-70-3  | 181.45 | 62-63   | Solvent for resins; intermediate in agrochemical and dye synthesis; herbicide production             |
| 148 | Triethylamine Hydrochloride    | 554-68-7  | 137.63 | 254-258 | Ionic liquid precursor; reaction base in organic synthesis; pharmaceutical salt preparation          |
| 157 | 2,5-Thiophenedicarboxylic Acid | 4282-31-9 | 172.16 | >300    | Monomer for polyesters and polyamides; pharmaceutical intermediate; bioisostere of terephthalic acid |

|     |                           |             |        |                 |   |
|-----|---------------------------|-------------|--------|-----------------|---|
| 159 | Isatin                    | 91-56-5     | 147.13 | 199<br>-<br>201 | Heterocyclic scaffold in medicinal chemistry; synthesis of antivirals, antibacterials, anticancer agents  |
| 161 | 1,3-Dimethylurea          | 96-31-1     | 88.11  | 102<br>-<br>106 | Intermediate in chemical synthesis; pharmaceutical excipient; resin crosslinker                           |
| 165 | Maleic Anhydride          | 108-31-6    | 98.06  | 52-<br>54       | Production of resins, plastics, coatings; synthesis of fumaric and malic acids; >2 million tons/year      |
| 168 | Dicyandiamide             | 461-58-5    | 84.08  | 207<br>-<br>212 | Fertilizer additive (nitrification inhibitor); production of guanidine compounds, resins; flame retardant |
| 173 | 2-Bromo-5-hydroxypyrazine | 374063-92-0 | 175.00 | 159<br>-<br>162 | Building block for pharmaceutical synthesis; heterocyclic intermediate                                    |
| 174 | Methyl Paraben            | 99-76-3     | 152.15 | 131<br>-<br>133 | Antimicrobial preservative in cosmetics, food, and pharmaceuticals; E-number E218                         |

|     |                                  |           |        |                  |  |
|-----|----------------------------------|-----------|--------|------------------|--|
| 175 | Trimethylolethane                | 77-85-0   | 120.15 | 199<br>-<br>202  | Monomer for alkyd resins, polyurethanes, lubricants, and coatings; crosslinking agent                    |
| 180 | Sodium Acetate                   | 127-09-3  | 82.03  | 324<br>(dec<br>) | Food preservative (E262); buffer in chemical synthesis; heating pad material; photographic fixer         |
| 183 | 3,5-Dinitrobenzoic Acid          | 99-34-3   | 212.12 | 205<br>-<br>207  | Analytical reagent; detection of alcohols and reducing sugars; synthesis of pharmaceutical intermediates |
| 186 | Potassium Benzoate               | 582-25-2  | 160.21 | 250<br>-<br>260  | Food preservative (E212); antimicrobial in acidic foods; pharmaceutical and cosmetic preservative        |
| 192 | d-Camphor-10-Sulfonic Acid       | 3144-16-9 | 232.30 | 195<br>-<br>197  | Chiral resolving agent; asymmetric synthesis; acid catalyst; pharmaceutical intermediate                 |
| 195 | Bis-2-hydroxyethyl Terephthalate | 959-26-2  | 254.24 | 109<br>-<br>110  | PET (polyethylene terephthalate) degradation product; monomer recycling; sustainable chemistry           |
| 196 | Lauric Acid                      | 143-07-7  | 200.32 | 43-<br>45        | Surfactant and detergent raw   |

|     |   |                 |        |                        |  |
|-----|---|-----------------|--------|------------------------|--|
|     |   |                 |        |                        | material;<br>antimicrobial<br>properties;<br>coconut oil<br>component;<br>cosmetics                          |
| 198 | 3-Chlorophthalic<br>Anhydride             | 117-21-<br>5    | 182.56 | 99-<br>101             | Intermediate for<br>polyimides, dyes,<br>and<br>pharmaceutical<br>synthesis;<br>separation from 4-<br>isomer |
| 199 | 4-Chlorophthalic<br>Anhydride             | 118-45-<br>6    | 182.56 | 97-<br>99              | Intermediate in<br>synthesis of<br>pharmaceuticals,<br>dyes, and polymer<br>additives                        |
| 201 | 2,2-<br>Bis(hydroxymethyl)butyric<br>Acid | 10097-<br>02-6  | 134.13 | 90-<br>93              | Monomer for<br>waterborne<br>polyurethane<br>dispersions;<br>coatings and<br>adhesive industry               |
| 202 | Calcium Sulfate Dihydrate                 | 10101-<br>41-4  | 172.17 | ~14<br>50<br>(anh<br>) | Gypsum; plaster<br>of Paris;<br>construction<br>materials; food<br>additive (E516);<br>medical casting       |
| 204 | 3-Pentadecylphenyl<br>Acrylate            | 119080<br>-22-7 | 358.57 | 32-<br>34              | Monomer from<br>natural cardanol;<br>bio-based polymer<br>synthesis;<br>coatings and<br>resins               |
| 205 | Methanesulfonamide                        | 3144-<br>09-0   | 95.10  | 87-<br>90              | Pharmaceutical<br>intermediate;<br>reagent in organic<br>synthesis;<br>carbonic                              |

|     |                                   |            |        |         |  |
|-----|-----------------------------------|------------|--------|---------|--|
|     |                                   |            |        |         | anhydrase inhibitor model  |
| 208 | 4-Methylphthalic Anhydride        | 19438-61-0 | 162.14 | 52-54   | Intermediate for polyimides, alkyd resins, dyes; asymmetric synthesis reagent  |
| 209 | 1,5-Pentylendiamine Hydrochloride | 541-69-5   | 124.61 | 220-225 | Biobased precursor to pentamethylene diisocyanate (PDI) for polyurethane synthesis                                   |
| 213 | 6-Chloropyridazin-3-amine         | 5469-69-2  | 129.55 | 190-192 | Heterocyclic intermediate in pharmaceutical synthesis; building block for CNS drugs                                  |
| 215 | 2-Naphthaldehyde                  | 66-99-9    | 156.18 | 59-62   | Fragrance intermediate; synthesis of naphthalene derivatives; dye intermediate                                       |
| 222 | Ethylene Thiourea                 | 96-45-7    | 102.15 | 203-206 | Vulcanization accelerator for neoprene rubber; fungicide intermediate; pharmaceutical synthesis                      |
| 226 | 2-Amyl Anthraquinone              | 13936-21-5 | 278.35 | 54-57   | Working carrier in hydrogen peroxide (H <sub>2</sub> O <sub>2</sub> ) production via anthraquinone oxidation process |
| 227 | N-Ethyl-2,2-diisopropylbutylamide | 7087-68-5  | 213.36 | ~10     | Synthetic cooling agent (WS-27); topical cooling   |

|     |                                |            |        |           |  |
|-----|--------------------------------|------------|--------|-----------|--|
|     |                                |            |        |           | sensation in cosmetics, oral care, and food  |
| 231 | 2-Amino-4,6-dichloropyrimidine | 56-05-3    | 164.00 | 209 - 212 | Building block for pharmaceuticals (antivirals, antimalarials, herbicides); heterocyclic chemistry |
| 232 | N-Acetyl-1,3-phenylenediamine  | 102-28-3   | 150.18 | 78-81     | Intermediate in dye synthesis; antioxidant for rubber; pharmaceutical intermediate                 |
| 234 | 3-Amino-6-bromopyridazine      | 88497-27-2 | 174.00 | 150 - 153 | Heterocyclic building block for pharmaceutical synthesis; antimicrobial and antifungal compounds   |
| 236 | 3-Methyl-1,2-cyclopentanedione | 765-70-8   | 112.13 | 215 - 218 | Flavor compound; maple syrup aroma; food flavoring; synthesis of natural product analogs           |
| 237 | 3-Ethoxysalicylaldehyde        | 492-88-6   | 166.17 | 73-76     | Intermediate in synthesis of Schiff base ligands, dyes, and pharmaceutical compounds               |
| 238 | Glutaric Anhydride             | 108-55-4   | 114.10 | 55-57     | Synthesis of glutaric acid derivatives; crosslinking agent; polymer                                |

|     |                            |          |        |           |  |
|-----|----------------------------|----------|--------|-----------|--|
|     |                            |          |        |           | and pharmaceutical intermediate  |
| 243 | 4,4'-Dinitrodiphenyl Ether | 101-63-3 | 260.20 | 141 - 143 | Intermediate for polyimide synthesis; high-performance polymer monomers; electronic applications   |
| 244 | 2-Benzimidazolone          | 615-16-7 | 134.14 | 317 - 320 | Building block for pharmaceuticals, dyes (benzimidazolone pigments), and agricultural chemicals    |
| 245 | Musk Ketone (repeat)       | 81-14-1  | 294.35 | 135 - 136 | Nitro musk fragrance compound; perfumery and cosmetics; currently restricted in many jurisdictions |
| 251 | Fluorene                   | 86-73-7  | 166.22 | 114 - 116 | PAH compound; synthesis of fluorene-based polymers for OLEDs; pharmaceutical intermediate          |
| 252 | 4-Biphenylcarboxylic Acid  | 92-92-2  | 198.22 | 225 - 228 | Monomer for high-performance polymers; liquid crystal materials; pharmaceutical intermediate       |

|     |                              |          |        |                 |   |
|-----|------------------------------|----------|--------|-----------------|---|
| 254 | Dicyandiamide (repeat)       | 461-58-5 | 84.08  | 207<br>-<br>212 | Soil nitrification inhibitor; epoxy resin hardener; guanidine compound precursor                |
| 257 | 2,3,4-Trimethoxybenzoic Acid | 573-11-5 | 212.20 | 148<br>-<br>150 | Pharmaceutical intermediate; veratrum acid derivative; synthesis of colchicine analogs          |
| 258 | 2-Naphthoxyacetic Acid       | 120-23-0 | 202.21 | 156<br>-<br>158 | Plant growth regulator; fruit thinning agent; pharmaceutical intermediate                       |
| 261 | 4-Fluorobenzoic Acid         | 456-22-4 | 140.11 | 182<br>-<br>185 | Pharmaceutical intermediate; PET tracer precursor; synthesis of fluorinated compounds           |
| 262 | 3-Nitrobenzonitrile          | 619-24-9 | 148.12 | 111<br>-<br>112 | Pharmaceutical intermediate; synthesis of triazoles and tetrazoles; agrochemical building block |
| 264 | Diphenolic Acid              | 126-00-1 | 270.32 | 171<br>-<br>174 | Bisphenol A analog from levulinic acid; bio-based monomer for resins and polymers               |
| 265 | Isatoic Anhydride            | 118-48-9 | 163.13 | 244<br>-<br>246 | Reagent for synthesis of anthranilic acid amides; pharmaceuticals,                              |

|     |  |            |        |             |   |
|-----|--|------------|--------|-------------|---|
|     |  |            |        |             | agrochemicals, and dyes   |
| 266 | 2-Anilino-6-(dibutylamino)-3-methylfluoran | 89331-94-2 | 532.69 | 64-68       | ODB-2 leuco dye; thermal paper developer for receipt and label printing   |
| 268 | N,N'-Diphenylthiourea                      | 102-08-9   | 228.31 | 153-155     | Vulcanization accelerator for rubber; corrosion inhibitor; flotation agent in mining                            |
| 270 | Ammonium Chloride                          | 12125-02-9 | 53.49  | 338 (sub l) | Fertilizer nitrogen source; soldering flux; food additive (E510); cold pack coolant; pharmaceutical expectorant |
| 271 | 2-Amino-6-chloropyrazine                   | 33332-28-4 | 129.55 | 158-161     | Heterocyclic intermediate; pharmaceutical synthesis building block for kinase inhibitors                        |

## 6.5 Agrochemicals

**Table 6.5 Agrochemical compounds – molecular properties and applications**

| No. | Compound Name | CAS No.     | MW (g/mol) | T <sub>m</sub> (°C) | Primary Uses  |
|-----|---------------|-------------|------------|---------------------|---|
| 3   | Spirotetramat | 203313-25-1 | 373.46     | 148-149             | Systemic insecticide and acaricide; controls sucking pests (aphids, whiteflies, mites) in agriculture |
| 217 | Diflufenican  | 83164-33-4  | 394.28     | 159-161             | Herbicide; inhibits carotenoid biosynthesis; control of broad-leaved weeds in cereals                 |

|     |                                     |         |        |         |  |
|-----|-------------------------------------|---------|--------|---------|--|
| 260 | 2-Methyl-4-chlorophenoxyacetic Acid | 94-74-6 | 200.62 | 119-121 | Systemic herbicide (MCPA); selective control of broad-leaved weeds in cereals and turf |
|-----|-------------------------------------|---------|--------|---------|--|

## 6.6 Energetic Materials

**Table 6.6 Energetic Material compounds – molecular properties and applications**

| No. | Compound Name                          | CAS No.    | MW (g/mol) | T <sub>m</sub> (°C) | Primary Uses   |
|-----|--|------------|------------|---------------------|--|
| 1   | Tetranitroglycoluril                   | N/A        | 316.11     | Decomposes >260     | High-energy density material; used in propellants, explosives, and pyrotechnics                                  |
| 16  | Guanidine Nitrate                      | 506-93-4   | 122.10     | 213-215             | Gas generator propellant in automotive airbags; pyrotechnic compositions; precursor to guanidine derivatives     |
| 28  | 2,4,6-Trinitro-3-Bromoanisole          | 30566-49-1 | 336.07     | 63-65               | Energetic compound; intermediate in synthesis of nitroanisole derivatives; research purposes                     |
| 57  | 1,3-Diaminoguanidine Monohydrochloride | 36062-19-8 | 124.53     | >250                | Energetic material precursor; synthesis of tetrazoles and other nitrogen-rich compounds; propellant applications |

|    |                     |            |        |       |  |
|----|---------------------|------------|--------|-------|--|
| 96 | 1,3-Dinitropyrazole | 38858-81-0 | 158.07 | 90-92 | High-energy density material; pharmaceutical synthesis intermediate; energetic binder research |
|----|---------------------|------------|--------|-------|--|

## 6.7 Sugars, Polyols, and Amino Acids

**Table 6.7 Sugar/Polyol compounds – molecular properties and applications**

| No. | Compound Name | CAS No.  | MW (g/mol) | T <sub>m</sub> (°C) | Primary Uses  |
|-----|---------------|----------|------------|---------------------|---|
| 33  | Erythritol    | 149-32-6 | 122.12     | 119-122             | Zero-calorie sweetener; food additive (E968); humectant in cosmetics; low glycemic index sugar substitute |
| 69  | D-Tagatose    | 87-81-0  | 180.16     | 133-135             | Low-calorie sweetener; antidiabetic effects; prebiotic activity; used in food and pharmaceutical industry |
| 135 | d-Sorbitol    | 50-70-4  | 182.17     | 93-97               | Sugar alcohol sweetener; humectant in cosmetics; laxative; pharmaceutical excipient; food additive        |
| 274 | D-Psicose     | 551-68-8 | 180.16     | 109-111             | Rare C-3 epimer of fructose; low-calorie sweetener (0.2 kcal/g); anti-obesity and antidiabetic effects    |

## 7. Conclusion

### 7.1 Summary of Principal Findings

This systematic review has synthesised solid–liquid equilibrium data, thermodynamic modelling results, and solvent-effect analyses from 296 peer-reviewed publications spanning the years 2012 to 2026. The comprehensive dataset covers more than 200 distinct chemical entities across seven compound categories: pharmaceuticals, natural products, organic acids, industrial chemicals, agrochemicals, energetic materials, and sugars/polyols. The following principal conclusions emerge from this synthesis.

## 7.2 Universal Temperature Dependence

Solubility increases monotonically with temperature for the vast majority of compounds and solvents studied in this review a fundamental consequence of the predominantly endothermic character of dissolution for organic solids. The van't Hoff equation provides a quantitative description of this temperature dependence and serves as the primary tool for extracting standard dissolution enthalpies and entropies. Rare cases of negative temperature dependence (exothermic dissolution) were documented for  $\beta$ -arbutin in organic solvents, sodium acetate in trifluoroethanol, and certain dicyandiamide systems. [52], [174], [186], [275]

The temperature sensitivity of solubility quantified as  $d(x)/dT$  ranges from modest ( $\sim 1$ – $3\%$  per K for simple salts) to dramatic (20-fold increase over 40 K for clorsulon in ethylene glycol). Understanding and quantifying this sensitivity is essential for designing cooling crystallisation processes: compounds with high  $d(x)/dT$  are ideal for cooling crystallisation, while those with weak temperature dependence require antisolvent strategies. [49]

## 7.3 Dominance of the Modified Apelblat Equation

The three-parameter modified Apelblat equation is the most universally applicable and most accurate model for correlating experimental SLE data, providing ARD values below 2% for the majority of studied systems. Its flexibility from linear to strongly non-linear temperature dependence encompasses the full diversity of compound–solvent combinations encountered. The Apelblat equation is strongly recommended as the primary correlation equation for new SLE datasets, with the  $\lambda h$  and van't Hoff equations providing two-parameter alternatives that enable direct thermodynamic interpretation.

Activity coefficient models (Wilson, NRTL, UNIQUAC) provide physically richer descriptions of non-ideal solution behaviour and should be preferred when thermodynamic mixing properties ( $\Delta G_{\text{mix}}$ ,  $\Delta H_{\text{mix}}$ ,  $\Delta S_{\text{mix}}$ , activity coefficients) are required, as these cannot be extracted from empirical equations. The NRTL model demonstrated the best and most consistent performance among activity coefficient models across diverse compound classes.

## 7.4 Thermodynamic Character

The dominant thermodynamic character of dissolution across the reviewed compounds is endothermic, entropy-driven, and non-spontaneous under saturation conditions ( $\Delta H^\circ > 0$ ,  $\Delta S^\circ > 0$ ,  $\Delta G^\circ > 0$ ). The positive entropy contribution arising from lattice disruption and mixing typically dominates the dissolution Gibbs energy, making entropic driving forces the primary thermodynamic explanation for why organic solids dissolve in organic solvents at all. The enthalpy term opposes

dissolution (unfavourable, endothermic) but is overcome by the entropic driving force at temperatures above the melting point/eutectic temperature.

The enthalpy–entropy compensation analysis across multiple compounds confirms that  $\Delta\%TS > 50\%$  for approximately 80% of the pharmaceutical compounds reviewed, firmly establishing entropy as the dominant contributor to the dissolution free energy in this class. In contrast, smaller molecules (amino acids, simple organic acids) show a somewhat more balanced enthalpy/entropy split, reflecting their greater involvement of hydrogen-bond network disruption in the dissolution process.

## 7.5 Solvent Selection Principles

The solvent-effect analyses conducted using KAT-LSER and HSP frameworks across approximately 90 of the reviewed articles provide convergent, quantitative guidance for solvent selection in pharmaceutical and industrial crystallisation:

- For polar APIs with multiple hydrogen-bond donors (sulfonamides, amines, alcohols): Polar aprotic solvents (DMSO, DMF, DMAC, NMP) with high  $\beta$  (hydrogen-bond acceptor) capacity provide the highest solubility and are thus best for dissolution and re-crystallisation. The cavity term (high cohesive energy density) should be minimised in the solvent.
- For lipophilic compounds (terpenoids, steroids, lipid-like drugs): Non-polar or weakly polar solvents (toluene, esters, chlorinated solvents) with low  $\delta H$  are preferred. PEG-400 is highly effective as a pharmaceutical solvent for many lipophilic APIs due to its unusual combination of amphiphilicity and low cohesive energy density.
- For ionic compounds (hydrochloride salts, sodium salts): Water and lower alcohols are typically most effective. The solubility order within alcohols consistently follows the decreasing polarity trend: methanol > ethanol > propanols > butanols.
- For crystallisation using antisolvent approaches: Water addition to organic solvent systems provides the greatest solubility reduction for most organic compounds, enabling efficient crystallisation yield. The optimal organic solvent:water ratio for maximum yield should be identified from binary SLE data.

The Hansen solubility parameter analysis consistently identifies the best solvent as the one with the minimum total Ra distance to the solute in three-dimensional ( $\delta D$ ,  $\delta P$ ,  $\delta H$ ) space. This simple geometric criterion, derived from purely computational data without experimental measurement, correctly predicted the experimental solubility order in approximately 75% of cases across the reviewed articles a remarkable predictive power that validates the thermodynamic basis of the HSP framework.

## 7.6 Polymorphism and Solid-Form Considerations

Several of the reviewed compounds are known to exist in multiple polymorphic forms, and the influence of polymorphism on solubility is an important theme. Dabigatran

etexilate mesylate (Forms I, II, M, and Hemihydrate) was studied in five solvents (2020), demonstrating that solubility differs significantly between polymorphs, with the thermodynamically stable form (lowest Gibbs energy solid) showing the lowest solubility. Rivaroxaban forms I and II were compared in seven solvents (2017), confirming that the metastable form II has higher solubility than the stable form I a classical result in pharmaceutical polymorphism.

The prevalence of polymorphic transformation during solubility measurement (monitored by PXRD in approximately 150 articles) underscores the importance of solid-state characterisation as an integral component of any SLE study. Failure to verify solid-form identity can result in mixed-phase solubility measurements that are thermodynamically meaningless.

### **7.7 Implications for Pharmaceutical Development**

The solubility and thermodynamic data compiled in this review have direct and immediate implications for pharmaceutical development:

- Crystallisation process design: The comprehensive SLE data enable selection of optimal solvent systems for crystallisation, calculation of theoretical yield as a function of temperature and composition, and rational design of seeding, cooling, and antisolvent profiles.
- Solubility enhancement: The HSP and KAT-LSER analyses identify the physicochemical drivers of solubility, guiding the selection of co-solvents, surfactants, cyclodextrin complexation partners, or co-crystal formers to enhance bioavailability of BCS Class II compounds.
- Stability assessment: Thermodynamic data from SLE measurements ( $\Delta G^\circ$ , activity coefficients) inform stability predictions for solid dispersions, amorphous formulations, and co-crystals, where thermodynamic stability against crystallisation is a key quality attribute.
- Salt and polymorph screening: The ranking of solubilities across solvent classes provides guidance for salt form selection (more hydrophilic counterions for better aqueous solubility) and identifies solvents for polymorph screening during solid-state development.

### **7.8 Future Research Directions**

Despite the comprehensive coverage of the 296 reviewed articles, several research areas remain underexplored and represent priority directions for future work:

- Green and bio-based solvents: Only a small fraction of reviewed studies examined bio-based solvents (cyclopentyl methyl ether, 2-methyltetrahydrofuran, ethyl lactate, limonene) or deep eutectic solvents (DES). Given the increasing regulatory and sustainability pressure to replace traditional organic solvents, systematic SLE measurements in these media are urgently needed.
- Machine learning integration: The comprehensive dataset compiled in this review with over 10,000 individual solubility data points spanning >200 compounds, >50 solvents, and 50-year temperature ranges provides an ideal training set for

machine learning models predicting solubility from molecular structure and solvent properties.

- Supercooled liquid systems: Amorphous formulations of poorly soluble drugs represent a growing area of pharmaceutical practice. SLE measurements on supercooled liquid forms and amorphous dispersions extend classical SLE theory into kinetically controlled regimes.
- Multicomponent systems: Most reviewed studies address binary (solute + single solvent) or ternary (solute + binary solvent) systems. Quaternary and more complex systems relevant to pharmaceutical processing (including excipients, buffers, and counter-ions) remain largely unstudied.

## 8. Reference

[1] *tetranitroglycoluril*. Solubility and dissolution thermodynamics of tetranitroglycoluril in organic solvents at 295–318 K. (2017). <https://doi.org/10.1134/S0036024417080374>

[2] *pioglitazone hydrochloride*. Determination of the Solubility, Dissolution Enthalpy, and Entropy of Pioglitazone Hydrochloride (Form II) in Different Pure Solvents. (2013). <https://doi.org/10.1021/ie303588j>

[3] *spirotetramat*. Solubility determination and correlation for spirotetramat in different solvent systems at T = 278.15–318.15 K. (2022). <https://doi.org/10.1016/j.jct.2022.106854>

[4] *Sulfanilic Acid*. Thermodynamic Models for Determination of the Solubility of Sulfanilic Acid in Different Solvents at Temperatures from (278.15 to 328.15) K. (2014). <https://doi.org/10.1021/je500867u>

[5] *Emtricitabine*. Solubility, Hansen Solubility Parameters and Thermodynamic Behavior of Emtricitabine in Various (Polyethylene Glycol-400 + Water) Mixtures: Computational Modeling and Thermodynamics. (2020). <https://doi.org/10.3390/molecules25071559>

[6] *brigatinib*. Solubility determination, computational modeling, Hansen solubility parameters and apparent thermodynamic analysis of brigatinib in (ethanol + water) mixtures. (2020). <https://doi.org/10.1515/zpch-2020-1715>

[7] *2-Methylnaphthalene*. Solubility Determination and Thermodynamic Models for 2-Methylnaphthalene in Different Solvents from T = (278.15 to 303.15) K. (2015). <https://doi.org/10.1021/je5010627>

[8] *succinic acid*. Solubility of succinic acid in different aqueous solvent mixtures: Experimental measurement and thermodynamic modeling. (2013). <https://doi.org/10.1016/j.fluid.2012.12.018>

- [9] *cabozantinib malate*. Equilibrium solubility determination, Hansen solubility parameters and solution thermodynamics of cabozantinib malate in different monosolvents of pharmaceutical importance. (2021). <https://doi.org/10.1016/j.molliq.2020.115146>
- [10] *Curcumin*. Temperature Effects on Thermodynamic Parameters and Solubility of Curcumin O/W Nanodispersions Using Different Thermodynamic Models. (2019). <https://doi.org/10.1515/ijfe-2018-0311>
- [11] *actarit*. Research on solubility modelling of actarit in different solvents: Solvent effect, Hansen solubility parameter, molecular interactions and solution thermodynamics. (2022). <https://doi.org/10.1016/j.molliq.2021.117965>
- [12] *Dibenzothiophene*. Thermodynamic Models for Determination of the Solubility of Dibenzothiophene in Different Solvents at Temperatures from (278.15 to 328.15) K. (2014). <https://doi.org/10.1021/je500437m>
- [13] *phthalic anhydride*. Solubility and dissolution thermodynamics of phthalic anhydride in organic solvents at 283–313 K. (2017). <https://doi.org/10.1134/S0036024417080179>
- [14] *vanillic acid*. Temperature dependent solubility of vanillic acid in aqueous methanol mixtures: Measurements and thermodynamic modeling. (2016). <https://doi.org/10.1016/j.molliq.2016.04.095>
- [15] *4,4'-Dihydroxydiphenyl Sulfone*. Solubility Measurement and Modeling of 4,4'-Dihydroxydiphenyl Sulfone in Nine Organic Solvents from T = (278.15 to 313.15) K and Thermodynamic Property of Dissolution. (2015). <https://doi.org/10.1021/acs.jced.5b00714>
- [16] *guanidine nitrate*. Correlation of solubility and calculation of thermodynamic properties of guanidine nitrate in different solvents. (2015). <https://doi.org/10.1016/j.fluid.2014.12.037>
- [17] *lidocaine hydrochloride*. Determination and correlation of solubility with thermodynamic analysis of lidocaine hydrochloride in pure and binary solvents. (2018). <https://doi.org/10.1016/j.molliq.2018.06.035>
- [18] *hydrocortisone*. Thermodynamic equilibrium of hydrocortisone form I in different solvent systems. (2017). <https://doi.org/10.1016/j.fluid.2017.09.007>
- [19] *thymol*. Solubility and solution thermodynamics of thymol in six pure organic solvents. (2016). <https://doi.org/10.1016/j.jct.2015.09.010>

- [20] *ethenzamide*. Determination and correlation of solubility and solution thermodynamics of ethenzamide in different pure solvents. (2016). <https://doi.org/10.1016/j.fluid.2016.08.019>
- [21] *regorafenib*. Solubility measurement, thermodynamic modeling, and molecular dynamic simulation of regorafenib in pure and binary solvents. (2022). <https://doi.org/10.1016/j.jct.2021.106720>
- [22] *Ipriflavone*. Solid-liquid equilibrium solubility, thermodynamic properties, solvent effect of Ipriflavone in twelve pure solvents at various temperatures. (2020). <https://doi.org/10.1016/j.jct.2020.106231>
- [23] *baicalein*. Solubility and thermodynamic properties of baicalein in water and ethanol mixtures from 283.15 to 328.15 K. (2019). <https://doi.org/10.1080/00986445.2019.1700116>
- [24] *Terbinafine Hydrochloride*. Solubility Determination and Thermodynamic Correlation for Terbinafine Hydrochloride in Several Mono-solvents from 283.15 to 323.15 K. (2023). <https://doi.org/10.1021/acs.jced.2c00731>
- [25] *marbofloxacin*. Solubility measurement, correlation and dissolution thermodynamics properties of marbofloxacin in binary solvents. (2022). <https://doi.org/10.1016/j.molliq.2022.119288>
- [26] *Levetiracetam*. Solubility Measurement and Thermodynamic Properties of Levetiracetam in Pure and Mixed Solvents. (2018). <https://doi.org/10.1021/acs.jced.8b00720>
- [27] *Diphenoxylate*. Solubility and Solution Thermodynamics of Diphenoxylate in Different Pure Solvents. (2015). <https://doi.org/10.1021/je5010033>
- [28] *2,4,6-Trinitro-3-Bromoanisole*. Solid-Liquid Equilibrium Solubility and Thermodynamic Properties of 2,4,6-Trinitro-3-Bromoanisole in Different Pure Solvents. (2025). <https://doi.org/10.1007/s10953-025-01490-z>
- [29] *2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside*. Determination and correlation of the solubility and thermodynamic parameters of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside in pure organic solvents. (2018). <https://doi.org/10.1016/j.molliq.2018.02.046>
- [30] *2,3,4-trichloro-1,5-dinitrobenzene*. Solubility measurement, correlation and thermodynamic properties of 2,3,4-trichloro-1,5-dinitrobenzene in fifteen mono-solvents at temperatures from 278.15 to 323.15 K. (2023). <https://doi.org/10.1016/j.cjche.2022.10.022>

- [31] *2-acrylamido-2-methyl-1-propane-sulfonic acid*. Determination and correlation of solubility data and dissolution thermodynamic data for 2-acrylamido-2-methyl-1-propane-sulfonic acid in seven pure solvents. (2020). <https://doi.org/10.1007/s43153-020-00014-0>
- [32] *Nifedipine*. Determination and correlation thermodynamic models for solid–liquid equilibrium of the Nifedipine in pure and mixture organic solvents. (2016). <https://doi.org/10.1016/j.jct.2016.07.035>
- [33] *erythritol*. Solubility of erythritol in methanol, ethanol and methanol + ethanol: Experimental measurement and thermodynamic modeling. (2013). <https://doi.org/10.1016/j.fluid.2013.09.027>
- [34] *phthalimide*. Solubility modelling and thermodynamic dissolution functions of phthalimide in ten organic solvents. (2016). <https://doi.org/10.1016/j.jct.2015.10.024>
- [35]  *$\beta$ -lapachone*. Solubility evaluation and thermodynamic modeling of  $\beta$ -lapachone in water and ten organic solvents at different temperatures. (2018). <https://doi.org/10.1016/j.fluid.2018.05.005>
- [36] *Emtricitabine*. Solubility Data, Solubility Parameters and Thermodynamic Behavior of an Antiviral Drug Emtricitabine in Different Pure Solvents: Molecular Understanding of Solubility and Dissolution. (2021). <https://doi.org/10.3390/molecules26030746>
- [37] *methyleneaminoacetonitrile*. Measurement and correlation of solubility of methyleneaminoacetonitrile in pure and binary solvents and thermodynamic properties of solution. (2019). <https://doi.org/10.1016/j.jct.2019.01.015>
- [38] *Nicotinamide*. Solid–Liquid Phase Equilibrium of Nicotinamide in Different Pure Solvents: Measurements and Thermodynamic Modeling. (2014). <https://doi.org/10.1021/ie403628d>
- [39] *oxaprozin*. Thermodynamic modelling, Hansen solubility parameter and solvent effect of oxaprozin in thirteen pure solvents at different temperatures. (2020). <https://doi.org/10.1016/j.jct.2020.106239>
- [40] *3,4-Dichloronitrobenzene*. Solubility of 3,4-Dichloronitrobenzene in Methanol, Ethanol, and Liquid Mixtures (Methanol + Water, Ethanol + Water): Experimental Measurement and Thermodynamic Modeling. (2013). <https://doi.org/10.1021/je400507u>
- [41] *chlorzoxazone*. Correlation of solubility data and solution properties of chlorzoxazone in pure solvents. (2022). <https://doi.org/10.1016/j.jct.2022.106777>

- [42] *5-Fluorouracil*. Solubility, Hansen solubility parameter, molecular simulation and apparent thermodynamic analysis of 5-Fluorouracil in four binary solvents. (2022). <https://doi.org/10.1016/j.molliq.2022.119759>
- [43] *Ibuprofen Sodium Dihydrate*. Solubility of Ibuprofen Sodium Dihydrate in Acetone + Water Mixtures: Experimental Measurement and Thermodynamic Modeling. (2014). <https://doi.org/10.1021/je5004093>
- [44] *N-hydroxymethyl acrylamide*. Determination of the solubility, dissolution enthalpy and entropy of N-hydroxymethyl acrylamide in different solvents. (2016). <https://doi.org/10.1016/j.molliq.2016.10.098>
- [45] *Mifepristone*. Measurement and Correlation of the Solubility of Mifepristone in Eight Pure and Water + Methanol Mixed Solvents at Temperatures from 273.15 to 318.15 K. (2019). <https://doi.org/10.1021/acs.jced.8b01062>
- [46] *Thiamphenicol*. Solubility Modeling and Mixing Thermodynamics of Thiamphenicol in Water and Twelve Neat Organic Solvents from T = (278.15 to 318.15) K. (2017). <https://doi.org/10.1021/acs.jced.7b00542>
- [47] *Stearic acid*. Stearic acid solubility in mixed solvents of (water + ethanol) and (ethanol + ethyl acetate): Experimental data and comparison among different thermodynamic models. (2019). <https://doi.org/10.1016/j.molliq.2019.112101>
- [48] *Bupivacaine Hydrochloride*. Solubility Modeling of a Bupivacaine Hydrochloride in Various Solvents over a Wide Temperature Range. (2023). <https://doi.org/10.1021/acs.jced.2c00741>
- [49] *clorsulon*. Systematic thermodynamic study of clorsulon dissolved in ten organic solvents: Mechanism evaluation by modeling and molecular dynamic simulation. (2021). <https://doi.org/10.1016/j.molliq.2021.117217>
- [50] *tylosin tartrate*. Determination and correlation of solubility of tylosin tartrate in alcohol mixtures. (2015). <https://doi.org/10.1016/j.jct.2014.08.026>
- [51] *Amitriptyline Hydrochloride*. Solubility Determination and Thermodynamic Modeling of Amitriptyline Hydrochloride in 13 Pure Solvents at Temperatures of 283.15–323.15 K. (2021). <https://doi.org/10.1021/acs.jced.0c00796>
- [52]  *$\beta$ -Arbutin*. Solubility and Data Correlation of  $\beta$ -Arbutin in Different Monosolvents from 283.15 to 323.15 K. (2019). <https://doi.org/10.1021/acs.jced.9b00703>

- [53] *4,4'-oxydianiline*. Measurement and correlation of the solubility of 4,4'-oxydianiline in different organic solvents. (2013). <https://doi.org/10.1016/j.fluid.2013.07.010>
- [54] *Esculetin*. Solubility Determination and Thermodynamic Model Analysis of Esculetin in Different Solvents from 273.15 to 318.15 K. (2024). <https://doi.org/10.1021/acs.jced.3c00771>
- [55] *P-Chloroaniline*. Solubility Measurement, Model Correlation, Solvent Effects and Thermodynamic Analysis of Thirteen Pure Organic Solutions of P-Chloroaniline. (2025). <https://dx.doi.org/10.2139/ssrn.5266778>
- [56] *thiomalic acid*. Thermodynamics of solubility of thiomalic acid in different organic solvents from 278.15 K to 333.15 K. (2013). <https://doi.org/10.1016/j.fluid.2013.05.002>
- [57] *1,3-Diaminoguanidine Monohydrochloride*. Solubility Determination, Hansen Solubility Parameter, Molecular Simulation, and Thermodynamic Properties of 1,3-Diaminoguanidine Monohydrochloride in 12 Monosolvents from 273.15 to 323.15 K. (2025). <https://doi.org/10.1021/acs.jced.5c00018>
- [58] *2-chloro-3-(trifluoromethyl)pyridine*. Measurement and correlation of solubility of 2-chloro-3-(trifluoromethyl)pyridine in pure solvents and ethanol + n-propanol mixtures. (2017). <https://doi.org/10.1016/j.molliq.2017.04.083>
- [59] *isovanillin*. Solubility determination, model evaluation and solution thermodynamics of isovanillin in 15 pure solvents and 4 binary solvents. (2021). <https://doi.org/10.1016/j.molliq.2021.116847>
- [60] *m-hydroxyacetophenone*. Solubility measurement, modeling, and solvent effect of m-hydroxyacetophenone in ten pure and binary mixed solvents from T = (289.15–325.15) K. (2022). <https://doi.org/10.1016/j.molliq.2022.118798>
- [61] *(-)-shikimic acid*. Thermodynamic models for determination of the solubility of (-)-shikimic acid in different pure solvents and in (H<sub>2</sub>O + ethanol) binary solvent mixtures. (2015). <https://doi.org/10.1016/j.jct.2015.04.009>
- [62] *Capsaicin*. Correlation of Solubility and Prediction of the Mixing Properties of Capsaicin in Different Pure Solvents. (2012). <https://doi.org/10.1021/ie202917x>
- [63] *dabigatran etexilate mesylate Form II*. Measurement and prediction of dabigatran etexilate mesylate Form II solubility in mono-solvents and mixed solvents. (2016). <https://doi.org/10.1016/j.jct.2016.07.048>

- [64] *Ascorbic Acid*. Ascorbic Acid Solubility and Thermodynamic Characteristics in Several Neat Solvents with Temperatures Ranging from 293 to 313 K. (2022). <https://doi.org/10.1007/s10765-022-03055-4>
- [65] *sorbic acid*. Solubility and solution thermodynamics of sorbic acid in eight pure organic solvents. (2015). <https://doi.org/10.1016/j.jct.2015.02.004>
- [66] *N, N'-Oxalyldiglycine*. Solubility Measurement and Model Correlation of N, N'-Oxalyldiglycine in Eleven Pure Solvents and a Binary Solvent from 293.15 to 333.15 K. (2023). <https://doi.org/10.1021/acs.jced.3c00424>
- [67] *1-nitronaphthalene*. Solubility measurement, correlation, thermodynamic analysis and molecular simulation of 1-nitronaphthalene in twelve pure solvents. (2022). <https://doi.org/10.1016/j.molliq.2022.120475>
- [68] *Rosiglitazone*. Solubility behavior of Rosiglitazone in ten pure solvents: Model correlation, thermodynamic calculations, and molecular simulation. (2025). <https://doi.org/10.1016/j.molliq.2024.126543>
- [69] *D-Tagatose*. Investigation of solid–liquid equilibrium and thermodynamic models of D-Tagatose in mono-solvents and binary solvents. (2022). <https://doi.org/10.1016/j.ctta.2022.100084>
- [70] *doxofylline*. The solubility profile and apparent thermodynamic analysis of doxofylline in pure and mixed solvents. (2020). <https://doi.org/10.1016/j.jct.2020.106126>
- [71] *nortriptyline hydrochloride*. Solubility and solution thermodynamics of nortriptyline hydrochloride in organic solvents: Experiment and correlation. (2025). <https://doi.org/10.1016/j.fbp.2024.12.008>
- [72] *4'-bromomethyl-2-cyanobiphenyl*. Thermodynamics of 4'-bromomethyl-2-cyanobiphenyl in different solvents. (2015). <https://doi.org/10.1016/j.jct.2014.12.002>
- [73] *2,3,4,5-tetrabromothiophene*. Measurement and correlation of the solubility of 2,3,4,5-tetrabromothiophene in different solvents. (2012). <https://doi.org/10.1016/j.jct.2012.06.005>
- [74] *cefuroxime acid*. Determination and correlation of cefuroxime acid solubility in (acetonitrile + water) mixtures. (2014). <https://doi.org/10.1016/j.jct.2014.05.018>
- [75] *dabigatran etexilate mesylate polymorphs*. Solubility measurement, correlation and molecular simulation of dabigatran etexilate mesylate polymorphs in five mono-solvents. (2020). <https://doi.org/10.1016/j.molliq.2020.113676>

- [76] *N-acetylglucosamine*. Solubility and thermodynamic properties of N-acetylglucosamine in mono-solvents and binary solvents at different temperatures. (2018). <https://doi.org/10.1080/00319104.2018.1506921>
- [77] *trans-3-Hydroxycinnamic Acid*. Solubility Measurement, Correlation, and Thermodynamic Study of trans-3-Hydroxycinnamic Acid in Nine Pure Solvents and (Ethanol + Ethyl Acetate) Cosolvent Mixtures at Temperatures from 293.15 to 333.15 K. (2023). <https://doi.org/10.1021/acs.jced.3c00198>
- [78] *para-Methoxyphenylacetic Acid*. Solubility Measurement, Modeling, and Thermodynamic Functions for para-Methoxyphenylacetic Acid in Pure and Mixed Organic and Aqueous Systems. (2018). <https://doi.org/10.1021/acs.jced.8b00271>
- [79] *furosemide (form I)*. Research on furosemide (form I) in sixteen mono-solvents: Solubility determination and models, thermodynamic analysis, DFT calculation and molecular dynamic simulation. (2026). <https://doi.org/10.1016/j.jct.2025.107579>
- [80] *Sulfanilamide*. Solubility and Thermodynamic Modeling of Sulfanilamide in 12 Mono Solvents and 4 Binary Solvent Mixtures from 278.15 to 318.15 K. (2019). <https://doi.org/10.1021/acs.jced.9b00411>
- [81] *omeprazole*. Thermodynamic models for determination of the solubility of omeprazole in pure and mixture organic solvents from T = (278.15 to 333.15) K. (2016). <https://doi.org/10.1016/j.jct.2015.11.005>
- [82] *tartaric acid*. Correlation and prediction of the solubility of the racemic tartaric acid-ethanol-water system with the NRTL model. (2016). <https://doi.org/10.1016/j.molliq.2016.01.080>
- [83] *Mequindox*. Solubility and dissolution thermodynamic properties of Mequindox in binary solvent mixtures. (2020). <https://doi.org/10.1016/j.molliq.2020.112619>
- [84] *Cefixime Disodium*. Solubility of Cefixime Disodium in Seven Pure Solvents. (2020). <https://doi.org/10.1134/S0036024420060333>
- [85] *verapamil hydrochloride*. Solubility determination and thermodynamic modelling of verapamil hydrochloride in methanol-water binary solvent systems from 293.15 K to 323.15 K. (2024). <https://doi.org/10.1016/j.ctta.2024.100148>
- [86] *Tanshinone I*. Solubility Determination, Modeling, and Solvent Effect Analysis of Tanshinone I in Several Solvents at (278.15–323.15) K. (2025). <https://doi.org/10.1021/acs.jced.5c00094>

- [87] *dibenzothiophene*. Solubility of dibenzothiophene in nine organic solvents: Experimental measurement and thermodynamic modelling. (2019).  
<https://doi.org/10.1016/j.jct.2018.09.017>
- [88] *Lidocaine*. Measurement and correlation of the solubility of Lidocaine in eight pure and mixed solvents at temperatures from (292.15 to 332.15) K. (2017).  
<https://doi.org/10.1016/j.molliq.2017.06.110>
- [89] *Cabozantinib Malate*. Solubility and Thermodynamics Data of Cabozantinib Malate in Various Aqueous Solutions of Dimethyl Sulfoxide at Different Temperatures. (2023). <https://doi.org/10.3390/molecules28237805>
- [90] *Favipiravir*. Solubility determination, model correlation, thermodynamic analysis, molecular dynamic simulation of Favipiravir in twelve pure solvents. (2023). <https://doi.org/10.1016/j.molliq.2023.122208>
- [91] *sulfamonomethoxine*. Solubility measurement and thermodynamic properties of sulfamonomethoxine in pure solvents and sulfamonomethoxine hydrate in acetone + water binary solvent at different temperature. (2021).  
<https://doi.org/10.1016/j.cjche.2020.10.037>
- [92] *itraconazole*. Experimental measurement – correlation of solubility and dissolution thermodynamics study of itraconazole in pure monosolvents at various temperatures. (2021). <https://doi.org/10.1080/03639045.2021.1879841>
- [93] *Benzohydrazide/ 2-Hydroxybenzohydrazide*. Measurement, Solvent Effect, and Thermodynamic Modeling of the Solubility of Benzohydrazide and 2-Hydroxybenzohydrazide in Six Pure Solvents. (2024).  
<https://doi.org/10.1021/acs.jced.4c00217>
- [94] *vanillic acid*. Measurement and Correlation of the Solubility of Vanillic Acid in Eight Pure and Water + Ethanol Mixed Solvents at Temperatures from (293.15 to 323.15) K. (2015). <https://doi.org/10.1021/acs.jced.5b00619>
- [95] *tylosin tartrate*. Solubility correlation and thermodynamic analysis of solution of tylosin tartrate in methanol + tetrahydrofuran or acetone) mixtures. (2015).  
<https://doi.org/10.1016/j.molliq.2014.12.040>
- [96] *ethyl 5-amino-4-cyano-3-(2-ethoxy-2-oxoethyl)-2-thiophenecarboxylate*. Solubility and solution thermodynamics of ethyl 5-amino-4-cyano-3-(2-ethoxy-2-oxoethyl)-2-thiophenecarboxylate in nine organic solvents at evaluated temperatures. (2016).  
<https://doi.org/10.1016/j.jct.2015.11.025>

- [97] *cefazolin acid*. Solubility and thermodynamic functions of cefazolin acid in pure and mixed solvents at (278.15–308.15) K. (2015).  
<https://doi.org/10.1016/j.fluid.2014.12.020>
- [98] *1, 3-dinitropyrazole*. Equilibrium solubility, solvent effect, solvation and thermodynamic modeling of 1, 3-dinitropyrazole in solutions of methyl alcohol /ethyl alcohol + water. (2025). <https://doi.org/10.1016/j.bpc.2025.107430>
- [99] *Thiamine Nitrate*. Measurement and Correlation of Solubility of Thiamine Nitrate in Three Binary Solvents and Thermodynamic Properties for the Solutions in Different Binary Mixtures at (278.15–313.15) K. (2023).  
<https://doi.org/10.3390/molecules28135012>
- [100] *4-acetylbenzoic acid*. Thermodynamics of the solubility of 4-acetylbenzoic acid in different solvents from 303.15 to 473.15 K. (2013).  
<https://doi.org/10.1016/j.molliq.2013.01.023>
- [101] *aceclofenac*. Solubility and thermodynamic analysis of aceclofenac in different {Carbitol + water} mixtures at various temperatures. (2024).  
<https://doi.org/10.1186/s13065-024-01287-z>
- [102] *musk ketone*. Determination and correlation of solubility and solution thermodynamics of musk ketone in twelve pure solvents. (2019).  
<https://doi.org/10.1016/j.molliq.2019.111437>
- [103] *sodium theophylline salt*. Solubility and thermodynamic properties of sodium theophylline salt in aqueous sodium hydroxide solution at different temperatures. (2023). <https://doi.org/10.1177/17475198231166563>
- [104] *Dienogest*. Measurement and Correlation of the Solubility of Dienogest in Twelve Pure and Water + Methanol Binary Solvents at Temperatures from 273.15 to 318.15 K. (2019). <https://doi.org/10.1021/acs.jced.9b00696>
- [105] *indapamide*. Investigation on the Hansen solubility parameter, solvent effect and thermodynamic analysis of indapamide dissolution and molecular dynamics simulation. (2021). <https://doi.org/10.1016/j.molliq.2021.116489>
- [106] *Clarithromycin (form II)* . Solubility measurement, thermodynamic modeling and solubility parameters of Clarithromycin (form II) in aqueous ethanolic solution. (2022). <https://doi.org/10.1080/00319104.2022.2122057>
- [107] *phenylphosphonic acid*. Determination and correlation of solubility of phenylphosphonic acid in selected solvents. (2016).  
<https://doi.org/10.1016/j.molliq.2016.03.021>

- [108] *Febuxostat*. Solubility and Thermodynamic Properties of Febuxostat in Various (PEG 400 + Water) Mixtures. (2022).  
<https://doi.org/10.3390/ma15207318>
- [109] *Febuxostat*. Solubility and Thermodynamic Data of Febuxostat in Various Mono Solvents at Different Temperatures. (2022).  
<https://doi.org/10.3390/molecules27134043>
- [110] *m-Aminobenzoic Acid*. Solubility Measurement and Thermodynamic Correlation of m-Aminobenzoic Acid in 12 Pure Solvents from 283.15 to 323.15 K. (2021). <https://doi.org/10.1021/acs.jced.1c00247>
- [111] *edaravone*. Co-solvent phenomenon and thermodynamic properties of edaravone in pure and mixed solvents. (2019).  
<https://doi.org/10.1016/j.jct.2019.06.018>
- [112] *allantoin*. Determination and correlation of solubility and Thermodynamic properties of allantoin in four binary solvents from 288.15 K to 333.15 K. (2023).  
<https://doi.org/10.1080/00986445.2023.2218268>
- [113]  *$\alpha$ -glycine*. Solubility of  $\alpha$ -glycine in water with additives at a temperature range of (293.15–343.15) K: Experimental data and results of thermodynamic modeling. (2017). <https://doi.org/10.1016/j.fluid.2016.12.003>
- [114] *temozolomide*. The dissolution behavior and apparent thermodynamic analysis of temozolomide in pure and mixed solvents. (2019).  
<https://doi.org/10.1016/j.jct.2018.11.026>
- [115] *Gibberellin A4*. Solubility and Solution Thermodynamics of Gibberellin A4 in Different Organic Solvents from 278.15 K to 333.15 K. (2015).  
<https://doi.org/10.1021/acs.jced.5b00190>
- [116] *1,3-Dinitropyrazole*. Solubility Measurement, Correlation, and Hansen Solubility Parameter of 1,3-Dinitropyrazole in Twelve Solvents. (2025).  
<https://doi.org/10.1007/s10953-024-01426-z>
- [117] *pazopanib*. Solubility enhancement, solvent effect and thermodynamic analysis of pazopanib in co-solvent mixtures. (2021).  
<https://doi.org/10.1016/j.jct.2020.106343>
- [118] *L- $\alpha$ -glyceryl phosphorylcholine*. Comments Regarding “Solubility determination and thermodynamic model analysis of L- $\alpha$ -glyceryl phosphorylcholine in different organic solvents of 278.15–323.15 K”. (2024).  
<https://doi.org/10.1016/j.jpba.2024.116217>

- [119] *linezolid form II*. Determination and correlation of solubility of linezolid form II in different pure and binary solvents. (2017).  
<https://doi.org/10.1016/j.fluid.2016.10.021>
- [120] *genistein*. Dissolution thermodynamics and preferential solvation of genistein in some (ethanol + water) mixtures at different temperatures. (2022).  
<https://doi.org/10.1080/03639045.2022.2141775>
- [121] *triamterene*. Research on triamterene equilibrium solubility in mono-solvents and aqueous solutions according to solvent effect, models, thermodynamic analysis and quantum chemical calculation. (2024).  
<https://doi.org/10.1016/j.jct.2024.107324>
- [122] *itopride hydrochloride*. Equilibrium solubilities, model analysis, solvent effect, molecular dynamic simulation, and thermodynamic properties of itopride hydrochloride in eleven organic pure solvents at different temperatures. (2024).  
<https://doi.org/10.1016/j.jct.2023.107224>
- [123] *caffeic acid*. Measurement and correlation of the solubility of caffeic acid in eight mono and water + ethanol mixed solvents at temperatures from (293.15 to 333.15) K. (2016). <https://doi.org/10.1016/j.molliq.2016.10.110>
- [124] *R-(+)-2-(4-hydroxyphenoxy) propanic acid*. Determination of the solubility, dissolution enthalpy and entropy of R-(+)-2-(4-hydroxyphenoxy) propanic acid in different solutions. (2017). <https://doi.org/10.1080/00319104.2017.1371168>
- [125] *Thymoquinone*. Solubility Determination, Hansen Solubility Parameters and Thermodynamic Evaluation of Thymoquinone in (Isopropanol + Water) Compositions. (2021). <https://doi.org/10.3390/molecules26113195>
- [126] *rebamipide*. Solvent effect and solubility modeling of rebamipide in twelve solvents at different temperatures. (2019).  
<https://doi.org/10.1016/j.molliq.2019.111041>
- [127] *chrysin*. Solid-liquid equilibria of chrysin in six pure solvents and in aqueous methanol mixtures: temperature dependence and thermodynamics. (2019).  
<https://doi.org/10.1007/s00706-019-02386-7>
- [128] *urea*. Measurement and mathematical correlation of the solubility of urea in polar protic solvents. (2025). <https://doi.org/10.1016/j.jct.2024.107427>
- [129] *1-Hydroxybenzotriazole*. Thermodynamic Functions for Solubility of 1-Hydroxybenzotriazole in Sixteen Solvents at Temperatures from (278.15 to 313.15) K and Mixing Property of Mixtures. (2017).  
<https://doi.org/10.1021/acs.jced.7b00316>

- [130] *dehydroepiandrosterone acetate*. Solubility measurement and thermodynamic functions of dehydroepiandrosterone acetate in different solvents at evaluated temperatures. (2016). <https://doi.org/10.1016/j.jct.2016.01.023>
- [131] *Ammonium Sulfate*. Determination and Correlation of the Solubility of Ammonium Sulfate in Aqueous Solutions of Caprolactam with Different Concentrations. (2025). <https://doi.org/10.1007/s10953-025-01525-5>
- [132] *Gestodene*. Measurement and Correlation of the Solubility of Gestodene in 11 Pure and Binary Mixed Solvent Systems at Temperatures from 283.15 to 323.15 K. (2021). <https://doi.org/10.1021/acs.jced.1c00408>
- [133] *cyclododecanone*. Equilibrium solubility, solvent effect, equation correlation, and thermodynamic properties of cyclododecanone in twelve organic solvents. (2023). <https://doi.org/10.1016/j.molliq.2023.122857>
- [134] *pterostilbene*. Solubility data, Hansen solubility parameters and thermodynamic behavior of pterostilbene in some pure solvents and different (PEG-400 + water) cosolvent compositions. (2021). <https://doi.org/10.1016/j.molliq.2021.115700>
- [135] *Domiphen Bromide*. Equilibrium Solubility of Domiphen Bromide in 12 Mono Solvents: Determination and Correlation. (2024). <https://doi.org/10.1021/acs.jced.3c00598>
- [136] *carvedilol (Form I)*. Equilibrium solubility and solute-solvent interactions of carvedilol (Form I) in twelve mono solvents and its application for supercritical antisolvent precipitation. (2019). <https://doi.org/10.1016/j.molliq.2019.111622>
- [137] *eszopiclone*. Determination and correlation of solubility and thermodynamic properties of eszopiclone in pure and mixed solvents. (2016). <https://doi.org/10.1016/j.molliq.2016.04.121>
- [138] *apixaban*. Dissolution behavior and thermodynamic properties of apixaban in pure and mixed solvents. (2020). <https://doi.org/10.1016/j.jct.2019.105949>
- [139] *d-sorbitol*. Measurement and correlation of solubility of d-sorbitol in different solvents. (2013). <https://doi.org/10.1016/j.molliq.2013.07.014>
- [140] *Isotretinoin*. Solubility and Thermodynamic Analysis of Isotretinoin in Different (DMSO + Water) Mixtures. (2023). <https://doi.org/10.3390/molecules28207110>
- [141] *N,2,3-trimethyl-2-isopropylbutamide*. Solid-liquid equilibrium and thermodynamic properties of N,2,3-trimethyl-2-isopropylbutamide in seventeen

mono solvents from  $T = (273.15 \text{ to } 319.15) \text{ K}$ . (2019).  
<https://doi.org/10.1016/j.molliq.2019.03.120>

[142] *2,5-Furandicarboxylic Acid*. Determination of Solubility and Thermodynamic Analysis of Solubility Behavior of 2,5-Furandicarboxylic Acid in Water and Ether Binary Solvent System. (2023). <https://doi.org/10.1021/acs.jced.2c00730>

[143] *caprolactam*. Solubility behavior and thermodynamic properties of caprolactam in four pure solvents and two cosolvent mixtures. (2024).  
<https://doi.org/10.1016/j.fluid.2024.114101>

[144] *Esmolol Hydrochloride*. Uncovering the Solution Thermodynamic Properties of Esmolol Hydrochloride: Experiments and Molecular Simulations. (2025).  
<https://doi.org/10.1021/acs.jced.5c00305>

[145] *Syringic Acid*. Solubility and Thermodynamic Behavior of Syringic Acid in Eight Pure and Water + Methanol Mixed Solvents. (2017).  
<https://doi.org/10.1021/acs.jced.7b00333>

[146] *Dimethyl Terephthalate*. Solubility and Thermodynamic Modeling of Dimethyl Terephthalate in Pure Solvents and the Evaluation of the Mixing Properties of the Solutions. (2019). <https://doi.org/10.1021/acs.jced.9b00658>

[147] *1,3,5-Trichlorobenzene*. Solubility and Dissolution Thermodynamics for 1,3,5-Trichlorobenzene in Organic Solvents. (2015).  
<https://doi.org/10.1021/acs.jced.5b00607>

[148] *Nintedanib*. Solid-liquid phase equilibrium of Nintedanib in ten pure solvents: Determination, thermodynamic analysis, model correlation and molecular simulation. (2021). <https://doi.org/10.1016/j.jct.2021.106595>

[149] *dimetridazole*. Solid-liquid equilibrium behavior, thermodynamic analysis and molecular simulation of dimetridazole in twelve organic solvents. (2021).  
<https://doi.org/10.1016/j.molliq.2021.116252>

[150] *Dimethyl Terephthalate*. Solubility and Thermodynamic Modeling of Dimethyl Terephthalate in Pure Solvents and the Evaluation of the Mixing Properties of the Solutions. (2019). <https://doi.org/10.1021/acs.jced.9b00658>

[151] *Carvedilol*. Determination and Correlation of Solubility of Carvedilol in Six Pure Solvents and Three Binary Solvent Mixtures at  $T = 278.15\text{--}313.15 \text{ K}$ . (2020).  
<https://doi.org/10.1021/acs.jced.0c00040>

[152] *androstenedione*. Solubility of androstenedione in lower alcohols. (2014).  
<https://doi.org/10.1016/j.fluid.2013.11.008>

- [153] *hippuric acid*. Solubility and solution thermodynamics of hippuric acid in various solvents from 298.15 K to 328.15 K. (2017).  
<https://doi.org/10.1016/j.molliq.2017.04.122>
- [154] *Triethylamine Hydrochloride*. Solubility Determination and Model Evaluation of Triethylamine Hydrochloride in Three Binary Mixed Solvents. (2024).  
<https://doi.org/10.1007/s10953-024-01379-3>
- [155] *nevirapine*. Solubility determination and thermodynamic model analysis of nevirapine in different organic solvents from 278.15 K to 328.15 K. (2022).  
<https://doi.org/10.1016/j.molliq.2022.120173>
- [156] *2-Ethoxybenzamide*. Solubility Determination and Thermodynamic Correlation of 2-Ethoxybenzamide in 12 Pure Solvents from 288.15 to 328.15 K. (2021).  
<https://doi.org/10.1021/acs.jced.0c01081>
- [157]  *$\beta$ -Cyclodextrin*. Measurement and Correlation of the Solubility of  $\beta$ -Cyclodextrin in Different Solutions at Different Temperatures and Thermodynamic Study of the Dissolution Process. (2019). <https://doi.org/10.3390/pr7030135>
- [158] *isosorbide 5-mononitrate*. Effects of intermolecular interactions and solvent properties on the solid-liquid phase equilibrium of isosorbide 5-mononitrate. (2022). <https://doi.org/10.1016/j.molliq.2022.119974>
- [159] *praziquantel*. Uncovering the effect of solvents on solid-liquid phase equilibrium of praziquantel. (2020). <https://doi.org/10.1016/j.molliq.2019.111917>
- [160] *dl-malic acid*. Solubility of dl-malic acid in water, ethanol and in mixtures of ethanol + water. (2014). <https://doi.org/10.1016/j.fluid.2014.06.017>
- [161] *rivaroxaban polymorphs*. Solubility measurement, model evaluation and thermodynamic analysis of rivaroxaban polymorphs in organic solvents. (2017).  
<https://doi.org/10.1016/j.jct.2016.09.036>
- [162] *Oxalic Acid*. Exploration of the Solid–Liquid Equilibrium Characteristics of Oxalic Acid in 12 Solvents: Investigation into Solubility, Model Correlation, and Molecular Simulation. (2025). <https://doi.org/10.1021/acs.jced.4c00697>
- [163] *2,5-thiophenedicarboxylic acid*. Solid–liquid equilibrium and thermodynamic of 2,5-thiophenedicarboxylic acid in different organic solvents. (2014).  
<https://doi.org/10.1016/j.fluid.2014.05.003>
- [164] *methyl gallate*. Measurement and correlation of solubility of methyl gallate in nine pure and ethanol + n-propanol mixed solvents at temperatures within 293.15–333.15 K. (2019). <https://doi.org/10.1016/j.molliq.2019.111531>

- [165] *Isatin*. Solubility and Thermodynamic Functions of Isatin in Pure Solvents. (2014). <https://doi.org/10.1021/je500396b>
- [166] *rhein*. Solubility and solution thermodynamics of rhein in eight pure solvents from (288.15 to 313.15) K. (2015). <https://doi.org/10.1039/C5RA17881A>
- [167] *1,3-dimethylurea*. Measurement and correlation of solubility and solution thermodynamics of 1,3-dimethylurea in different solvents from T = (288.15 to 328.15) K. (2016). <https://doi.org/10.1016/j.jct.2015.12.032>
- [168] *Adefovir*. Solubility Determination and Thermodynamic Model Analysis of Adefovir in Different Solvents from 278.15 to 328.15 K. (2024). <https://doi.org/10.1021/acs.jced.3c00700>
- [169] *Iohexol*. Solubility in Different Solvents, Correlation, and Solvent Effect in the Solvent Crystallization Process of Iohexol. (2019). <https://doi.org/10.1021/acs.jced.8b01101>
- [170] *(R,S)-Mandelic acid*. (R,S)-Mandelic acid in pure and binary solvents solubility measurement and its correlation with thermodynamic models. (2021). <https://doi.org/10.1016/j.molliq.2021.116768>
- [171] *maleic anhydride*. Solubility of maleic anhydride in methanol + (acetone, ethyl acetate) from 278.15 to 323.15 K. (2014). <https://doi.org/10.1016/j.molliq.2014.04.011>
- [172] *Eplerenone*. Thermodynamic Analysis of Eplerenone in 13 Pure Solvents at Temperatures from 283.15 to 323.15 K. (2024). <https://doi.org/10.1021/acsomega.4c01550>
- [173] *4-hydroxy-2,5-dimethyl-3(2H)-furanone*. Thermodynamic equilibrium of 4-hydroxy-2,5-dimethyl-3(2H)-furanone in different solvent systems. (2016). <https://doi.org/10.1016/j.jct.2015.08.035>
- [174] *Dicyandiamide*. Measurement and Correlation of Solubility of Dicyandiamide in Five Binary Solvents from 283.15 to 323.15 K. (2023). <https://doi.org/10.1021/acs.jced.3c00414>
- [175] *Cyproterone Acetate*. Determination and Correlation of the Solubility of Cyproterone Acetate in Fourteen Pure Solvents and Water + Ethanol Mixed Solvents at Temperatures from 273.15 to 318.15 K. (2020). <https://doi.org/10.1021/acs.jced.0c00803>

- [176] *EGCG Peracetate*. Solubility Determination and Modeling of EGCG Peracetate in 12 Pure Solvents at Temperatures from 278.15 to 318.15 K. (2019). <https://doi.org/10.1021/acs.jced.9b00428>
- [177] *17- $\alpha$  Hydroxyprogesterone*. Solubility, Thermodynamic Parameters, and Dissolution Properties of 17- $\alpha$  Hydroxyprogesterone in 13 Pure Solvents. (2024). <https://doi.org/10.1021/acsomega.3c09922>
- [178] *Limonin*. Determination and Thermodynamic Analysis of the Solubility of Limonin in Eight Organic Solvents and Ethyl Acetate + 2-Propanol Binary Solvents from 283.2 to 323.2 K. (2018). <https://doi.org/10.1021/acs.jced.7b00851>
- [179] *2-Bromo-5-hydroxypyrazine*. Solubility and Data Correlation of 2-Bromo-5-hydroxypyrazine in Four Cosolvent Mixtures and Ten Mono-Solvents from 278.15 to 323.15 K. (2023). <https://doi.org/10.1021/acs.jced.2c00604>
- [180] *methyl paraben*. Experimental measurements, equilibrium study and model correlation of methyl paraben in ethanol and methanol aqueous solutions from = (293.15 to 323.15) K. (2019). <https://doi.org/10.1016/j.molliq.2019.111505>
- [181] *trimethylolethane*. Measurement and correlation of solubility of trimethylolethane in different pure solvents and binary mixtures. (2017). <https://doi.org/10.1016/j.cjche.2017.05.007>
- [182] *dihydromyricetin*. Solubility of dihydromyricetin in ethanol and water mixtures from 288.15 to 323.15 K. (2025). <https://doi.org/10.1016/j.molliq.2015.07.007>
- [183] *Salbutamol*. Measurement and Correlation of the Solubility of Salbutamol in Ten Pure and Binary Mixed Organic Solvents from T = 283.15–328.15 K. (2022). <https://doi.org/10.1021/acs.jced.2c00255>
- [184] *benzoic acid*. Solubility of benzoic acid in twelve organic solvents: Experimental measurement and thermodynamic modeling. (2020). <https://doi.org/10.1016/j.jct.2020.106234>
- [185] *Azithromycin Monohydrate*. Measurement and Correlation of Solubility of Azithromycin Monohydrate in Five Pure Solvents. (2014). <https://doi.org/10.1021/je400899e>
- [186] *sodium acetate*. Measurement and correlation of the solubility of sodium acetate in eight pure and binary solvents. (2022). <https://doi.org/10.1016/j.cjche.2021.06.029>

- [187] *Sulfaguanidine*. Solid-Liquid Equilibrium, Molecular Simulation and Thermodynamic Properties of Sulfaguanidine in Pure and Binary Solvents. (2023). <https://dx.doi.org/10.2139/ssrn.4432712>
- [188] *isonicotinamide (form II)*. Determination and correlation of solubility and mixing properties of isonicotinamide (form II) in some pure solvents. (2016). <https://doi.org/10.1016/j.tca.2016.01.012>
- [189] *3,5-Dinitrobenzoic Acid*. Solubility Measurement, Thermodynamic Correlation, and Comprehensive Analysis of 3,5-Dinitrobenzoic Acid in 13 Pure Solvents. (2022). <https://doi.org/10.1021/acs.jced.2c00369>
- [190] *A-Ketoglutaric Acid*. Solubility Determination and Correlation, Solvent Effect and Thermodynamic Analysis of A-Ketoglutaric Acid in Pure and Binary Solvents at 283.15-328.15 K. (2024). <https://ssrn.com/abstract=4705858>
- [191] *L-α-glycerol phosphorylcholine*. Solubility determination and thermodynamic model analysis of L-α-glycerol phosphorylcholine in different organic solvents of 278.15 K to 323.15 K. (2024). <https://doi.org/10.1016/j.jpba.2024.115998>
- [192] *4-hydroxy-2,5-dimethyl-3(2H)-furanone*. Experimental determination and correlation of the solubility of 4-hydroxy-2,5-dimethyl-3(2H)-furanone (DMHF) in binary (ethanol + water) solvent mixtures. (2015). <https://doi.org/10.1016/j.molliq.2015.04.041>
- [193] *Stearic acid*. Comments on “Stearic acid solubility in mixed solvents of (water + ethanol) and (ethanol + ethyl acetate): Experimental data and comparison among different thermodynamic models”. (2021). <https://doi.org/10.1016/j.molliq.2020.114962>
- [194] *4,4'-Diaminodiphenylmethane*. Measurement and Correlation of the Solubility for 4,4'-Diaminodiphenylmethane in Different Solvents. (2015). <https://doi.org/10.1021/je501111d>
- [195] *N-Ethyl-p-toluenesulfonamide*. Solubility, solvent effects and thermodynamic properties of N-Ethyl-p-toluenesulfonamide in twelve pure organic solvents. (2025). <https://doi.org/10.1016/j.jtice.2025.106009>
- [196] *itraconazole*. Solubilization and determination of solution thermodynamic properties of itraconazole in different solvents at different temperatures. (2019). <https://doi.org/10.1080/03639045.2019.1602138>
- [197] *chlorfenapyr*. Studies on dissolution equilibrium of chlorfenapyr in five mono-solvents and two mixed solvents ranging from 288.15 to 328.15K. (2020). <https://doi.org/10.1016/j.fluid.2020.112560>

[198] *abscisic acid*. Solid-liquid equilibrium of abscisic acid in twelve pure solvents: Experiments, modeling, and molecular simulation. (2025).  
<https://doi.org/10.1016/j.jct.2025.107472>

[199] *hydroxyapatite*. Thermodynamic parameters on corresponding solid-liquid equilibrium of hydroxyapatite in pure and mixture organic solvents. (2017).  
<https://doi.org/10.1016/j.molliq.2016.12.082>

[200] *arbidol hydrochloride monohydrate*. Comments concerning “Solid-liquid phase equilibrium, Hansen solubility parameters and thermodynamic behavior of arbidol hydrochloride monohydrate in eleven mono-solvents”. (2022).  
<https://doi.org/10.1016/j.molliq.2022.118836>

[201] *succinic acid / fumaric acid*. Solubility study and thermodynamic modelling of succinic acid and fumaric acid in bio-based solvents. (2023).  
<https://doi.org/10.1016/j.molliq.2022.120836>

[202] *hyodeoxycholic acid*. Experimental measurement and thermodynamic models for solid-liquid equilibrium of hyodeoxycholic acid in different organic solvents. (2015). <https://doi.org/10.1016/j.molliq.2014.12.007>

[203] *potassium benzoate*. Solubility and dissolution thermodynamic properties of potassium benzoate in pure solvents. (2026).  
<https://doi.org/10.1016/j.jct.2025.107569>

[204] *triethylamine hydrochloride*. Measurement, correlation, and analysis of the solubility of triethylamine hydrochloride in ten pure solvents. (2023).  
<https://doi.org/10.1016/j.molliq.2023.123040>

[205] *Zaltoprofen*. Solubility and Dissolution Properties of Zaltoprofen in Alcohol, Acid, and Ester Solvents at Atmospheric Pressure and Different Temperatures. (2019). <https://doi.org/10.1134/S0036024419040253>

[206] *L-malic acid*. Remarks on “Measurement and correlation solubility and mixing properties of L-malic acid in pure and mixed organic solvents [Fluid Phase Equilibria 360 (2013) 466–471]”. (2018).  
<https://doi.org/10.1016/j.fluid.2017.10.016>

[207] *4-(4-aminophenyl)-3-morpholinone*. Thermodynamic models for determination of the solubility of 4-(4-aminophenyl)-3-morpholinone in different pure solvents and (1,4-dioxane + ethyl acetate) binary mixtures with temperatures from (278.15 to 333.15) K. (2016). <https://doi.org/10.1016/j.jct.2016.01.022>

- [208] *Cefpodoxime Proxetil*. An Investigation into the Solubility and Solution Thermodynamics of Cefpodoxime Proxetil in Different Solvents that Vary with Temperature. (2022). <https://doi.org/10.1007/s42250-022-00364-x>
- [209] *maleic anhydride*. Measurement and correlation of the solubility of maleic anhydride in different organic solvents. (2014). <https://doi.org/10.1016/j.fluid.2014.01.008>
- [210] *aprepitant (form I)*. Solubility measurement, model evaluation and molecular simulations of aprepitant (form I) in eight pure solvents. (2020). <https://doi.org/10.1016/j.molliq.2020.112723>
- [211] *d-camphor-10-sulfonic acid*. Measurement and correlation of solubility of d-camphor-10-sulfonic acid in pure solvents. (2015). <https://doi.org/10.1016/j.fluid.2015.04.014>
- [212] *rutaecarpine and evodiamine*. Solubility of rutaecarpine and evodiamine in (ethanol + water) mixed solvents at temperatures from (288.2 to 328.2) K. (2015). <https://doi.org/10.1016/j.jct.2014.12.004>
- [213] *bis-2-hydroxyethyl terephthalate*. Solubility determination and thermodynamic modeling of bis-2-hydroxyethyl terephthalate (BHET) in different solvents. (2022). <https://doi.org/10.1016/j.cjche.2021.03.024>
- [214] *Lauric Acid*. Determination and Correlation of Solubilities of Lauric Acid in Eight Alcohols. (2014). <https://doi.org/10.1021/je500222s>
- [215] *praziquantel*. The dissolution behaviour and thermodynamic properties calculation of praziquantel in pure and mixed organic solvents. (2020). <https://doi.org/10.1016/j.jct.2020.106062>
- [216] *Loxoprofen*. Equilibrium Solubility of Loxoprofen in 14 Monosolvents: Determination, Correlation, and Hansen Solubility Parameter. (2025). <https://doi.org/10.1021/acs.jced.4c00567>
- [217] *niflumic acid*. Solubility measurement and correlation of niflumic acid in fourteen single solvents from 288.15 K to 328.15 K. (2025). <https://doi.org/10.1016/j.molliq.2025.128413>
- [218] *3-Chlorophthalic Anhydride and 4-Chlorophthalic Anhydride*. Solubilities of 3-Chlorophthalic Anhydride and 4-Chlorophthalic Anhydride in Different Pure Solvents. (2015). <https://doi.org/10.1021/acs.jced.5b00526>

- [219] *Salicylanilide*. Solubility Measurement and Data Correlation of Salicylanilide in 12 Pure Solvents at Temperatures Ranging from 283.15 to 323.15 K. (2021). <https://doi.org/10.1021/acs.jced.0c01078>
- [220] *2,2-bis(hydroxymethyl)butyric acid*. Solubility modelling and solvent effect on solid-liquid equilibrium of 2,2-bis(hydroxymethyl)butyric acid at different temperatures. (2020). <https://doi.org/10.1016/j.molliq.2020.113370>
- [221] *Calcium Sulfate Dihydrate*. Thermodynamic Models and Central Composite Design for Calcium Sulfate Dihydrate Solubility. (2020). <https://doi.org/10.1002/ceat.201900643>
- [222] *l-Glutamic Acid*. Measurement and Modeling of Solid–Liquid Equilibria of l-Glutamic Acid in Pure Solvents and Aqueous Binary Mixtures. (2019). <https://doi.org/10.1021/acs.jced.8b01084>
- [223] *4-hydroxy-2,5-dimethyl-3(2H)-furanone*. Experimental determination and correlation of the solubility of 4-hydroxy-2,5-dimethyl-3(2H)-furanone (DMHF) in six different solvents. (2015). <https://doi.org/10.1016/j.jct.2015.08.028>
- [224] *3-pentadecylphenyl acrylate*. Determination of the solubility, dissolution enthalpy and entropy of 3-pentadecylphenyl acrylate in different organic solvents. (2012). <https://doi.org/10.1016/j.tca.2012.06.025>
- [225] *Methanesulfonamide*. Solubility Determination and Thermodynamic Modeling of Methanesulfonamide in 13 Pure Solvents at Temperatures of 283.15–323.15 K. (2022). <https://doi.org/10.1021/acs.jced.2c00012>
- [226] *Progesterone*. Solubility determination and thermodynamic modelling of Progesterone in twelve pure solvents and three binary solvents at 278.15 to 323.15 K. (2021). <https://doi.org/10.1016/j.molliq.2020.114715>
- [227] *Trans-Resveratrol*. Solubilization of Trans-Resveratrol in Some Mono-Solvents and Various Propylene Glycol + Water Mixtures. (2021). <https://doi.org/10.3390/molecules26113091>
- [228] *4-methylphthalic anhydride*. Experiment, correlation and molecular simulation for solubility of 4-methylphthalic anhydride in different organic solvents from T = (278.15 to 318.15) K. (2019). <https://doi.org/10.1016/j.molliq.2018.10.158>
- [229] *1,5-Pentylenediamine Hydrochloride*. Thermodynamics, Solubility, and Crystallization of 1,5-Pentylenediamine Hydrochloride in Mixed Solvent Systems. (2024). <https://doi.org/10.1021/acs.iecr.4c01524>

[230] *daidzin*. Solubility of daidzin in different organic solvents and (ethyl alcohol + water) mixed solvents. (2015). <https://doi.org/10.1016/j.jct.2015.04.025>

[231] *polymorphic cytarabine*. Thermodynamic analysis of the solubility of polymorphic cytarabine in a variety of pure solvents. (2017). <https://doi.org/10.1016/j.fluid.2017.04.021>

[232] *Satranidazole*. Thermodynamic Modeling and Solubility Study of Satranidazole in Different Monosolvents at Different Temperatures. (2021). <https://doi.org/10.1021/acs.jced.1c00385>

[233] *6-Chloropyridazin-3-amine*. Solubility of 6-Chloropyridazin-3-amine in Different Solvents. (2012). <https://doi.org/10.1021/je3001188>

[234] *Diclazuril*. Measurement of the Solubility of Diclazuril and Discussion of the Effect of the Cosolvent. (2019). <https://doi.org/10.1021/acs.jced.9b00353>

[235] *2-Naphthaldehyde*. Solubility Measurement and Correlation for 2-Naphthaldehyde in Pure Organic Solvents and Methanol + Ethanol Mixtures. (2015). <https://doi.org/10.1021/acs.jced.5b00377>

[236] *cefixime trihydrate*. Experimental and thermodynamic modeling of cefixime trihydrate solubility in an aqueous deep eutectic system. (2020). <https://doi.org/10.1016/j.molliq.2020.112727>

[237] *m-aminobenzoic acid form III*. Solubility study of m-aminobenzoic acid form III in different mono-solvents by thermodynamic analysis and molecular simulation. (2022). <https://doi.org/10.1016/j.molliq.2022.118871>

[238] *Diflufenican*. Solubility of Diflufenican in Pure and Binary Solvent Systems. (2018). <https://doi.org/10.1021/acs.jced.8b00632>

[239] *4-(4-Hydroxyphenyl)-2-butanone*. Solubility and Solution Thermodynamic Properties of 4-(4-Hydroxyphenyl)-2-butanone (Raspberry Ketone) in Different Pure Solvents. (2017). <https://doi.org/10.1007/s10953-017-0681-0>

[240] *l-Carnitine*. Measurement and Correlation of the Solubility of l-Carnitine in Different Pure Solvents and Ethanol–Acetone Solvent Mixture. (2014). <https://doi.org/10.1021/je500078n>

[241] *etodolac*. Solubility, Hansen solubility parameter and thermodynamic properties of etodolac in twelve organic pure solvents at different temperatures. (2020). <https://doi.org/10.1016/j.molliq.2020.113779>

- [242] *oxcarbazepine*. Solubility, solvent effect, and modelling of oxcarbazepine in mono-solvents and N-methyl-2-pyrrolidone + water solvent mixtures at different temperatures and its application for the preparation of nanosuspensions. (2021). <https://doi.org/10.1016/j.molliq.2021.116792>
- [243] *ethylene thiourea*. The effects of solvent properties on solid-liquid phase equilibrium of ethylene thiourea. (2019). <https://doi.org/10.1016/j.molliq.2019.03.178>
- [244] *Menadiol Diacetate*. Determination and Simulation of Menadiol Diacetate Solubility in 14 Solvents at Temperatures from 283.15 to 323.15 K. (2023). <https://doi.org/10.1021/acs.jced.2c00734>
- [245] *diprophylline*. The dissolution behaviour and apparent thermodynamic analysis of diprophylline in pure and mixed solvents. (2019). <https://doi.org/10.1016/j.jct.2019.06.007>
- [246] *metronidazole benzoate*. Uncovering dissolution behavior and thermodynamic properties of metronidazole benzoate in twelve mono-solvents by experiments and molecular simulation. (2024). <https://doi.org/10.1016/j.molliq.2023.123539>
- [247] *2-Amyl Anthraquinone*. Unveiling the solvent effects on the solubility of 2-Amyl Anthraquinone in eleven single solvents. (2025). <https://doi.org/10.1016/j.molliq.2025.127079>
- [248] *N-ethyl-2,2-diisopropylbutylamide*. Dissolution behavior and thermodynamic study of N-ethyl-2,2-diisopropylbutylamide in fourteen mono solvents by experiments and molecular simulation. (2024). <https://doi.org/10.1016/j.tca.2024.179762>
- [249] *Doxofylline*. Solubility and Model Correlation of Doxofylline in Pure Solvents at the Temperature Range of 283.15–323.15 K. (2021). <https://doi.org/10.1021/acs.jced.0c01088>
- [250] *naftopidil*. Solubility of naftopidil in pure and mixed solvents at 273.15–313.15 K and its correlation with the Jouyban-Acree and CNIBS/R-K models. (2020). <https://doi.org/10.1016/j.jct.2019.105969>
- [251] *Omeprazole Sulfide*. Solubility of Omeprazole Sulfide in Different Solvents at the Range of 280.35–319.65 K. (2013). <https://doi.org/10.1007/s10953-013-0110-y>
- [252] *2-Amino-4,6-dichoropyrimidine*. Solubility Measurement and Modeling of 2-Amino-4,6-dichoropyrimidine in Ten Pure Solvents and (Ethyl Acetate + Ethanol) Solvent Mixtures. (2018). <https://doi.org/10.1021/acs.jced.8b00292>

- [253] *N-acetyl-1,3-phenylenediamine*. Apparent thermodynamic models for determination of the solubility of N-acetyl-1,3-phenylenediamine in eight pure solvents and two different miscible systems at T = (278.15–323.15) K. (2017). <https://doi.org/10.1016/j.molliq.2017.08.030>
- [254] *Spectinomycin Dihydrochloride Pentahydrate*. Solubility Measurement, Model Correlation, and Solvent Effect Analysis of Spectinomycin Dihydrochloride Pentahydrate in Three Binary Solvents. (2024). <https://doi.org/10.1007/s10953-024-01385-5>
- [255] *3-Amino-6-bromopyridazine*. Equilibrium Solubility, Modeling, and Extended Hildebrand Solubility Parameter Approach Analysis of 3-Amino-6-bromopyridazine in Four Cosolvent Blends and Ten Pure Solvents at T = 278.15 to 323.15 K. (2023). <https://doi.org/10.1021/acs.jced.2c00794>
- [256] *Quetiapine Fumarate*. Solubility Measurements and Correlation of Quetiapine Fumarate in 12 Individual Solvents and Tetrahydrofuran–Water from 283.15 to 323.15 K. (2025). <https://doi.org/10.1021/acs.jced.5c00103>
- [257] *3-methyl-1,2-cyclopentanedione*. Solubility, solvent effect, correlation and thermodynamic properties of 3-methyl-1,2-cyclopentanedione in twelve pure organic solvents from 278.15 K to 313.15 K. (2024). <https://doi.org/10.1016/j.molliq.2024.125848>
- [258] *3-ethoxysalicylaldehyde*. Solubility measurement and data correlation of 3-ethoxysalicylaldehyde in twelve pure solvents at temperatures from 278.15 to 313.15 K. (2024). <https://doi.org/10.1016/j.jct.2023.107162>
- [259] *glutaric anhydride*. Solubility, solvent effects, correlation, and thermodynamic properties of glutaric anhydride in ten individual organic solvents from 278.15 to 313.15 K. (2026). <https://doi.org/10.1016/j.fluid.2025.114643>
- [260] *Doxycycline Hyclate*. Solubility Measurement and Correlation of Doxycycline Hyclate in 10 Pure Solvents and Mixtures Solvents at 278.15–323.15 K. (2020). <https://doi.org/10.1021/acs.jced.0c00097>
- [261] *l-malic acid*. Measurement and correlation solubility and mixing properties of l-malic acid in pure and mixed organic solvents. (2013). <https://doi.org/10.1016/j.fluid.2013.10.011>
- [262] *ribociclib*. Temperature-dependent solubilization and thermodynamic characteristics of ribociclib in varied {PEG 400 + water} combinations. (2025). <https://doi.org/10.1186/s13065-025-01461-x>

- [263] *Biotin*. Experimental Measurement and Modeling of the Solubility of Biotin in Six Pure Solvents at Temperatures from 298.15 K to 333.85 K. (2014). <https://doi.org/10.1021/je500787x>
- [264] *4,4'-Dinitrodiphenyl Ether*. Measurement and Correlation of the Solubility of 4,4'-Dinitrodiphenyl Ether in Fourteen Monosolvents from T = 283.15 to 323.15 K. (2025). <https://doi.org/10.1021/acs.jced.4c00440>
- [265] *2-Benzimidazolone*. Solubility Determination and Thermodynamic Correlation of 2-Benzimidazolone in Twelve Pure Solvents from 283.15 to 323.15 K. (2020). <https://doi.org/10.1021/acs.jced.0c00165>
- [266] *Musk Ketone*. Determination and Correlation of the Solubility of Musk Ketone in Pure and Binary Solvents at 273.15–313.15 K. (2019). <https://doi.org/10.1021/acs.jced.9b00310>
- [267] *Bicalutamide Form I*. Solubility Profile and Intermolecular Force Analysis of Bicalutamide Form I in Mono Solvents at Several Temperatures. (2023). <https://doi.org/10.1021/acs.jced.3c00149>
- [268] *benflumetol*. Solubility determination, model evaluation, Hansen solubility parameter, molecular simulation and thermodynamic properties of benflumetol in four binary solvent mixtures from 278.15 K to 323.15 K. (2021). <https://doi.org/10.1016/j.molliq.2021.115867>
- [269] *p-Coumaric Acid*. Measurement and Correlation of the Solubility of p-Coumaric Acid in Nine Pure and Water + Ethanol Mixed Solvents at Temperatures from 293.15 to 333.15 K. (2016). <https://doi.org/10.1021/acs.jced.6b00361>
- [270] *L-Pyroglutamic acid*. Solubility and thermodynamic properties of L-Pyroglutamic acid in pure and binary solvents. (2020). <https://doi.org/10.1016/j.j.molliq.2020.114361>
- [271] *d-(-)-quinic acid*. Measurement and thermodynamic functions of solid–liquid phase equilibrium of d-(-)-quinic acid in H<sub>2</sub>O, methanol, ethanol and (H<sub>2</sub>O + methanol), (H<sub>2</sub>O + ethanol) binary solvent mixtures. (2016). <https://doi.org/10.1016/j.jct.2016.04.002>
- [272] *Fluorene*. Solubility Measurement and Thermodynamic Properties of Fluorene in 14 Pure Solvents at Temperatures from 278.15 to 318.15 K. (2023). <https://doi.org/10.1021/acs.jced.3c00364>
- [273] *4-Biphenylcarboxylic Acid*. Measurement and Correlation of the Solubility of 4-Biphenylcarboxylic Acid in Nine Pure and Binary Mixed Organic Solvents from T = 293.15 to 328.15 K. (2021). <https://doi.org/10.1021/acs.jced.1c00596>

- [274] *sulfaguanidine*. Solid-liquid equilibrium, molecular simulation and thermodynamic properties of sulfaguanidine in pure and binary solvents from 288.15 K to 343.15 K. (2024). <https://doi.org/10.1016/j.jct.2023.107198>
- [275] *dicyandiamide*. Measurement, correlation and thermodynamic analysis of the solubility of dicyandiamide in three binary solvents. (2024). <https://doi.org/10.1016/j.jct.2024.107312>
- [276] *Benzethonium Chloride*. Solubility and Thermodynamics Profile of Benzethonium Chloride in Pure and Binary Solvents at Different Temperatures. (2023). <https://doi.org/10.1021/acsomega.2c07877>
- [277] *Cytosine*. Measurement and Correlation of Solubility Data for Cytosine in Fourteen Pure Solvents from 288.15 to 328.15 K. (2022). <https://doi.org/10.1021/acs.jced.2c00507>
- [278] *2,3,4-trimethoxybenzoic acid*. Solubility measurement and thermodynamic modeling of 2,3,4-trimethoxybenzoic acid in 12 solvents across a temperature range of 278.15 K–318.15 K. (2026). <https://doi.org/10.1016/j.jct.2025.107562>
- [279] *2-naphthoxyacetic acid*. Solubility and thermodynamic properties of 2-naphthoxyacetic acid in twelve mono-solvents. (2023). <https://doi.org/10.1016/j.jct.2022.106934>
- [280] *benorilate*. Solubility determination, model evaluation, Hansen solubility parameter and thermodynamic properties of benorilate in six pure solvents and two binary solvent mixtures. (2021). <https://doi.org/10.1016/j.jct.2020.106301>
- [281] *2-Methyl-4-chlorophenoxyacetic Acid*. Determination and Correlation of the Solubility of 2-Methyl-4-chlorophenoxyacetic Acid in 12 Pure Solvents at Temperatures from 278.15 to 323.15 K. (2025). <https://doi.org/10.1021/acs.jced.4c00466>
- [282] *4-Fluorobenzoic Acid*. Revealing Solid–Liquid Equilibrium Behavior of 4-Fluorobenzoic Acid in 12 Pure Solvents from 283.15 to 323.15 K by Experiments and Molecular Simulations. (2024). <https://doi.org/10.1021/acs.jced.3c00623>
- [283] *3-Nitrobenzotrile*. Thermodynamic Functions for the Solubility of 3-Nitrobenzotrile in 12 Organic Solvents from T/K = (278.15 to 318.15). (2017). <https://doi.org/10.1021/acs.jced.7b00615>
- [284] *Pregabalin*. Solubility, Hansen solubility parameter, molecular dynamic simulation and thermodynamic analysis of Pregabalin in eight pure solvents and

one binary solvent at various temperature. (2025).  
<https://doi.org/10.1016/j.molliq.2025.127855>

[285] *diphenolic acid*. Solid-liquid phase equilibrium of diphenolic acid in thirteen mono-solvents: determination, correlation, molecular simulation and thermodynamic analysis. (2025). <https://doi.org/10.1016/j.molliq.2025.128182>

[286] *Isatoic Anhydride*. Solubility Measurement and Data Correlation of Isatoic Anhydride in 12 Pure Solvents at Temperatures from 288.15 to 328.15 K. (2020). <https://doi.org/10.1021/acs.jced.9b01164>

[287] *2-anilino-6-(dibutylamino)-3-methylfluoran*. Solubility determination, Hansen solubility parameter, molecular simulation and thermodynamic properties of 2-anilino-6-(dibutylamino)-3-methylfluoran in four binary solvent mixtures from 283.15 K to 323.15 K. (2024). <https://doi.org/10.1016/j.jct.2024.107314>

[288] *riluzole*. The solubility data, Hansen solubility parameter and dissolution thermodynamic properties of riluzole in twelve organic solvents. (2021). <https://doi.org/10.1016/j.jct.2021.106569>

[289] *N, N'-diphenyl thiourea*. Solid-liquid phase equilibrium of N, N'-diphenyl thiourea (DPTU) in twelve pure solvents: Solubility determination, correlation, molecular simulation and thermodynamic analysis. (2021). <https://doi.org/10.1016/j.jct.2021.106605>

[290] *Arbidol hydrochloride monohydrate*. Solid-liquid phase equilibrium, Hansen solubility parameters and thermodynamic behavior of Arbidol hydrochloride monohydrate in eleven mono-solvents. (2022). <https://doi.org/10.1016/j.molliq.2021.118300>

[291] *Ammonium Chloride*. Ammonium Chloride Solubility Measurement, Molecular Simulation, and Correlation in Binary Solvents from 283.15 to 323.15 K. (2025). <https://doi.org/10.1021/acs.jced.5c00396>

[292] *2-amino-6-chloropyrazine*. Solubility, modelling, preferential solvation and solvent effect of 2-amino-6-chloropyrazine in ten pure mono-solvents and four solvent mixtures at 278.15 K to 323.15 K. (2023). <https://doi.org/10.1016/j.jct.2023.107109>

[293] *Clotrimazole*. Solubility and Thermodynamic Properties of Clotrimazole in 16 Organic Solvents at Temperature of 283.15 to 323.15 K. (2023). <https://doi.org/10.1021/acs.jced.2c00680>

[294] *4-aminobenzenesulfonamide*. Determination and correlation of solubility and solution thermodynamics of 4-aminobenzenesulfonamide in five binary solvent

mixtures from 278.15 to 318.15 K. (2020).  
<https://doi.org/10.1016/j.molliq.2020.112670>

[295] *D-Psicose*. Determination and Correlation of the Solubility of D-Psicose in 15 Pure Solvents at Temperatures of 283.15 to 323.15 K. (2024).  
<https://doi.org/10.1021/acs.jced.4c00300>.

[296] *2-Hydrazino-4-methylbenzothiazole*. Study on 2-Hydrazino-4-methylbenzothiazole in Nine Monosolvents and Four Mixed Solvents at 273.15 to 318.15 K: Solubility Determination and Modeling. (2024).  
<https://doi.org/10.1021/acs.jced.4c00506>.